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Abstract
Conventional subunit vaccine regimes can be modified in order to stimulate strong 
immune responses resulting in memory cell formation. An adjuvant system that has 
gained increased attention in recent years is the use of particulate antigen delivery. 
Particulate systems have a number of advantages over conventional approaches since 
they are believed to be taken up preferentially by dendritic cells (DC) where they 
prolong the release of antigen resulting in enhanced T cell stimulation. Furthermore, 
they offer a versatile system that allows for targeted delivery of antigen and adjuvant to 
the same DC.
A wide range of particle types have been used to enhance vaccine potency. 
Poly (lactic-co-glycolic) acid (PLGA), in particular, has been used successfully by 
many groups. However, there are a great variety of means to synthesise and 
characterise the desired particles. This study, firstly, set out to develop and optimise a 
protocol to generate nanoparticles with defined properties. A number of parameters 
were evaluated including, particle size, protein loading, protein coating and surface 
charge. In addition to conventional methods, such as electron microscopy and 
dynamic light scattering, particles were characterised by novel flow cytometric 
methods.
While particles have been shown to adjuvant candidate vaccine proteins, this 
property should be enhanced when the particle is targeted to dendritic cells by 
increasing specific uptake. Specific targeting has previously been performed through 
either targeting with natural receptor ligands or monoclonal antibodies. However, there 
is currently conflicting data in other studies as to whether this can be achieved. It was 
thus the second objective of this study to devise methods to implement this technology 
and to determine whether targeting can be achieved through either approach. It was
1
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found that there was potential in targeting DC populations with monoclonal antibodies, 
while targeting with natural ligands yielded more mixed results.
As a final component, the adjuvant properties of the particles rationally loaded 
with antigens and molecular adjuvant was tested in vivo in cattle using a viral 
challenge model. The experiment had a promising outcome with the vaccine particles 
inducing both T cell and antibody responses resulting in a degree of protection against 
virus challenge. Furthermore, it highlighted areas where the system, both the particles 
and the model, may be improved, which could form the basis of future work.
2
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Chapter 1: Introduction
1.1. Subunit vaccines
Prophylactic vaccination remains a key strategy in the prevention and control of 
disease and this is especially so with viral infections. This is primarily due to the lack of 
chemotherapeutic agents against viruses, which possess minimalist genomes that can 
readily mutate and escape selection pressures. The ideal vaccine should trigger an 
immune response mimicking that of the virus infection, whilst carrying minimal risk of 
contraindications to the subject. For some diseases this has been achieved 
successfully through the use of either a whole virus, inactivated or live-attenuated, or a 
component based system, whereby an antigenic fraction of the virus is used as the 
vaccine. More recently there has been some success demonstrated by various novel 
vaccination systems, such as modified viral or bacterial vectors, and DNA vectors 
(often referred to as third generation vaccines). In humans most of these approaches 
are currently at the experimental or trial stages, with few examples of licensed third 
generation vaccines available. In the field of veterinary medicine however, there are 
examples of commercially produced vectored vaccines, such as the ALVAC® (Merial) 
vaccine for horses against West Nile virus (El Garch, Minke et al. 2008)
Amongst the types of vaccines, live attenuated vaccines often provide the most 
effective protection as they are able to stimulate a response that is representative of 
one stimulated by the virus itself. A prime example of this is the yellow fever vaccine, 
the attenuated 17D strain, which is often considered to be the ‘gold standard’ of 
vaccines. The attenuated virus is highly effective because it stimulates both cell 
mediated and humoural adaptive immune responses as well as innate immune 
mechanisms, resulting in strong responses and long lasting memory (Pulendran 2009). 
However, there are many cases where attenuation of virus is not an option. There is 
diminishing public acceptance of live vaccines spurred on by the fear that vaccination 
may, in an exceptional and small number of circumstances, cause adverse reactions. 
There is some published evidence for this, for example, a live rotavirus vaccine (RRV-
4
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TV) was successfully developed but it carried a 1 in 10,000 risk of intussusceptions. 
Since rotavirus was only responsible for on average 20 deaths per annum in the US 
the vaccine was withdrawn (Perrie, Mohammed et al. 2008). There is also the chance 
that the vaccine virus strain is unstable and in which case may revert to virulence. 
Following vaccination this is seen in the case of the Sabin polio vaccine, making it 
dangerous if herd immunity is not established (Agol 2006). In the field of veterinary 
vaccines, there may be an additional hurdle to overcome, since if a whole virus is used 
it is often impossible to distinguish infected from vaccinated animals (DIVA). This 
represents a significant problem in controlling epizootic outbreak situations or in 
disease eradication programmes (Meeusen, Walker et al. 2007). Vaccine formulations 
intended for animals must also be cheap and easy to manipulate, unfortunately live 
attenuated viruses do not always offer this (Scheerlinck, Gloster et al. 2006).
To counter these problems two alternate types of vaccines can be used: 
inactivated vaccines consisting of viral particles that have been denatured, commonly 
with formalin, phenol or heat, and subunit vaccines which contain a defined 
immunogenic molecule, most commonly a protein expressed through recombinant 
technologies. Both of these strategies overcome some the previously listed problems 
associated with live attenuated vaccines. They have fewer safety issues; since there is 
no possibility of the subject acquiring the infection from the vaccine itself, and the 
absence of nucleic acid in the vaccine ensures there is no recombination with field 
virus. Furthermore, in the case of subunit vaccines they may allow for DIVA as only 
antibodies against the specific protein component develop. However, inactivated and 
subunit vaccines often fail to show the same immunogenicity and efficacy of live 
vaccines and require the use of adjuvants to stimulate protective immune responses. 
This is due to the artificial nature and behaviour of the vaccine in vivo. For instance, 
the antigenic components of inactivated or subunit vaccines may preferentially 
stimulate antibody responses, which differ from the response triggered in a natural
5
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infection, where the additional involvement of cell mediated responses may be 
essential (Azizi and Diaz-Mitoma 2007). The difference in these responses may arise 
from many factors, including an inappropriate site of entry, or the lack of 
accompanying or appropriate immunomodulatory danger signals which shape the 
ensuing response (Shi, Evans et al. 2003).
Despite this, some subunit vaccines have shown to be successful. An example 
of a highly effective subunit vaccine is the hepatitis B virus (HBV) surface antigen 
vaccine. This vaccine is safe, suitable for high risk infants and affords long term 
protection (Poorolajal, Mahmoodi et al. 2010; Romano and Zanetti 2011). The only 
other subunit vaccine currently licensed for human use is the recently developed 
human papillomavirus (HPV) vaccine, which consists of the L1 surface protein that has 
been self-assembled into virus-like particles (VLPs; (Bryan 2007). However, in contrast 
to the aforementioned yellow fever vaccine, the immunity warranted by both HBV and 
HPV vaccines is predominantly antibody mediated (Bryan 2007; Michel and Tiollais 
2010). This is also true of bacterial polysaccharide-conjugate vaccines which stimulate 
B cells in the absence of any T helper (Th) cell response (Pirofski and Casadevall 
1998). This response may be linked to the choice of adjuvant used in the vaccine. In 
each case, aluminium salts (alum) are used, which promote antibody and Th2 
responses (Andre 1989; Palmer, Jenson et al. 2009). It is thus apparent that if a cell 
mediated response is necessary to confer immunity, which is the case for many viral 
infections, subunit approaches require some modifications. Two approaches, which 
are the topic of much research, including this thesis, will be explored in this 
introduction; firstly, targeting the delivery of the vaccine to professional antigen 
presenting cells (APCs), dendritic cells (DCs), and secondly, by co-delivery with a 
relevant adjuvant.
6
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1.2. Dendritic cell mediated immunisation
Dendritic cells were originally described in 1973 by Steinman and Cohn and 
were identified based on their morphological features, in particular by their probing 
‘dendrites’ (Steinman and Cohn 1973). Initially they were described as having a 
greater endocytic capacity when compared with macrophages, and were unable to 
produce antibody distinguishing them from B cells (Steinman and Cohn 1973). Over 
the course of the subsequent decades, their role as the major APC of the immune 
system became more apparent as their ability to process and present antigen as well 
as prime or tolerise T lymphocytes, was elucidated (Banchereau and Steinman 1998).
DCs are often described as bridging the gap between the innate and adaptive 
immune systems. They are present in both lymphoid and non-lymphoid tissues 
continually surveying the local environment through processes such as 
macropinocytosis and receptor mediated endocytosis (Steinman 2001). They are 
particularly efficient at priming T cells, due to the abundance of major histocompatibility 
complexes (MHC), co-stimulatory, and adhesion molecules on their surface. It has 
been estimated that they are one thousand times more competent at simulating T cells 
than other APCs (Gogolak, Rethi et al. 2003). These factors have lead to them being 
described as the professional antigen presentation cell of the immune system. 
Following infection, their role is to process antigen into MHC pathways and present the 
epitopes on the cell surface. DCs then migrate to the T cell rich areas of lymphoid 
tissues where cells are primed and clonal expansion arises.
The sole function of DCs is to initiate an immune response to a pathogen. They 
are uniquely capable of utilizing the cross presentation pathway whereby exogenously 
derived antigen is presented to CD8 T cells in the context of MHC class I (Heath, Belz 
et al. 2004). This, combined with their ability to selectively target and prime T cells, 
makes them an ideal choice for targeted vaccine antigen delivery. Studies have
Chapter 1: Introduction
revealed that as few as one thousand antigen bearing DCs reaching the lymph node is 
sufficient to induce protective immune responses, this is done quickly with significantly 
long lasting immunity (Ludewig, Ehl et al. 1998). It is believed that the density of 
antigenic peptide loaded MHC molecules upon individual DCs is a more important 
factor than the number of DCs presenting the epitope (Yu, Babiuk et al. 2007). 
Therefore, if a concentrated dose of vaccine could reach even a small number of cells, 
a strong immune response may be provoked. Most current subunit vaccines are 
inefficient and vaccination regimes demand several administrations over a period of 
time before effective memory develops.
The concept of DC cell vaccination was developed in the 1990s and is currently 
being applied to the treatment of conditions most notably against cancers (reviewed in 
(Banchereau and Palucka 2005). DCs are derived in vitro from culture of the patient’s 
monocytes (MoDC) in the presence of recombinant IL-4 and GM-CSF. The MoDC are 
then pulsed with the relevant antigen(s) and inoculated back into the patient. In this 
sense DCs are discussed as having an adjuvant role in vaccination (Steinman and 
Pope 2002). However, DC cell vaccination often has rather limited success; Soruri and 
Zwirner (2005) argued that MoDCs do not equate to immature DCs (iDCs) and are 
limited in their migration in vivo (Soruri and Zwirner 2005). Work performed also 
indicated that for DC vaccines to be effective they must transfer antigen to resident 
DCs, thus limiting their therapeutic use in subjects where DC function is impaired 
(Kleindienst and Brocker 2003). DC vaccination is also a very costly approach and is 
unsuitable for widespread application such as prophylaxis against infectious diseases 
in both human and veterinary medicine. An alternative strategy that is being pursued 
by many research groups is the targeting of vaccines to DCs in vivo. For this approach 
there are a number of factors to consider when designing a DC targeted vaccine. 
Firstly, DCs are relatively sparse in peripheral tissue and there are numerous 
mechanisms of uptake, each of which may have a different outcome. Secondly, the
8
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vaccine must be adjuvanted in the correct way to stimulate maturation and the 
desirable adaptive response. Finally, although DCs may be talked about as a single 
population, there are many different types with differing roles (Steinman 2008).
1.3. Considerations when designing a DC targeted vaccine.
1.3.1. Targeting vaccine to the right DC.
DCs represent a small minority of immune cells reaching, at their highest, only 
1.6% of total nucleated cells in the spleen (Steinman and Cohn 1973) and in peripheral 
tissues macrophages are much greater in number. DCs are traditionally described as 
being responsible for initiating a primary immune response and, unlike macrophages, 
are capable of priming CD8 T cells against exogenous antigen (Jung, Unutmaz et al. 
2002). Though this is now debated, it is clear that macrophages require a greater 
quantity of antigen (10 times as much) in order to prime naïve T cells, this possibly 
being due to their limited migratory capacity (Pozzi, Maciaszek et al. 2005). Thus in the 
rational design of a vaccine it should aim to either be preferentially targeted towards 
DCs or selectively exclude other cells.
DCs comprise heterogeneous populations, both in terms of phenotype and 
function. They can be divided, based on myeloid or lymphatic lineages, into 
plasmacytoid (pDCs) and myeloid DCs, the former having limited antigen presenting 
capacity and are generally considered to be inefficient at T cell priming compared to 
their myeloid counterparts (Villadangos and Young 2008). Despite this pDC have been 
shown to be able to cross prime T cells following Toll like receptor (TLR) stimulation 
(Mouries, Moron et al. 2008). Myeloid DCs are considered to be conventional DCs 
(cDCs) and are usually identified based on the expression of the integrin CD11c 
(Robinson, Patterson et al. 1999). DC heterogeneity is a fast moving field and novel 
DC phenotypes are frequently being identified or re-categorised. Of the cDCs, the
9
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types which have been of particular interest to vaccine designers are described in 
mouse to be CD8+ CD205+ and in humans to express the blood dendritic cell antigen 3 
(BDCA3, CD141) (Heath, Belz et al. 2004; Bachem, Guttler et al. 2010). These cells 
are especially good at cross-presenting exogenous antigen and triggering cell 
mediated responses (den Haan, Lehar et al. 2000). Indeed, it has been shown in mice 
that after intravenous administration of soluble antigen, it is the CD8+ cDCs which are 
responsible for stimulation of CD8 T cells and the CDS' DCs, which stimulate CD4 T 
cells (Pooley, Heath et al. 2001).
The provenance of CD8+ cDC is not well understood and it was originally 
speculated that they could be differentiated from pDCs (Martin, del Hoyo et al. 2000). 
This conclusion has been cast into doubt as it has been shown that pDC can only be 
differentiated into CD8+ cDCs in the presence of certain TLR agonists and not in the 
steady state (O'Keeffe, Hochrein et al. 2002). Interestingly, it has been shown that 
CD8+ DCs can be derived from CDS' DCs, though this is a rare and disputed 
occurrence (Martinez del Hoyo, Martin et al. 2002; Naik, Vremec et al. 2003). It is more 
likely that CD8+ cDCs represent a distinct sub lineage fully differentiated after leaving 
the bone marrow (Shortman and Heath 2010). CD8+cDC are primarily resident in the T 
cell zone of the spleen, which is consistent with their purported function. Targeting of 
CD8+ cDC with anti-CD205 conjugated OVA, resulted in the induction of both CD4 and 
CD8 T cell responses, whereas targeting CD8" DC with anti-DCIR2 only induced CD4 
T cell reactivity (Dudziak, Kamphorst et al. 2007). In humans, unlike mice, cDCs are 
also in circulation and they are especially efficient at internalizing antigen and 
migrating to the lymph nodes where priming takes place (Geissmann, Manz et al. 
2010). Other DCs which occupy a defined anatomical location may be better at 
stimulating a certain type of response based on their migratory pathways. For 
instance, it has been speculated that dermal DCs are biased towards migration to the 
B cell follicles and stimulation of a humoral response (Palucka, Banchereau et al.
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2010). Whilst only limited data exists on DC subsets in species of veterinary interest, 
the existence of CD8+ like DCs have recently been described in sheep (Contreras, 
Urien et al. 2010). In cattle there has been several DC subsets isolated, at least two 
subsets can be identified based on the expression of CD172a and CD11a within the 
afferent lymph (Clark 2007). These subsets have been shown to differentially stimulate 
CD4 or CD8 T cells (Hope, Sopp et al. 2001). Groups have also looked into extracting 
naive DCs from bovine peripheral blood which are defined by the absence of lineage 
markers as well as functional behaviour (Lin, Zhan et al. 2008). Furthermore, there is 
strong evidence to suggest the presence of a bovine pDC like cell having been 
identified (Gibson, Miah et al. 2012)
1.3.2. Targeting vaccine to the right antigen uptake pathway
In their immature state, DCs have the potential to use various methods of 
antigen uptake and the route chosen in many cases dictates the MHC processing and 
presentation pathway utilised. These mechanisms can be broadly divided into 
phagocytosis, pinocytosis and endocytosis. Endocytosis can be further divided into 
receptor mediated, clathrin dependent/independent or caveolae mediated. These are 
reviewed by (Burgdorf and Kurts 2008) who speculate that MHC class II restriction can 
be achieved through pinocytosis. Both MHC class I and II presentation can occur after 
phagocytosis depending on the persistence of antigen, and the outcome of receptor 
mediated endocytosis is dependent on the receptor.
There are a large number of antigen receptors which can be described as 
having a C type lectin structure, these fall into two categories; type I, mannose 
receptor (MR, CD206) like, or type II, dendritic cell-specific I CAMS grabbing non 
integrin (DC-SIGN, CD209) like (McGreal, Miller et al. 2005). The receptor used can 
contribute to the localisation of the antigen within the cell, for instance the MR recycles 
to the early endosome whereas DEC205 (CD205), another type I lectin, progresses to 
the late endosome following internalisation (Thery and Amigorena 2001). The receptor
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may also polarize the response, for example, DEC205 targeted antigens are known to 
trigger T cell anergy in the absence of danger signals (Hawiger, Inaba et al. 2001). 
This is likely to be due to the nature of its natural ligands, which are believed to be 
proteins associated with cell death (Shrimpton, Butler et al. 2009). The most studied 
lectin is the MR, however its role in antigen uptake is controversial; for instance it has 
been speculated that it is not an endocytic receptor merely a binding receptor which 
must work in partnership with another unidentified glucan recognition molecule (Le 
Cabec, Emorine et al. 2005). This is supported by the observation that transfection of 
fibroblasts with the MR has no effect on their antigen presentation capacity (Napper 
and Taylor 2004). Building on this hypothesis, it was shown that MR gene knock-out 
mice can respond equally well to fungal pathogens as wild-type mice and that the MR 
is not responsible for phagocytosis of the pathogen in vitro (Lee, Zheng et al. 2003). 
Indeed, it has been proposed that in the steady state the MR functions to remove self­
glycoproteins which otherwise would accumulate (Swain, Lee et al. 2003). In contrast, 
it has been demonstrated that cross-presentation of the model antigen ovalbumin 
(OVA) is dependent on the MR and it is abrogated in MR deficient mice (Burgdorf, 
Kautz et al. 2007). In one study, when mannosylated OVA was used as the antigen, 
presentation was enhanced but Th1 responses were found to be impaired. This, they 
speculate, may be due to T cell tolerisation (Kel, de Geus et al. 2008). A recent study 
showed that simultaneous stimulation of the MR and DC-SIGN drives Th1 responses, 
but also inhibits signals from Dectin 1, which stimulated a Th17 response. The roles of 
the individual receptors were not identified (Zenaro, Donini et al. 2009). Contrary to 
this it has also been shown that the MR is instrumental in stimulating an IL-17 
response against Candida, furthermore this is impaired in individuals who do not 
express Dectin 1 (van de Veerdonk, Marijnissen et al. 2009). Thus a complex picture 
of the MR builds, with multiple lectins either agonising or synergizing and TLR 
engagement beginning to play a role. If it were the case that the MR was merely a
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binding receptor for multiple endocytotic receptors it may go some way to explaining 
these observations.
Table 1.1 APC subsets and the C-type lectins they express
|uM W * tcP'-PM) j I DC, LC, M(D,Mo Terminal mannose residue
i d c (c d 8+), lc, doc ?
' " l  I M(D Collagen, N-acetyl glycosamine, mannose, fructose
l 'W m % a  | II DC, LC p-glucan
I T W iïn ÿ )  '""1 II DC, LC Mannose rich
II LC N-acetyl glycosamine, high mannose/fructose
| M DC, dDC Complex mannose and fructose residues
n pd c , m o , m © ?
Im gm    1  ii dc ?
I M B  I M pDC,DC, LC,M(D,Mo ?
( 1 II BDCA3 DC, Mo Filamentous actin
Abbreviations: DC, Dendritic cell; LC, Langerhan Cell; dDC, Dermal Dendritic cell, 
pDC, Plasmacytoid Dendritic Cell; Mo, Monocyte; Met), Macrophage (Figdor, van 
Kooyk et al. 2002; Ebner, Ehammer et al. 2004; McGreal, Miller et al. 2005; Robinson, 
Sancho et al. 2006; Geijtenbeek and Gringhuis 2009)
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In terms of interest to the field of vaccinology, DEC-205 has far surpassed the 
mannose receptor (MR). Human phase I trials of a DEC-205 targeting vaccine for the 
therapeutic treatment of HIV are underway and due for completion in 2013 (Jefferys 
2010). DEC-205 was first identified in 1995 in the mouse, its human equivalent, which 
shares 77% homology, being indentified in 2000 (Jiang, Swiggard et al. 1995; Guo, 
Gong et al. 2000). It has a wide expression pattern and is highly expressed on CD8+ 
cDC, pDC and monocytes, and to a lesser extent on lymphocytes (Kato, McDonald et 
al. 2006; Tel, Benitez-Ribas et al. 2011). This receptor is attractive for antigen 
targeting since it recycles to MHC class II rich endosomes, and antigens targeted to it 
have shown a hundred fold increase in presentation (Mahnke, Guo et al. 2000). 
Compared to DC-SIGN and MR, antigens targeted to DEC-205 by mAbs are superior 
at stimulating a CDS T cell response. This is despite all targeting mAbs being bound 
and endocytosed by their respective receptor (Bozzacco, Trumpfheller et al. 2007).
DC-SIGN is the archetypal type II lectin, it differs from the MR in both its 
structure and its ligands, but targeting it has likewise been shown to improve immune 
responses (Singh, Stephani et al. 2009). The ligands for DC-SIGN are more complex 
than those for the MR, which bind to terminal mannose residues, and are believed to 
comprise oligomers of glucose, fructose, galactose, and to a lesser extent mannose 
(van Liempt, Bank et al. 2006) Using specifically designed oligosaccharides, DC-SIGN 
can be selectively targeted, leading to improved immune responses being observed. 
Responses of a similar magnitude were not achieved when monomeric sugars, 
including mannose, were used (Adams, Ratner et al. 2008). Targeting to DC-SIGN 
may have advantages over DEC-205, as its expression pattern is more limited to DCs 
and a few macrophage subsets (Soilleux, Morris et al. 2002). DC-SIGN can recycle to 
the lysosomes or the endosomes depending on the maturation status of the cell, and 
antigen targeted to this receptor can be presented to T cells (Engering, Geijtenbeek et 
al. 2002 ).
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Other receptors which have shown potential as vaccine targets include Clec9A 
(Caminschi, Proietto et al. 2008), Endo 180, LSECtin (Dominguez-Soto, Aragoneses- 
Fenoll et al. 2007) and Dectinl (Leibundgut-Landmann, Osorio et al. 2008). Dectin-1 is 
a glucan receptor and is a promising target if an antibody biased type 2 immune 
response is sought (Herre, Gordon et al. 2004; Carter, Thompson et al. 2006). The 
sheer number of DC receptors with overlaps in specificity and function makes the 
study of individual receptors difficult. While monoclonal antibodies and gene knock-out 
animals will assist in elucidating their roles, the lack of knowledge poses a problem for 
selecting the right receptor for a DC targeted vaccine.
Depending on the nature of the antigen, phagocytosis may result in class I or II 
biased responses mediated by Th1 and Th2 cells respectively. For instance, antigen 
coated onto beads, which are phagocytosed, are presented via MHC class I, whereas 
antigens contained within cell fragments are predominantly MHC class II restricted 
(Kovacsovics-Bankowski, Clark et al. 1993; Inaba, Turley et al. 1998). It has been 
shown in a murine tumour challenge model that phagocytosed antigen bound to beads 
can access cross presentation pathways (Ackerman, Kyritsis et al. 2003; Houde, 
Bertholet et al. 2003). Such presentation results in protective CD8 T cell responses 
which were not seen following immunisation with soluble antigen (Falo, Kovacsovics- 
Bankowski et al. 1995). The role of DC receptors in phagocytosis is still debatable as 
establishing a direct causal link is often difficult (Kerrigan and Brown 2009). In contrast 
to phagocytosis, which is responsible for uptake of large particles, lipid raft mediated 
endocytosis takes up small particles and many viruses are known to enter the cell 
through caveolae mediated endocytosis, including BARS (Wang, Yang et al. 2008) 
and RSV (Werling, Hope et al. 1999). However, the effects of delivering antigens via 
this pathway have not yet been well described.
Though targeting of antigen to specific receptors has been shown to have 
encouraging effects on antigen presentation and to influence the ensuing immune
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response, the type of DC being targeted is often overlooked. Targeting the correct DC 
is an important consideration, as some DC subsets are specialised in cross- 
presentation and not all DC types express every receptor (Schnorrer, Behrens et al. 
2006; Burgdorf, Schuette et al. 2010). A recent study showed that targeting of an HIV 
peptide to different receptors (specifically CD205, CD207 and ClecQA) expressed 
specifically on CD8+ cDCs resulted in comparable Th1 and CDS T cell responses 
(Idoyaga, Lubkin et al. 2011), suggesting that the phenotype of the targeted cell may 
play a more important role than the receptor itself. What this study did not address was 
the potential roles that adjuvants may play in shaping the immune response.
1.4. The role of adjuvants in potentiating subunit vaccines
1.4.1. The appropriate adjuvant for the appropriate response
Traditionally, vaccine adjuvants were identified on an empirical basis. Using 
this method several commonly used adjuvants such as alum and Freund’s adjuvants 
were discovered. It is only recently that their method of action has been, to some 
extent, elucidated. Many of these adjuvants such as Freund’s and QuilA are unsuitable 
for immunisation of humans due to contraindications (Aguilar and Rodriguez 2007). 
Others such as alum are widely used, however the response stimulated is strongly 
biased towards stimulation of Th2 with almost no CDS cytotoxic T lymphocyte (CTL) or 
Th1 activation observed (HogenEsch 2002). There is a growing interest in using Toll­
like receptor (TLR) ligands as vaccine adjuvants with the TLR-4 agonist 
monophosphoryl lipid A (MPL) having been licensed for use in humans (Reed, 
Bertholet et al. 2009). TLR ligands are molecules commonly shared by pathogens; 
termed pathogen associated molecular patterns (PAMPs), which allow cells to identify 
when they may be under microbial attack. The TLRs themselves share several 
features. For instance, all have leucine-rich repeats in their extracellular domain, which 
are important for ligand recognition, and all have intracellular domains involved in cell
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signalling (Werling, Jann et al. 2009). In most cases, downstream signalling is 
mediated by a Myd88 cascade and subsequent activation on N F-kB  (Kaisho and Akira 
2002). However, for TLR-4 and -3 signalling, Myd88 is dispensable and both can 
stimulate the release of large quantities of IFN-(3 through alternative mechanisms 
(Takeda and Akira 2004). As a result of TLR signalling there is a release of 
inflammatory cytokines and, in certain cases, type I IFNs (Boehme and Compton 
2004).
TLR mediated DC maturation represents a significant stage in immunity, as 
antigen presentation in the absence of a maturation signal leads to tolerance (Probst, 
Lagnel et al. 2003) and TLR stimulation enables DCs to prime naive T cells (Kaisho 
and Akira 2003). The signal provided by TLRs has been described as signal 0, where 
signals 1 and 2 are T cell receptor stimulation and co-stimulation, respectively. This 
clearly illustrates the importance of TLRs as initiators of the immune response (Schijns 
2000). The nature of the danger signal received is pivotal in deciding the type of 
immune response to be generated (Coffman, Sher et al. 2010).
Due to the intracellular nature of viral replication, these infections tend to 
stimulate receptors situated either within the endosome or in the cytosol. However, the 
exact usage of the receptor is dependent on the type of virus. For instance, coxsackie 
virus can activate TLR-4, while herpes viruses have CpG motifs on their DMA that are 
recognised by TLR-9. Other enveloped viruses such as Flaviviruses can activate TLR- 
2 (Finberg, Wang et al. 2007). TLR-3 and TLR-7/8, which are both located in 
endosomes, are also relevant in viral infection since they recognise double and single 
stranded viral RNA, respectively. Double stranded RNA is also recognised as a danger 
signal by the cytosolic RNA helicases, MDA5 and RIG-I (Matsumoto and Seya 2008).
Polyinosinic-polycytidylic acid (Poly (l:C)) is a commercially available dsRNA 
analogue shown to bind both TLR3 and cytosolic RNA helicases. Poly (l:C) stimulates 
the maturation of DCs and polarises them towards a Th1 response (Navabi, Jasani et
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al. 2009). The induction of Th1 polarizing cytokines, particularly IL-12, by poly (l:C) is 
superior to TLR7/8 agonists. Furthermore, not only does it induce IFN-y secreting Th1 
cells, but also actively inhibits IL-5 secreting Th2 cell differentiation (Benwell, Hruska et 
al. 2010). In addition, poly (l:C) has been shown to increase cross-presentation and 
thus induce CTL responses (Schulz, Diebold et al. 2005). Of the other TLR ligands, 
only CpG deoxynucleotides have been found to induce cross-presentation to the same 
extent (Datta, Redecke et al. 2003). Whilst cross-presentation has been shown to be 
enhanced through TLR-3 signalling, induction of MDA-5 by poly (l:C) prolongs the 
survival of CTL, resulting in improved memory (Wang, Celia et al. 2010). Poly (l:C) 
has shown to be an effective adjuvant in a number of vaccine settings. For instance, 
when combined with hepatitis C virus (HCV) NS3 protein, cell mediated immunity 
develops and this leads to long term protection (Zabaleta, Arribillaga et al. 2007). 
Indeed, by employing a systems biology approach it has been demonstrated that poly 
(l:C) delivered subcutaneously induces a similar transcriptomic profile to that of the 
successful yellow fever virus vaccine (Caskey, Lefebvre et al. 2011). In vivo, the use 
of poly (l:C) to treat cancer reached phase II trials, but was abandoned due to 
observed toxicity after repeated administration of high doses (Lahiri, Das et al. 2008).
1.4.2. Particulate systems as adjuvants
In previous studies the combination of poly (l:C) with particulate systems has 
been explored. It was found that the formulation of polyketal particles with poly (l:C) 
induced greater CD8 T cell responses than particles alone (Heffernan, Kasturi et al.
2009). Poly (lactic: glycolic) acid microparticles have been coated in poly (l:C) which, 
when endocytosed, induced maturation of DCs (Wischke, Zimmermann et al. 2009). 
Other studies have shown that co-encapsulation of antigen and poly (l:C) stimulates 
DC resulting in a CD4 and CD8 T cell mediated immunity (Hamdy, Elamanchili et al.
2007). Despite the differing strategies, the consensus reached in these studies is that 
poly (l:C) is more effective when delivered constrained to an antigen loaded particle
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compared to co-administration. This may be due to the sustained release of poly (l:C) 
or the ability of nanoparticles to reach endosomal or cytosolic compartments.
There is increasing evidence to suggest that delivery of antigen contained 
within a discrete particle may have advantages over soluble antigen. For instance, 
particles formulated with tumour antigen and Monophosphoryl Lipid A are better at 
priming naïve T cells than both components delivered separately (Elamanchili, Diwan 
et al. 2004). This example highlights another feature of particulate delivery in that the 
adjuvant and the antigen can be delivered to the same ARC at the same time, which 
according to the classical paradigm, is necessary to stimulate a good immune 
response (Storni, Kundig et al. 2005). Co-encapsulation of antigen and adjuvant within 
a single particle has been shown to increase vaccine potency one hundred fold in 
comparison to soluble adjuvant such as TLRL (Tacken, Zeelenberg et al. 2011). The 
dose limitation and slow sustained release negates potential harmful effects, such as 
cytokine storm which is the release of pro inflammatory cytokines (especially TNFa) en 
masse leading to fever and malaise, these are usually seen during infection but may 
also be induced following systemic administration of TLR agonists (Clark 2007; 
Tacken, Zeelenberg et al. 2011). In a second study it was shown that both coating and 
loading peptide onto a particle increased the vaccine potency by twenty fold (Clawson, 
Huang et al. 2010). Particulate systems have been specifically shown to improve both 
MHC class I and II presentation by DC by a factor of fifty. Furthermore, the antigen 
presentation window: the duration of time the antigen is displayed on the MHC is 
extended (Audran, Peter et al. 2003; Waeckerle-Men, Allmen et al. 2006)
It has been demonstrated that particles, even without the addition of adjuvant, 
are comparable to incomplete Freund’s adjuvant in their potential to stimulate T cells 
and antibody production (Mueller, Schlosser et al. 2011). This example illustrates that 
the adjuvant effects observed with particles are likely to be due to the colloidal nature 
of the system and the sustained release of antigen, as is the case with Freund’s
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(Billiau and Matthys 2001). Compared to alum, particulate systems have demonstrated 
a significant improvement in the immune response. This was shown using a HBV 
vaccine antigen in a therapeutic setting (Yue, Wei et al. 2011). Nanoparticles were 
shown to enhance both the CTL and antibody response, an effect the authors attribute 
to the intracellular trafficking of the antigen (Yue, Wei et al. 2011).
The behaviour of the particle within the cell is another interesting property of 
particulate delivery in that particles enhance cross presentation. It is therefore 
theorized that the antigen can escape the endosome or phagosome to the cytostol 
(Walter, Dreher et al. 2001; Shen, Ackerman et al. 2006). This would support the 
hypothesis that particulate antigen is cross presented using the more traditional 
phagosome to cytosol mechanism. Recently however, it has been reported that while 
the antigen is cross-presented the particle remains constrained in the phagosome 
(Walter, Dreher et al. 2001; Schliehe, Thiry et al. 2011). This therefore leads to the 
conclusion that the antigen must be released from the particle and travel to the cytosol, 
possibly leaving the particle constrained within the intact endosome, Sec61, which is a 
channel protein mediating movement between membrane bound organelles and the 
cytosol, has been implicated in this role (Lin, Zhan et al. 2008; Amigorena and Savina 
2010). The use of the phagosome to cytosol mechanism is controversial, however, as 
there are some who put forward a strong case supporting the theory that particulate 
antigen may also be presented via the vacuolar pathway (Rock and Shen 2005; 
Hamdy, Haddadi et al. 2011), which closely resembles the MHC class II pathway. For 
instance, it has been shown that cross-presentation of OVA loaded PLGA particles is 
unaffected by the presence of lactacystin, a proteosome inhibitor, and only slightly 
affected by brefeldin A, an ER/golgi transport inhibitor. MHC class I presentation is 
however strongly inhibited by chloroquine, an inhibitor of phagosomal enzymes, and is 
dependent on the transporter associated with antigen processing (TAP) (Gerelchuluun, 
Lee et al. 2007). It was thus concluded that at least the protein degradation process
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must occur within the phagosome as it bypasses the ubiquitin proteasome pathway. 
Indeed, it has been shown that phagosomes may be able to cross-present antigen, 
independent of the proteasome (Houde, Bertholet et al. 2003). Antigen is degraded by 
phagosomal peptidases such as cathepsin S, and subsequently fed into the recycling 
MHC class I pathway (Shen, Sigal et al. 2004; Gerelchuluun, Lee et al. 2007). The 
implications of this were demonstrated by Shen and Rock (2006) who showed that not 
only do particles enhance cross-presentation, they enable cells otherwise unable to 
cross-present, in this case B cells, and effectively stimulate CDS T cells (Shen and 
Rock 2006). It has also been suggested that the early events in particle processing are 
identical between different types of particles, while in the more mature phagosome 
there is differential regulation of cathepsin L (Oh and Swanson 1996). Certain types of 
particles, such as poly-ethylenimine (PEI), have been shown to enhance this property 
(Chen, Li et al. 2011). Furthermore, certain molecules used to coat the surface of the 
particles, for example protamine, have also shown to increase cross-presentation 
(Han, Zhu et al. 2011). It has been speculated that the extent and rate of acidification 
of the endosome is a key determinant of whether an antigen is cross-presented or not 
(Savina, Jancic et al. 2006). Buffering of the lysosome has also been observed in 
some types of particulate delivery (Hirosue, Kourtis et al. 2010). Interestingly, though 
the endosome is not acidified, the interior of the particle develops a very low pH due to 
a build-up of breakdown products with larger particles becoming more acidic than 
smaller ones (Fu, Pack et al. 2000). In addition, there seems to be a link between 
particle size and cross-presentation. Very small particles progress rapidly to the acidic 
compartments and are poorly cross-presented, whereas larger particles linger in more 
neutral compartments and are cross-presented well (Tran and Shen 2009). The effect 
of surface charge is not so clear, for example, both PEI and protamine are positively 
charged and it has been shown that the more positively charged the particle the more 
likely it is for antigen to be cross-presented (Yue, Wei et al. 2011). It is also known that
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antigens carried by PLGA particles, which are negatively charged, are also cross­
presented (Zhang, Tongchusak et al. 2011). If the reason for the enhanced cross­
presentation observed with particles is due to the buffering of the endosome, then 
logically it could be speculated that negatively charged particles would perform better 
as they could mop up excess hydrogen ions. However, from the given examples it is 
clear this is not always the case. An answer to this paradox may come in the form of 
the ‘proton sponge hypothesis’, according to which cationic micelles (in particularly 
PEI) may burst the endosome through induction of osmotic stress, and release their 
contents to the cytosol (Panyam, Zhou et al. 2002; Akinc, Thomas et al. 2005; Yue, 
Wei et al. 2011). Combining all these observations, it is clear that particulate systems 
have a privileged position in being able access cross-presentation pathways. This is 
likely to be due to a combination of their physical parameters and the inherent 
properties of the materials used in their production (Elamanchili, Lutsiak et al. 2007).
Stimulating both arms of the immune system is often an important 
consideration in designing a successful vaccine. Particulate systems have been used 
to stimulate the production of antibody in response to OVA to the same extent as 
complete Freund’s adjuvant. The predominant isotype was shown to be lgG1, and 
could be detected over a period of 18 weeks (Bennewitz and Babensee 2005). In other 
examples however, a higher lgG2a response has been observed (Mata, Igartua et al.
2010). In many cases it has been shown that particles are able to stimulate good cell 
and antibody mediated immune response simultaneously, which is often better than 
conventional adjuvants (Jaganathan and Vyas 2006; Saini, Jain et al. 2011). As with 
cell mediated responses, the physical properties of the particle have been shown to 
influence the strength of the antibody response. Though it has not been studied in 
detail, better antibody responses have been observed when using neutral or positively 
charged particles compared to strongly negatively charged particles (Thomas, Gupta 
et al. 2009). When coated with positively charged chitosan, otherwise negatively
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charged PLGA particles were shown to improve antigen specific antibody responses 
(Pandit, Cevher et al. 2007). Many authors attribute this to improved phagocytosis of 
cationic particles, though establishing a direct causal link may prove difficult (Martinez 
Gomez, Csaba et al. 2008). The size of the particles has an effect on the antibody titre; 
larger particles give rise to lower antibody titres (Katare, Muthukumaran et al. 2005). 
Taken together with the cross presentation observations, a complex picture builds, in 
which it is probable that the intracellular fate of the particle is pivotal in determining the 
magnitude and type of response generated. It is possible the efficient trafficking of 
protein from the particles to MHC class II rich compartments is particularly important in 
the generation of an antibody response. To complicate this picture further, it has 
recently been shown that adjuvant and antigen delivered in separate particles 
stimulates the best antibody response. This includes increased memory B cells and 
antibody titres which are several orders of magnitude greater than stimulated with co­
encapsulated antigen and adjuvant (Kazzaz, Singh et al. 2006; Kasturi, Skountzou et 
al. 2011). This indicates that there is a spatiotemporal relationship between the cells 
receiving the adjuvant and antigen. It is uncertain how this fits into the established 
dogma which suggests that concurrent delivery of both molecules to the same 
compartment provides the best response (Kasturi, Skountzou et al. 2011). It is likely 
that TLR signalling by the B cell itself plays an important role in the generation of the 
antibody response, as it has been shown that good lgG2b titres in response to 
particulate systems are dependent on MyD88 being present in the B cell and it is not 
required in the DC (Ruprecht and Lanzavecchia 2006; Hou, Saudan et al. 2011). The 
converse is observed when soluble antigen is used (Hou, Saudan et al. 2011).
Due to the versatility of particles, various modifications can be made, which 
could not be made to the antigen without potentially destroying immunogenicity. This 
allows for a more tailored immune response. These modifications may include; coating 
particles with cationic molecules (thus changing the charge), conjugation to ligands or
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other targeting molecules for DC receptors, or modification to delay mucosal 
clearance.
While there are many questions to be answered, the use of particulate systems 
to deliver vaccines is steadily becoming a more realistic prospect. Due to their 
successful application in in vitro and in vivo models, their relative safety and good cost 
to effectiveness ratio, it seems probable that the first particulate vaccines will become 
available within the coming decade (De Temmerman, Rejman et al. 2011).
1.5. Conclusions and study aims
Subunit vaccines are an attractive target to combat a wide range of viral diseases for 
which current vaccines are suboptimal or do not exist. However, subunit vaccine 
development has often stagnated due to an inability to trigger an immune response of 
the appropriate type or magnitude. Many methods have been devised to overcome 
these problems and some have shown success, though few have yet been made 
commercially available. Current literature strongly suggests that by selecting to target 
the vaccine to DCs, a significant increase in potency can be attained. Furthermore, by 
delivering the vaccine in a format which is representative of the pathogen the likelihood 
of stimulating the appropriate response is improved. To attain the optimal vaccine 
formulation these methods should be employed in unison. In the majority of studies, 
evaluation of novel technologies in vivo has utilized murine models, which are not 
always comparable with humans or veterinary species (Ferrie, Mohammed et al. 
2008). With these factors in mind, this project aimed to devise and evaluate a rationally 
formulated nanoparticulate subunit vaccine in a bovine model. The project consisted of 
three objectives, the results of which are presented in separate chapters.
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1.6. Objectives and hypothesis
Based on the strength of literature this project proposes to create and test a 
nanoparticulate sub unit vaccine delivery system. It is therefore hypothesised that an 
immunogenic viral antigens formulated within a nanoparticulate system should be able 
to protected model organisms from viral challenge. What’s more the levels of 
protection should be comparable to a traditional vaccine, which will be used as a proof 
of concept.
1. To establish and optimize protocols for the synthesis and characterisation of 
nanoparticles for antigen delivery.
2. To evaluate in vitro the uptake of nanoparticles by bovine DCs and the effects 
of coating with ligands for DC receptors and anti-receptor antibodies.
3. To evaluate in cattle the immunogenicity and efficacy of a rationally designed 
nanoparticulate formulation of bovine viral diarrhoea virus antigens.
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The Development of Methods to Synthesise 
and Characterise Poly (lactic:glycolic) acid
Nanoparticles
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2.1 Abstract
The use of poly(lactic:glycolic) acid (PLGA) to synthesise nanoparticulate 
systems for antigen/vaccine delivery is strongly supported in the literature. However, 
between groups there are great discrepancies in the methods used to generate and 
characterise nanoparticles. This chapter describes efforts to optimize an in-house 
procedure for the production of nanoparticles of desired properties for use in particulate 
vaccine production. Furthermore, it highlights the methods developed to characterise 
the resultant particles, in particular the relatively novel use of flow cytometry as a 
means of describing these particles which would overcome many limitations in the 
current systems. Various parameters within the methods were altered to determine 
their effect on the physical properties (such as charge and size) of the ensuing 
particles. It was found that sonication duration had little impact on size, the surfactant 
concentration likewise only slightly effected size, however, greatly impacted the charge. 
The loading of the particles with protein was in a large part determined by the starting 
levels of protein, with initial PLGA concentration playing a minor role. The particles 
generated were within the desired nano size range, displayed a net negative surface 
charge and could be loaded with 0.3 mg of protein per 50 mg PLGA. The methods for 
particle synthesis/characterisation reported in this chapter formed the basis for the 
subsequent research in this project.
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2.2 Introduction
2.2.1 Nanoparticles
A nanoparticle is, in essence, a particle falling in the nano size range (1 nm-999 
nm) usually consisting of either: a heavy metal (gold or silver are most common), a 
synthetic polymer (e.g. polystyrene) or a natural polysaccharide (e.g. chitosan) (Amidi, 
Romeijn et al. 2006; Dincer, Jones et al. 2006). Nanoparticles can be used to 
encapsulate, to conjugate to, or to incorporate (via cross linking with the polymer 
matrix) antigen and offer an attractive alternative to traditional vaccine delivery systems 
(Nimesh, Aggarwal et al. 2007). Nanoparticles are small enough to be efficiently taken 
up by professional antigen presenting cells (ARC), as they regularly sample the 
environment in search of exogenous antigens. In the literature, nanoparticles are 
usually described as being either an adjuvant or a delivery vehicle. In many regards 
both descriptions are correct, they act in a similar fashion to emulsion based adjuvants, 
since within the body they form a depot prolonging antigen release. However, whilst 
emulsion adjuvants form antigen depots within the extracellular space, nanoparticles 
form antigen depots within APCs, releasing antigen over a period of time.
2.2.2 Poly (Lactide-co glcolide) acid nanoparticles
Of the types of nanoparticles currently being evaluated for vaccine delivery, the 
biodegradable, non-toxic polymer poly (lactide-co glcolide) acid (PLGA) is one of the 
most promising (Wischke and Schwendeman 2008). There is some debate whether 
PLGA alone can cause maturation of DC, although data exists showing PLGA induced 
maturation of both human monocyte and murine bone marrow derived DCs (Yoshida 
and Babensee 2004; Yoshida, Mata et al. 2007). The fact that PLGA is hydrolysed 
slowly, allowing for prolonged antigen release and presentation make it the logical 
choice for nanoparticle production (Waeckerle-Men, Allmen et al. 2006). PLGA is an 
inert co polymer consisting of lactic and glycolic acid monomers. Due to the safety of its
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monomers the polymer is licensed for medical application by the Food and Drug 
Administration (FDA) in the USA. It is used commercially in the production of two 
drugs; Lupon Depot© for the delivery of leuprolide and Trelstar© for the delivery of 
triptorelin, both drugs are used clinically in the treatment of prostate cancer (Klose et al.
2008).
2.2.3 Properties of PLGA nanoparticles
PLGA is an incredibly versatile molecule that can be synthesised in a manner to 
produce desired properties. As mentioned previously, PLGA is a co polymer of lactic 
and glycolic acid linked together through ester bonding. The end terminal group of the 
polymer can either be modified into a methyl group (-CH3), ‘capped’, or left in its native 
carboxylic acid (-COOH) state, ‘uncapped’, the latter results in a more hydrophilic 
particle with an increased rate of degradation (Luan & Bodmeier 2006).
The ratio of lactic to glycolic acid is a key determinant in the speed at which the 
molecule is hydrolysed. Whilst glycolic acid is water soluble, lactic acid is insoluble in 
aqueous environments, thus altering the ratio in favour of glycolic acid results in a more 
rapid hydrolysis and protein release. Polymers with higher lactic acid content are more 
stable and have a steady release profile as the ester bonds are less accessible to 
water molecules (Shuyu Xie et al. 2009). Surprisingly polymers with equal monomer 
ratios degrade at the fastest rate and this is due to an autocatalytic effect triggered by 
the accumulation of break down products within the polymer matrix (Lu et al. 2000). All 
particles have what is described as a ‘biphasic’ release profile in which there is an 
initial ‘burst’ phase followed by a steadier leeching of protein. The burst phase is 
believed to be due to loosely bound protein being disassociated rapidly from the 
particle (Sneh-Edri, Likhtenshtein et al. 2011). Another associated factor that affects 
polymer degradation is the molecular weight, by increasing the length of the polymer it 
is more slowly hydrolysed thus affording a more sustained release (Mittal et al. 2007).
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2.2.4 Synthesis of PLGA nanoparticles
PLGA particles can be synthesised using a range of methods and these vary 
depending on the desired properties of the particles. The most commonly used 
technique is the solvent evaporation method, this has been used for encapsulation of 
both hydrophilic and hydrophobic molecules (Wischke and Schwendeman 2008; Xie, 
Wang et al. 2008). Using this method it is possible to generate particles in the nano 
and micro size range depending on the process parameters, particularly the rate at 
which the emulsion is formed (Mok and Park 2008). Other methods such as spray 
drying and salting out are also used, however the former is only applicable in the 
generation of micro sized particles (McCarron, Donnelly et al. 2006; Kim, Oh et al.
2009).
At the centre of all particle preparation procedures is the emulsion. In the case 
of the solvent evaporation method this is formed when PLGA, dissolved in the 
dispersed phase consisting of an organic solvent (o), is mixed rapidly with an aqueous 
or continuous phase (w) containing a stabilizer such as poly-vinyl alcohol (PVA). The 
solvent is then evaporated away either under atmospheric pressure with stirring or 
under the reduced pressure of a vacuum. The removal of the solvent triggers the 
precipitation and solidification of particles due to the insolubility of PLGA in the w 
phase. This oil/water (o/w) method is the simplest method of particle preparation and 
has been used to encapsulate hydrophobic drugs which are soluble in the dispersed 
phase (Wischke & Schwendeman 2008). A slightly more complex double emulsion 
method is used in the preparation of particles loaded with hydrophilic molecules, which 
are insoluble in the organic phase. In this method the molecule to be encapsulated is 
dissolved in an innocuous buffer forming the first aqueous phase (w-i) this is then 
emulsified with the oil phase containing the PLGA (w-i/o). The whole emulsion is then 
transferred to the second water phase containing the stabilizer (w2) thus forming a 
water/oil/water (wi/o/w2) emulsion and the solvent is then removed. This system is
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complex as there are a multitude of parameters, both physical and chemical, which can 
affect the stability of the emulsion as well as the quality of the particles generated.
The major drawback with PLGA nanoparticles is that the particle itself or the 
processing can directly affect the protein. This is reviewed by van de Weert et al. 
(2000) who highlight the possible stages in antigen/particle interaction where protein 
dénaturation could occur (van de Weert, Hennink et al. 2000). For instance, the protein 
may unfold in the reaction mixture during manufacture due to hydrophobic interactions 
or the protein may denature during particle degradation when the pH decreases to 1.5 
(Wang, Ge et al. 2004). Hydrophobic proteins are more unstable when formulated due 
to interactions with the solvent and a modified method may be used such as 
solid/oil/water or oil/oil to counter these problems (Kang and Singh 2003). Also the 
synthesis of particles involves sonication which may lead to protein dénaturation. This 
having been said, numerous studies have shown that antigen loaded nanoparticles, 
often produced by a variety of methods, can stimulate protective antibody responses, a 
process often highly dependent on protein conformity. It seems likely, therefore, that 
the stability of the protein is often more important than the method used to synthesise 
the particles (Rosas, Pedraz et al. 2002).
2.2.5 Characterisation and properties of PLGA nanoparticles
There are several parameters commonly measured when characterising nanoparticles.
2.2.5.1 Size of particles and the functional consequences.
The size of the particle is most commonly measured using dynamic light 
scattering (DLS). In this process, a laser beam is passed through a particle suspension 
and deflected photons are detected. The smaller the particle the more subject it is to 
Brownian motion and thus it scatters a greater amount of photons in a shorter period of 
time (Arcovito, Bassi et al. 1997). While this method is simple and effective, it requires 
costly specialist apparatus. Electron microscopy is an alternate method for analysing
31
Chapter 2: The development of methods to synthesis and characterise PLGA nanoparticles
size whereby particles can be measured against a graticule. This method’s reliably is 
dependent on the number of particles measured and the uniformity of the suspension.
The size of the particle has a significant effect on its performance in vivo, 
although there is some debate as to what the optimal size for antigen delivery is. 
Elamanchili et al. (2004) proposed that the effect of size is due to the various uptake 
methods available to APCs (Figure 2.1), arguing that larger particles, taken up by 
phagocytosis, provide the best outcome. The size of the particle can skew the type of 
immune response triggered; for stimulation of cytotoxic CDS T cell responses it has 
been suggested that 40-50 nm, approximately Flaviviridae size, provides the best 
response (Fifis, Gamvrellis et al. 2004). This differs from a humoral response, mediated 
by IL-4 and Th2 cell stimulation, which is optimally provoked after stimulation with 
particles c.100 nm in size (Mottram, Leong et al. 2007). It has further been speculated 
that larger particles (1pm and above) are mainly taken up by macrophages, while 
smaller particles target DC uptake (Xiang, Scholzen et al. 2006). Other groups propose 
that any particle within the nano size range will be taken up non-selectively by many 
different cell types in vivo (Jhunjhunwala, Raimondi et al. 2009). They therefore 
advocate the use of particles in the micro-range (microparticles) to target DCs. Larger 
particles c.SOOnm are also better at stimulating a Th1 orientated response (Brewer, 
Tetley et al. 1998)
To prevent the uptake of nanoparticles by non-APC, a ‘stealth’ layer of 
polyethylene glycol, which is repellent to proteins, at the surface of the particle may be 
added (Bazile, Prud'homme et al. 1995; Zahr, Davis et al. 2006). It appears that 
particles within the micro size range are inferior when receptor mediated endocytosis 
pathways are specifically targeted (Cruz, Tacken et al. 2010). This may be 
advantageous in some cases; Chakravarthi et al. (2009) capitalized on the ability of 
microparticles to remain bound to the surface of non-phagocytic cells, as a means to 
deliver anti-cancer drugs to the surface of solid tumours (Chakravarthi, De et al. 2010).
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Figure 2.1 Summary of cellular uptake pathways of particles of defined size
(From Xiang et al., 2006).
Size may also affect the localisation of particles following inoculation into he 
body. Larger particles remain near the site of inoculation where they are processed by 
the nearest ARC, commonly macrophages (depending on the site of inoculation) since 
they out number DCs in most peripheral tissues (Peyre, Fleck et al. 2004). In coniast, 
nanoparticles are taken up more rapidly and are quickly transferred from the 
inoculation site to lymphoid tissues (Horisawa, Kubota et al. 2002). It has alscbeen 
shown that for larger particles to be presented they must be taken up by CD and 
transported to the lymph node, this differs from smaller particles which do not eed to 
be cell associated to reach the lymph node, where they can be presentedby th e  
resident DC populations (Manolova, Race et al. 2008). This is due to thejmallest
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particles having direct access to the lymphatic system (Nishioka and Yoshino 2001; 
Oussoren and Storm 2001; Reddy, Rehor et al. 2006). Depending on the desired 
outcome this property could be considered both a positive and negative asset. The 
species of the subject seems to have no effect on the optimal size of the particle; 
similar results using same sized particles have been observed in murine, ovine and 
bovine models (Scheerlinck and Greenwood 2006; Greenwood, Dynon et al. 2008).
2.2.5.2 Loading efficiency/capacity o f PLGA nanoparticles
Loading enough drug/antigen, the loading efficiency, into the particle is a major 
obstacle. In the case of chitosan particles greater than 90% of the initial drug can be 
loaded (Liu and Park 2010) however with PLGA, depending on method, loading more 
than 50% is rare and 20%-30% is a more realistic expectation. A multitude of factors 
influence loading efficiency, including properties inherent to the polymer and its cargo 
but by far the most important factor is the method used to synthesise particles. In 
processes with a long evaporation step there is more chance of the cargo diffusing into 
the water phase before the particles have had chance to harden. This is particularly the 
case in the solvent evaporation method and can be overcome by using a spray drier or 
evaporating under reduced pressure, since both methods hasten the removal of the 
solvent. There is a great discrepancy between micro and nano particles with the former 
being able to carry a lot more antigen. Loading capacity, which differs from the loading 
efficiency, is a measurement of the proportion of loaded particles loaded compared to 
the unloaded. When using PLGA, due to the nature of the emulsion method, loading 
capacities of greater than 90% are often observed. The difference between loading 
efficiency and loading capacity is that, where the efficiency takes into account the 
starting amount of protein relative to the encapsulated amount, the loading capacity is 
a measure of the amount of particles able to be loaded with a given quantity of protein.
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2.2.5.3 Surface properties of PLGA nanoparticles
Depending on the type of particle the surface charge can vary considerably, for 
instance, chitosan has multiple amine groups giving the polymer a net positive charge, 
whereas PLGA carries a net negative charge due to acidic residues. The surface 
charge has an important role in stabilizing the emulsion during particle synthesis; if the 
particles have too weak a charge, the emulsion cannot support itself and will collapse.
Due to its anionic nature PLGA is difficult to use in combination with other 
negatively charged molecules such as nucleic acids, and as the cell membrane has a 
net negative charge, uptake may be impaired if used alone. This problem has been 
overcome in the past by including cationic coating molecules for instance 
polyethylenimine (PEI) (Martinez Gomez, Csaba et al. 2008), protamine, DEAE dextran 
and chitosan (Kumar, Mohapatra et al. 2004). This coating in turn can affect cellular 
processes, for example Fischer et al. (2007) demonstrated that an empty microsphere 
coated with PEI stimulated an IL-12 response whereas other cationic coating 
molecules trialled did not. If the particle carries too strong a positive charge it may be 
detrimental to cell viability due to accumulation of particles at the negative cell 
membrane preventing cellular transport (Regnstrom, Ragnarsson et al. 2003; Fischer, 
Uetz-von Allmen et al. 2007).
The surface may also be coated in order to confer a desirable property to the 
particle. For instance, particles may be coated in order to enhance muco-adhesion 
(Takeuchi, Yamamoto et al. 2001) if organs such as the gut (Makhlof, Werle et al.
2011) or the bladder (Barthelmes, Perera et al. 2011) are the desired targets. 
PEGylation of nanoparticles has been shown to be advantageous when targeting 
tumours due to delayed clearance time (Parveen and Sahoo 2011). Antigens, instead 
of being loaded, may be coated onto the surface of the particle. This method of delivery 
has many of the same advantages as loading in that it protects the antigen and allows 
for sustained release, though the extent to which the two methods are comparable has
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not been comprehensively described. Coating has been shown to induce strong 
humoral and cell mediated immunity (Ataman-Onal, Munier et al. 2006). Differences in 
immune responses between antigen loaded and antigen coated PLGA nanoparticles 
have yet to be established. However, when using liposomes there is data to suggest 
that coated antigen is better at stimulating antibody responses, which may be due to 
the antigen being more accessible to B cells (Latif and Bachhawat 1987).
Of the particles commonly described in the literature PLGA has many 
advantages over its counterparts, predominantly its safety, its relative ease of use and 
its versatility as a molecule. Siphoning from the literature the most desirable traits of a 
nanoparticulate system and the optimal means by which to construct such a system is 
challenging given the number of methods and parameters to consider.
2.2.6 Hypothesis
This section aims to establish a nanoparticulate system suitable for use in 
subsequent studies and large animal trials. Various methods will be used to alter the 
physical parameters and protein loading profile. The hypothesis is, therefore, that 
through modification of methods a particle can be formulated of approximately SOOnm 
which can incorporate sufficient amounts of protein to be used to vaccinate a large 
mammalian species.
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2.3 Materials & Methods
2.3.1 Particle synthesis
Acid terminated PLGA (Resomer RG502 H, 50:50, Mw 7-17 KDa, Sigma, Poole, UK) 
was dissolved in ethyl acetate (Sigma) at a concentration of 25 mg/ml to form the oil 
phase (o). The antigen to be encapsulated was diluted to 5 mg/ml in PBS (Invitrogen, 
Paisley, UK) to form the first water phase (wi). PVA 1% (w/v) (98% hydrolysed Mw 13- 
23 KDa, Sigma) in distilled water was used as a stabilizer in the second water phase 
(w2). To form the first emulsion (w-i/o), w-i was rapidly added to the oil phase at a ratio 
of 1:10 and sonicated for 30 sec at an intensity of 14 microns. To form the second 
emulsion (w^/o/w2), wVo was added to w2 at a ratio of 1:5 and sonicated for 2 min at 
intensity of 18 microns. The final emulsion was added to a larger vessel and the 
solvent was evaporated overnight with stirring (250 rpm) at 37°C. The particles were 
collected by ultracentrifugation 40000g for 20 min and washed twice with distilled water 
to remove excess PVA.
2.3.2 Bicinchoninic acid assay for protein concentration determination
Micro BCA protein assay kit (Thermo Fischer Scientific, Runcorn, UK) was used 
according to manufacturer’s specification. Component A was mixed with component B 
at a 1:50 ratio to make the working reagent. Working reagent (200 pi) was then added 
to 25pl of sample and incubated at 37°C for 30 min. The absorbance at 595 nm was 
measured using a Victors microplate reader (Perkin Elmer, Seer Green, UK). Protein 
concentrations were calculated using regression analysis against a bovine serum 
albumin (BSA) standard titrated two-fold from 2 mg/ml.
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2.3.3 Loading efficiency
To calculate the total protein loading, a representative sample of particles was digested 
in 1 ml 0.1 M NaOH with 2% SDS overnight. The protein in the cleared digestion was 
concentrated using 10000 MWCO Ultra 0.5 ml Amicon centrifuge columns (Millipore, 
Watford, UK). The protein concentration was calculated using a micro BCA assay 
(Thermo Fischer Scientific). Total protein loading was calculated using a standard of 
OVA dissolved in 0.1 M NaOH with 2% SDS and regression analysis.
2.3.4 Particle sizing and surface charge
The hydrodynamic diameter of the particles was calculated using the dynamic light 
scattering (DLS) technique. Particles were sonicated briefly, dispersed in distilled water 
and analysed on a Zetasizer 3000 (Malvern Instruments, Malvern, UK). Particles were 
read in a disposable curvette at 25°C with a scatter angle of 90°. Eleven readings were 
made in triplicate. The spread of the size range was given as the poly dispersity index. 
Zeta potential measurement was used to determine surface charge in accordance with 
the protocol described above. However, in place of the disposable curvette a 
disposable zeta cell (Malvern Instruments) was used. Twenty readings of each sample 
were made in triplicate.
2.3.5 Scanning electron microscopy
Particles were air dried onto poly-L-lysine coated covers!ips (BD Biosciences, Oxford, 
UK) for 15 min at 37°C. The cover slip was then applied to double sided carbon (Agar 
Scientific, Stansted, UK) attached to a 13 mm aluminium stub (Agar Scientific) and 
sputter coated with gold to a thickness of 15 nm using an Emitech K550X Sputter 
Coater (Quorum Technologies Ltd, Ashford, UK). Particles were visualized using a 
Zeiss Evo LS10 scanning electron microscope (Zeiss, Welwyn Garden City, UK) at an 
accelerating voltage of 10-20 Kv.
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2.3.6 Coating of nanoparticles with protein
Particles were suspended at 10 mg/ml based on the starting amount of PLGA in 0.1 M 
2-(N-morpholino)ethanesulfonic acid buffer (IVIES) (Sigma) adjusted to pH 5.2 with 
0.1 M Hydrochloric acid (HCI). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
and sulpho-N-Hydroxysuccinimide (Sulpho-NHS)(Sigma) were added at a final 
concentration of 0.1 M, and then proteins were added at a final concentration of 5 
mg/ml. The reaction was carried out overnight with stirring (250 rpm) at room 
temperature. Following incubation, particles were collected by centrifugation at 14000g 
for 5 min and washed twice with Tris buffered saline (TBS). To neutralize reactive 
groups not utilized in the process and isourea intermediates, NPs were resuspended in 
2 ml of TBS per 10 mg of PLGA for one hour.
2.3.7 Assessment o f nanoparticles using flow cytometry.
2.3.8.1 Estimation of particle size using flow cytometry.
PLGA nanoparticles (1 mg) were added to 1ml PBS and analysed using a MACSQuant 
flow cytometer (Miltenyi Biotec, Bisley, UK). The particles were gated using forward 
(FSC) and side scatter (SSC) measurements visualised on log scales. Commercially 
available polystyrene particles of 200 nm and 500 nm (Sigma) and calibration beads of 
2 pm and 3 pm (Mitenyi Biotec) were used as size standards. A sample containing no 
particles was run to exclude background electronic noise. Particle size was estimated 
using linear regression with the SSC mean fluorescence intensity (MFI) of the 
commercial particles forming the standard curve.
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2.3.8.2 Particle counting using flow cytometry.
PLGA nanoparticles (1 mg) were diluted 1:100 in PBS and analysed using a volumetric 
flow cytometer (Mitenyi Biotec). The particles were gated on basis of their FSC/SSC 
profile. The number of events/p I multiplied by the dilution factor was used to calculate 
the number of particles/pl.
23 .8 .3  Assessment o f loading capacity using flow cytometry.
PLGA nanoparticles were loaded with Alexa Flour-647 or -488 conjugated OVA 
(Molecular Probes, Invitrogen, Paisley, UK) Fluorescent particles (1 mg) were diluted 
1:100 in PBS and analysed using a MACSQuant flow cytometer (Mitenyi Biotec). The 
particles were gated firstly on their FSC/SSC profiles then analysed for their 
fluorescence. Particles displaying higher mean fluorescence intensity (MFI) than hollow 
particles were deemed to be loaded.
23.8.4 Assessment of nanoparticle coating using flow cytometry.
The presence of antigen on the surface of the particle was assessed by flow cytometry. 
A sample of particles was incubated with the appropriate mAb for 15 min at room 
temperature. Particles were then resuspended in 1 ml PBS and washed twice by 
centrifugation 14000g, 5 min. The particles were then incubated with a corresponding 
fluorophore conjugated secondary antibody for 15 min at room temperature. Particles 
were washed as above, resuspended in 1 ml PBS, and antibody staining assessed by 
flow cytometry as described above.
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2.3.8.5 Flow cytometric sorting of coated and loaded PLGA nanoparticles
To evaluate the ability to sort PLGA nanoparticles, 4 sets of particles were prepared; 
empty particles, particles loaded with Alexa Flour-647 conjugated OVA, particles 
coated with Alexa Flour-488 conjugated OVA or particles loaded/coated with both 
fluorescent proteins. The four sets of particles were mixed in equal ratios, diluted in 
PBS at a density of 2x107 particles/ml and filtered through a 40pm cell strainer (BD 
Biosciences). Particles were sorted on a MoFlo Astrios FACS Sorter (Beckman 
Coulter, High Wycombe, UK) based on the fluorescence properties and the efficiency 
of the sorted particle populations was confirmed by analysis on a MACSQuant flow 
cytometer. The cell sorter was operated by the cell sorting facility (AHVLA, Weybridge)
2.3.9 Statistical analysis
All statistical analysis was performed using Graphpad prism 5.04 (Graphpad Software 
Inc, La Jolla, CA, USA). Two or one way analysis of variance (ANOVA) followed by 
Bonferroni’s post-tests were used for the analysis where indicated. Student’s T test 
was also carried where appropriate.
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2.4 Results
2.4.1 Optimisation of parameters for PLGA nanoparticle synthesis.
2.4.1.1 Effect of sonication times on nanoparticles
Since sonication time is an important variable in the formation of nanoparticles and 
there is considerable variation between published protocols, it was first sought to 
determine the optimal sonication time for both the w/o emulsion and the w/o/w double 
emulsion. Particles were synthesised using the described method however the duration 
of sonication of the primary or secondary emulsion was evaluated at 30, 60 and 120 
sec. The sonication time of the emulsion not being addressed in a given experiment 
was kept at a constant 60 sec. There was no significant difference in terms of 
nanoparticle size between the sonication times of both the primary emulsion (w/o) and 
the double emulsion (w/o/w) (Figure 2.2). The resultant particles were sized at 190 nm. 
Also shown in Figure 2.2 is the polydispersity index this is a measurement of how 
random the system is, all these values are within the accepted range set by the zeta 
reader and thus the system can be treated as monodisperse.
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Figure 2.2 The effect of sonication duration on PLGA nanoparticle size.
Hollow nanoparticles were synthesised using the w/o/w double emulsion method with 
PBS making up the Wi phase. Sonication duration of either the w/o emulsion (A) or the 
w/o/w (B) emulsion was varied. Sizing of resulting particles was performed using DLS. 
Error bars correspond to SD. The numbers over the bars represent the polydispersity 
index (RDI) and SD, representative data from one of three experiments is shown.
2.4.1.2 The impact of PVA concentration on PLGA nanoparticle size and charge.
PVA is the preferred stabilizer of choice for many groups and is known to affect 
both the charge and size of particles. Particles were synthesised using a range of PVA 
concentrations ranging from 1% to 3% of the w2 phase. As shown in Figure 2.3 varying 
the PVA concentration from 1% to 3% resulted in a slight decrease in size. However, 
regardless of the PVA concentration all particles synthesised remained within the nano 
size range. Through zeta potential analysis the PVA concentration could be correlated 
to surface charge, with 3% PVA particles possessing a charge of -6.77mV whereas 1% 
PVA particles were more negatively charged at -15.5mV.
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Figure 2.3 The effect of PVA concentration on nanoparticle size and surface 
charge.
Hollow nanoparticles were synthesised using the w/o/w double emulsion method with 
PBS making up the w-i phase. The concentration of PVA making up the w2 phase 
ranged from 1% to 3%. Sizing and zeta potential measurements were performed using 
dynamic light scattering as described. The values obtained for both particle
size/polydispersity (values over bars) (A) and surface charge (B) are displayed with
error bars corresponding to SD ***p<0.001 data representative of one of three
experiments.
2.4.2 Characterisation of PLGA nanoparticles using electron microscopy
As an alternative to DLS, characterisation of nanoparticles by electron microscopy was 
carried out. Electron microscopy provides a quick and simple way to test the success of 
the emulsion procedure. Particles can be analysed for both size and surface
morphology using scanning electron microscopy after coating with an electron dense 
metal. As Figure 2.4 shows, the vast majority of particles are within the nano size 
range, they also display a smooth surface which is typically seen in solvent evaporation 
methods but rarely seen when harsher methods, such as a spray drying, are used. This
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suggests the emulsion formed using this protocol produces desirable particles. There is 
considerable clumping observed in Figure 2.4A, possibly due to the drying of particles 
residing in hydrophobic pockets in the aqueous media. In Figure 2.4B, individual 
particles are shown that display similar sizes.
Figure 2.4 Scanning electron micrographs of hollow PLGA nanoparticles.
Representative particles synthesised using the w/o/w solvent evaporation method were 
dried onto poly-L-lysine covers lips before being sputter coated with gold and viewed by 
scanning electron microscopy. While (A) shows a clump of particles varying in size (B) 
shows individual particles displaying remarkable homogeneity, arrows indicate single 
particles. Micrographs feature the graticule 1pm reading for size estimation.
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2.4.3 Loading PLGA nanoparticles with protein
Proteins and biologically active molecules can be loaded into PLGA 
nanoparticles by incorporating them into the w-i phase. Protein content can be 
estimated using alkali digestion of nanoparticles followed by a BCA assay for protein 
estimation. The BCA is a sensitive assay which can detect protein down to a 
concentration of 15 pg/ml. It was found that this method was suitable for use with 
PLGA as background levels of absorbance from dissolved hollow nanoparticles were 
comparable to both water and BCA reagent alone suggesting minimal levels of 
interference or non-specific absorbance (data not shown). There are a number of 
factors affecting protein loading, often related to the spatial formation of nanodroplets 
within either of the emulsions, such as sonication time and intensity or factors 
pertaining to the number of loaded particles generated such as starting quantities of 
protein polymer. Figure 2.5 shows that increasing the starting amount of protein 
increases the quantity of protein incorporated. The lowest level of detectable protein 
was extracted from particles synthesised using a starting quantity of 0.25 mg protein. 
At 0.5 mg the quantity of detectable protein greatly increased to 0.2 mg thus 40% of the 
starting protein was loaded (loading efficiency). Starting with 1 mg or greater of starting 
protein resulted in loading of 0.25-0.3 mg indicating that the loading capacity had been 
reached. The amount of starting PLGA can also affect the amount of protein loaded 
and it is generally assumed that a larger quantity of polymer leads to more 
nanoparticles, which facilitates a greater quantity of loaded protein. It was found in this 
study that while increasing the amount of PLGA does lead to an increase in 
encapsulation this increase was by no means proportional (Figure 2.5B). For example, 
doubling the amount of PLGA from 50 mg to 100 mg only resulted in an increase of a 
few micrograms of loaded protein. None of the differences are substantial enough to 
justify using greater than 50mg PLGA per preparation.
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Figure 2.5 The effect of starting quantities of PLGA and protein on the final 
amount of protein loaded.
PLGA nanoparticles were synthesised with a range of starting quantities of protein (A) 
or PLGA (B). Particles were digested using alkali hydrolysis and released protein was 
quantified using a BCA assay. Protein concentrations were calculated using linear 
regression from a standard curve of OVA in lysis buffer. Statistical analysis was 
performed using a one-way AN OVA *** p<0.001 * p<0.05. Mean and SD of 3 readings 
is shown.
As the spatial formation of the oil droplet within the w2 phase affects protein loading it 
logically follows that sonication time and speed should play an important role in the 
determination of final protein loading. The size of the nanodroplet is related to the 
volume of the internal phase and the larger the droplet prior to evaporation the greater 
the loading. Figure 2.6 shows that altering the time of the sonication of the primary 
emulsion from 30 sec to 120 sec caused an almost 75% reduction in loading. The 
effect of altering the sonication time of the secondary emulsion is less apparent but still 
shows a similar trend to that observed in the primary emulsion.
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Figure 2.6 The effect of sonication time on protein loading.
Protein loaded PLGA nanoparticles were synthesised using the w/o/w double emulsion 
method with 1mg of OVA in PBS making up the Wi phase. Sonication duration of either 
the w/o emulsion (A) or the w/o/w emulsion (B) was varied. Protein estimation was 
performed using alkali digestion followed by BCA protein assay. Statistical analysis 
was performed using a one-way AVOVA * p<0.05. Mean and SEM of 3 readings is 
shown.
Particles were assessed to determine how the act of loading alters their size. 
Figure 2.7 shows the effects of loading particles with OVA and OVA plus the synthetic 
RNA analogue, poly (l:C). As previously described, the unloaded particles were 200 
nm, while the OVA loaded particles were 238 nm and the OVA plus poly (l:C) were 280 
nm in diameter. The equivalent incremental increases of 40 nm is suggestive that the 
molecular weight of the poly(l:C), which was not determined by the supplier, may be 
similar to that of OVA.
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Figure 2.7 The effect of loading on particle size.
PLGA nanoparticles were synthesised using the w/o/w double emulsion method, with 
either OVA or OVA plus poly (l:C) included in the w-i phase. Sizing was performed 
using dynamic light scattering. Mean of n=3 experiments is shown analysis was 
performed by one way AN OVA ***p< 0.001, error bars represent the SD.
Having successfully loaded the particles their stability in aqueous environments 
was assessed. Figure 2.8 shows the release dynamics of loaded protein particles 
mixed in PBS at room temperature. As a quality control each of the batches used were 
digested and total protein loaded was calculated. Over the 35 day period assessed, 
there was minimal protein being leeched from the particles and detected in the 
supernatants. This in turn is consistent with subjective visual observations that showed 
there to be minimal degradation in quantity and quality of the particles throughout the 
time course (Data not shown).
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Figure 2.8 Evaluation of the release of protein from nanoparticles.
OVA loaded nanoparticles were synthesised using the w/o/w double emulsion method 
and incubated in PBS with shaking at room temperature. At the indicated time points 
supernatants were harvested by centrifugation, concentrated and protein contents 
assessed by BCA assay. Total protein loaded was determined following alkali digestion 
of particles. Means and SD of 3 readings are shown, data representative of one of two 
experiments.
2.4.4 PLGA nanoparticle assessment using flow cytometry
2.4.4.1 Particle detection and sizing
Flow cytometry is a powerful tool currently used routinely to define cell 
populations based on morphology and phenotypic signatures. This technology has yet 
to find its way into mainstream particle analysis. This study sought to evaluate its use 
for the determination of various particulate parameters. Figure 2.9 shows the 
applicability of this method for estimating the size of nanoparticles. Particles of all sizes 
ranging from 200 to 3000 nm fell within the limits of detection for this machine. There 
was substantial overlap between the 200 and 500nm particles, suggesting these sizes, 
though easily detected, may not be easily discerned. The standard curve showed a
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strong correlation between the size of particles and their mean SSC readings, with an 
R2 value of 0.96. Using flow cytometry, the average size of two particle preparations 
were calculated to be 1035.9 and 1349.1 nm, which was 200 -  300 nm greater than the 
sizes calculated by DLS, 771 and 1187nm respectively. There was also a large spread 
in the side scatter values, possibly due to clumping, which may have resulted in an 
overestimate of particle sizes.
51
Chapter 2: The development of methods to synthesis and characterise PLGA nanoparticles
- - : ri ;
s-.- I 200nm
le i  1e2
FSC-A
3
-1 0 1 lei
SSC-À
1e2 -1 0 1 le i 1e2 -1 0 1 lei
FSC-A
100
UL2
5wCO
.0.0013X
1000 1500 2000 2500  3000 350 (0 500
Size (nm)
Figure 2.9 Assessment o f the suitability o f Flow cytometry analysis for 
nanoparticle size estimation.
Polystyrene particles of sizes 200nm (A) 500nm (B) 2000nm and 3000nm (C) were 
suspended in PBS and individually analysed by flow cytometry. The particles were then 
collectively analysed (D) and the mean SSC measurements for each of these particles 
were plotted against their respective sizes (G). PLGA particles of 771 (E) or 1187 nm 
(F), as determined using DLS, were analysed by FACS and size estimated using the 
standard curve (H). Data representative of one of three experiments.
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2.4.4.2 Assessment of loading capacity of particles
When optimizing the synthesis of nanoparticles it was important to ensure that 
the majority of the particles contained protein. Utilising fluorescently labelled OVA this 
was assessed with the use of flow cytometry. Figure 2.10A shows that when 75pg 
OVA-Alexa Fluor 647 was loaded into nanoparticles, at levels below detection using 
the BCA assay, almost 100% of particles were loaded. These near total loadings of 
particles were observed at both double and quadruple the protein quantities, 150 and 
300 pg, respectively. Furthermore, using the mean fluorescence intensity (MFI) the 
relative loading could be calculated (Figure 2.10B). The fluorescence of the particles 
increased in proportion to the starting quantity of protein. This data shows that with 
increasing starting quantities of protein there is greater loading on a per particle basis 
as opposed to more loaded particles being generated. The total loading capacity of the 
particles must be based almost entirely on inherent properties of the polymer but 
limited by the method parameters.
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Figure 2.10 Evaluation of nanoparticle loading of fluorescently tagged protein by 
Flow cytometry analysis.
PLGA nanoparticles prepared using 75, 150 or 300 pg of OVA-Alexa Fluor 647 in the 
Wi phase were analysed using flow cytometry. Particles were gated on the basis of 
FSC vs. SSC visualised on log scaling, and Alexa Fluor 647 fluorescence measured. 
Loaded fluorescent particles were defined as having fluorescence which exceeded that 
of the gated unloaded particles (A). In addition, the mean fluorescent intensity (MFI) of 
loaded particles was measured (B). Data representative of one of three experiments.
2.4.4.3 Particle counting using flow cytometry
For experiments evaluating particles, it is important to use an equal number per 
condition, especially when comparing different batches. To this end, volumetric FACS 
analysis was used to measure particle density and facilitate adjustments to batches to 
ensure equal numbers. Figure 2.11 shows that when two batches of particles, loaded 
with two different fluorescently tagged proteins, are counted on a volumetric FACS 
analyser and adjusted to compensate for differing densities, there were equivalent 
proportions of MoDCs (see chapter 3.2 and 3.3 for introduction and methods) taking up 
either one of the particles (18.21% Alexa Flour-488 and 17.39% Alexa Flour-647) or 
both particles (19.92%). This result indicates that particle counting may be a suitable 
means to control for variation in densities between batches of nanoparticles.
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Figure 2.11 Evaluation of particle counting using flow cytometry.
PLGA nanoparticles were loaded with either OVA-Alexa Fluor-647 or OVA-Alexa Fluor- 
488 in the w1 phase. Particle densities were determined using a volumetric flow 
cytometer and adjusted to an equal density (A, B). Values shown represent the particle 
density per pi. Bovine MoDCs were unpulsed (E) or pulsed with an equal number of 
both fluorescent particles (F). For analysis of particle uptake, viable cells were gated on 
typical FSC/SSC profile (C) and lack of staining with a viability dye (D). Percentage of 
cells fluorescing with Alexa Fluor-488, -647 or both dyes was determined (F).
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2.4.5 Coating of nanoparticles with antigen
There are a range of methods that have been used to coat protein onto the 
surface of PLGA nanoparticles, which can be divided into affinity or chemical 
conjugation based methods. In this study, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and sulpho NHS were employed/evaluated to form a stable amine 
bond between the amine groups on the protein, particularly those of lysine residues, 
and the carboxylic acid end group of PLGA. Figure 2.12 shows the results of a study to 
assess the amount of OVA bound to the surface of the particles after the coating 
process. There was a substantial amount of protein, 200pg, associated with the 
particles in the absence of cross linker. However, EDC had a positive effect on the 
amount of protein coated, increasing it by just under 0.1 mg.
The effect of coating on particle size was assessed using DLS and Figure 
2.12B shows the sizes of both coated and uncoated nanoparticles. The uncoated 
particles were shown to be about 50nm smaller than the OVA coated particles, sized at 
200 and 250 nm respectively. OVA coating of particles was additionally assessed by 
immunostaining of particles with specific antibody and visualisation using flow 
cytometry (Figure 2.12 C-E). There was negligible staining of un coated or EDC coated 
particles suggesting, that there is minimal non-specific binding of antibody and that the 
protein reactive groups on the EDC coated particles have been successfully 
neutralized. The OVA coated particles stained strongly with antibody with greater than 
90% of events being stained positive for OVA. This method allows both a relative 
quantification of coated protein and a calculation of conjugation efficiency (% of coated 
particles).
Since considerable amounts of OVA were found to bind to the particle surface 
even in the absence of EDC cross-linking, an experiment was conducted, under tissue 
culture conditions, to determine the relative stability of both affinity and chemically 
coated particles. The expectation was that the affinity bound protein would be more
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readily lost, for example due to binding competition with serum proteins, in the tissue 
culture medium. Figure 2.13 shows relative quantity of OVA present on the surface of 
particles over 32 days in tissue culture conditions. There was minimal loss of protein 
from the surface of particles coated with both OVA alone and EDC cross-linked OVA 
suggesting both methods can be used to form stable links between protein and particle. 
Interestingly, the MFI of the OVA alone was similar to that of OVA cross-linked via 
EDC; this is at odds with previous results which showed that EDC enhanced protein 
coating. This observation could be due to EDC binding resulting in conformational 
changes in the protein that affected antibody binding.
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Figure 2.12 Evaluation of protein coating of nanoparticles.
PLGA nanoparticles were synthesised and coated as described with or without the 
addition of EDC. The unbound protein in wash supernatants was estimated by 
measuring absorbance at 280 nm. The amount of surface bound OVA was calculated by 
subtracting the unbound protein (A). Statistical analysis was performed using a one-way 
ANOVA * p<0.05. Mean and the SD of 3 readings is shown. The size of particles coated 
with OVA and EDC was established using DLS (B). Statistical analysis was carried out 
using a student’s t-test *** p<0.001. Mean and SD of 3 readings is shown. Finally, 
coating was assessed using flow cytometry. Particles that were uncoated (A), treated 
with EDC (B) or treated with EDC and OVA (C) were incubated with mouse anti-OVA 
mAb followed by anti-mouse lgG1-APC secondary antibody. Staining was assessed 
using a MACSQuant flow cytometer. Data representative of one of three experiments.
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Figure 2.13 Evaluation of the stability of OVA coating on nanoparticles under 
tissue culture conditions.
PLGA nanoparticles were untreated (NT), treated with EDC (EDC), incubated with OVA 
(OVA) or treated with EDC and OVA (EDC + OVA). An equal number of particles were 
resuspended in 1 ml of RPMI-1640 medium supplemented with 10% FBS and 
incubated at 37°C. On the indicated days, particles were harvested by centrifugation 
then stained for OVA, analysed by flow cytometry and results expressed as mean 
fluorescence intensity (MFI). Means and SD of 3 batches of particles are shown. 
Statistical analysis was performed using a two way ANOVA; ns -  not significant, ***
p<0.001.
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2.4.6 Flow cytometric sorting of nanoparticles based on coating and loading properties
Sorting of PLGA nanoparticles with desired properties was finally considered in 
a proof-of-concept experiment. Four sets of particles were synthesised; untreated, 
loaded with OVA-Alexa Fluor-647, coated with OVA, and OVA-Alexa Fluor-647 
loaded/OVA coated. Following staining with OVA specific mAb and FITC-conjugated 
secondary antibody, the four populations were mixed together and then sorted into the 
respective populations (Figure 2.14). Flow cytometry analysis revealed that all sorted 
particle populations had been achieved with a purity of >90%.
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Figure 2.14 Evaluation of nanoparticles sorted by flow cytometry.
Empty particles, particles loaded with OVA-AF-647, empty particles treated with 
EDC/OVA and OVA-AF-647 loaded particles treated with EDC/OVA were mixed 
together and stained with anti-OVA mAb followed by anti-mouse IgG-FITC (A, B). The 
mixed population was then sorted into its component. The purity of the sorted particles 
was assessed by flow cytometry analysis of FITC and AF-647 (ARC) fluorescence 
using flow cytometry (C-F).
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2.5. Discussion
This chapter describes the successful establishment and optimization of 
methods for the synthesis and characterisation of PLGA nanoparticles. Nanoparticles 
have been synthesised that have been loaded and/or coated with the model antigen 
OVA. It further describes the development of innovative means of characterising and 
quality controlling nanoparticle preparations using flow cytometry.
When establishing a protocol to synthesise nanoparticles there are numerous 
factors to consider. These include factors linked to the desired properties of the particle 
such as the molecular weight or end group functionalities of the polymer. In this study 
mid-weight 50:50 PLGA was used since it is most commonly used and its 
characteristics are well described in the literature. Furthermore, acid terminated PLGA 
was used due to the reactive nature of its end groups. There is uncertainty in the 
literature as to how method parameters effect factors such as size, loading and surface 
charge. It may even be suggested that for each individual group a novel protocol must 
be generated taking into account factors often overlooked or not described in published 
papers such as; sonication vessel volume and dimensions, and sonicator output 
capacity.
Sonication is the method by which firstly, nanodroplets of Wi are formed in the o 
phase forming the w,/o and secondly the primary emulsion is dispersed in the w2 
phase. Thus, nanoparticle generation is directly dependent on the energy transferred 
during this process. It would be expected that a longer sonication time leads to a 
greater transfer of energy and smaller particles being produced, especially in the 
secondary emulsion (Mainardes and Evangelista 2005; Son, Lee et al. 2009). 
However, this was found not to be the case in this study, where adjusting sonication 
parameters had minimal effect on particle size. This result is consistent with a previous 
study (Song, Zhao et al. 2008) and may be due to the intensity of the sonication. Many 
groups sonicate at ‘full power’ (Maa and Hsu 1999), which likely differs between
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instruments and it may be that the sonication in the present study was more intense 
than in other reports. Sonication times shorter than 30 sec were not explored, but may 
be applicable to generate larger particles. In the literature, the consensus is that a 
sonication step is used when nanoparticles are desired. Homogenisation and other 
forms of less energetic mixing can be used to synthesise microparticles (Wischke, 
Lorenzen et al. 2006). For this study, the shortest possible sonication time (30 sec w/o, 
1 min w/o/w) that gave a stable emulsion, reached loading capacity and produced a 
particle within the desired size range were used. Excessive sonication has been 
shown to produce adverse effects, such as polymer degradation (Reich 1998).
Increasing the PVA concentration resulted in a slight decrease in size. This is 
likely due to a greater exclusion of the oil phase from the water phases. As a general 
rule, increasing PVA concentration results in a smaller particle. However, once a 
threshold level of PVA is reached the w2 becomes too viscous and nano sized droplets 
are not readily formed (Zambaux, Bonneaux et al. 1998). However, it has also been 
demonstrated that a higher concentration of PVA is required to stabilize nano 
emulsions due to a higher interfacial area (Budhian, Siegel et al. 2007) Here it has 
been demonstrated that the difference in the size of particles when PVA is used 
between 1% and 3% is negligible for generation of nanoparticles and both produce a 
stabilizing emulsion. Greater than 5% PVA has previously been shown to be 
detrimental to loading efficiency (Feczko, Toth et al. 2008). The PVA concentrations 
had a greater effect on surface charge. This could be due, in part, to residual PVA at 
the surface of the particle shielding the inherent negativity of the PLGA from detection. 
Indeed it has been reported that regardless of the washing protocol some PVA remains 
surface bound (Prabha and Labhasetwar 2004). This should be seen as a more 
important factor when designing experiments as PVA has been shown to impact 
cellular uptake (Sahoo, Panyam et al. 2002). Subsequently, 1% PVA was selected for
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use, which represents a slight compromise in size for the sake of less surface bound 
PVA, which is likely to have a greater impact on subsequent work.
Particles have been successfully loaded with protein through incorporation of 
protein into the w-i phase. Detection of loaded protein was assessed using alkali 
digestion followed by BCA assay. This method is widely used in the literature 
(Hernadez, Igartua et al. 1998) though it is known to give a slight underestimation, an 
alternative would be to use DMSO/NaOH/SDS to dissolve to particle followed by the 
BCA assay (Sah 1997). However, this method is more complicated and time 
consuming. The total quantities of protein loaded, as well as the loading efficiency, 
were found to be dependent on the amount of starting protein. At 0.5 mg a substantial 
quantity of protein could be loaded. The levels of loading reached a plateau when 1 mg 
of starting protein was used; using this quantity no more than 0.3±0.05 mg was loaded. 
This was because the loading capacity of the PLGA was reached. To validate this, the 
effect of the amount of PLGA was investigated. Strangely, increasing the amount of 
PLGA had little effect with loading never exceeding 0.3±0.05 mg, which is contrary to a 
previous report of PLGA having a significant impact on loading (Song, Zhao et al.
2008). It could be speculated that in the present system the bias is towards forming 
larger particles as the amount of PLGA is increased but this was not further looked into. 
The use of different volumes in each of the phases, especially the Wi combined with an 
increased PLGA may result in more encapsulation (Zambaux, Bonneaux et al. 1998). 
Alternately the ratio of PLGA to protein has been shown to play an important role 
(Feczko, Toth et al. 2008) and this could be evaluated in future work.
The loading efficiency of the established method was calculated to be 29%, 
which is consistent with the findings of Newman et al. (1998) who described an 
efficiency of 23%, but it was more than that achieved by Barichello et al. (1999) and 
less than Chong et al. (2005). Loading efficiency is highly dependent on the method of 
synthesis, the molecule to be loaded, and the type and size of particle. It is therefore
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not surprising to observe these differences. It further stresses the need for nanoparticle 
synthesis to be well characterised before implementation. Interestingly, it was found 
that shorter sonication of the primary emulsion led to a greater loading. This is in 
disagreement with some groups, who found that longer sonication resulted in a finer 
emulsion and more loading (Son, Lee et al. 2009). Other groups have found that 
sonication has little effect on loading (Lee, Lee et al. 2011). Since this study had 
demonstrated that sonication times of greater than 30 sec did not affect size of particle, 
any enhancement in loading may be independent of size and the actual number of 
nanodroplets may be an alternative determinant. The loading of the particles was 
found to increase size in accordance with previous studies (Sandor, Enscore et al. 
2001). The size increase is most likely to be caused by the presence and type of 
macromolecule but could also be due to particle swelling in the aqueous phases as a 
result of osmotic forces exerted on the particle by the protein. After the loading 
parameters were characterised, we sought to determine the levels of protein released 
in aqueous media. It was expected that the hydrolysis of ester bonds would positively 
correlate with the time incubated with PBS. Indeed in the initial burst phase it has been 
demonstrated that 19% of the cargo can be released (Rosas, Hernandez et al. 2001). 
This was not observed in the release assay described here. Consistent with this 
observation, when loading fluorophore conjugated protein the particles remain 
fluorescent while the supernatant remains colourless for greater than 1 month 
suggesting limited release of cargo. It is also believed that the initial burst phase is due 
to surface bound protein being released (Wierenga, Egmond et al. 2006). However, 
only OVA coated and not OVA loaded particles could be stained with OVA specific 
mAb suggesting limited absorbed protein. In addition, when protein was absorbed to 
particle surfaces it remained stably bound, so there is little evidence to indicate a burst 
phase in this system. The total absence of detection of any released protein in vitro 
could be due to the fact that the system was not aggressively stirred which has been
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shown to be essential for release (Shi, Caulfield et al. 2002). How this translates to in 
vivo release is not known at present, but this question could be answered by 
monitoring release of protein within the cell; this could be performed by co- 
encapsulating a flourophore alongside a quencher and tracking fluorescence as the 
two molecules de-localise on release.
Currently there are three systems used to characterise particles; electron 
microscopy, DLS and flow cytometry. Electron microscopy is useful for initial 
confirmation of the presence of nanoparticles and data regarding size and morphology 
can be gathered, however, only a limited data set can be viewed. DLS is the gold 
standard for size, surface charge and polydispersity calculation but it is expensive and 
limited to these three measurements. Flow cytometry has the potential to offer a great 
deal more than the two aforementioned methods including sizing and detection of 
surface bound ligands. In this system, flow cytometry could easily be applied to the 
assessment of particles of greater than or equal to, 200 nm by using both FSC and 
SSC readings as has recently been described (van Gaal, Spierenburg et al. 2010). 
Compared to cell sizing, particle sizing has been shown to correlate better to SSC than 
FSC in accordance with Mie scatter theory, this may also due to the SSC detector 
being more sensitive (Nakamura and Ishimura 2010; van Gaal, Spierenburg et al. 
2010). It should also be noted that SSC measures refractive indices, both polystyrene 
and PLGA have a similar values at 1.51-1.67 and 1.57 respectively, (Patterson, 
Stayton et al. 2009) so SSC was appropriate for the particles utilised in this study. 
Differences in refractive indices must be considered when attempting to size using 
different polymer matrices. Flow cytometry assays sized particles as larger than values 
obtained by zeta sizing, however they could easily be visualized within the boundaries 
of the flow cytometer’s detection. Each flow cytometer must be individually assessed 
and calibrated for the ability to detect nano-sized particles as each has a given 
threshold below which no events can be accurately detected. Indeed, a number of
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machines were compared with various outcomes (Lacroix, Robert et al. 2010). Flow 
cytometry may therefore be better suited to sizing microparticles.
Using flow cytometry, a high loading capacity was observed; greater than 90% 
of the particles were loaded with OVA. This should logically be the case providing that 
the emulsion was stabilized correctly and the suspension was maintained. Even when 
0.075 mg of fluorescent OVA was used as a starting amount protein could be detected 
in the particles using flow cytometry, although was below the limits of detection for BOA 
assay. It should be noted that the use of flow cytometry to quantify loaded particles is 
limited to fluorescently tagged proteins. Counting of particles for subsequent in vitro 
work has never been performed before and was dependent on the volumetric feature of 
the MACSQuant flow cytometry analyser. This could also have been performed on 
standard flow cytometry analysers with the inclusion of counting beads such as BD 
TruCOUNT™ control beads. Conventionally, particles are freeze dried and a quantity is 
weighed and reconstituted for use (Park, Yong Lee et al. 1998). This may be 
disadvantageous as during the freeze drying process damage due to ice crystal 
formation could occur. Also it may be difficult to obtain a uniform suspension when 
reconstituting freeze dried particles. Furthermore, when comparing particles which 
have been treated differently, for instance coated versus uncoated, the weights of 
individual particles are likely to be different resulting in a different number of particles 
when weighed. Sorting particles from a mixed population was also evaluated with 
promising results as previously observed (van Gaal, Spierenburg et al. 2010). This 
technology could have future downstream applications such as sorting particles of a 
defined size from a heterogeneous preparation or removing un-reacted particles 
following a conjugation reaction.
Another means of associating antigen with particles is to coat it onto the 
surface. This has been performed using a range of methods, most frequently the 
inherent negative charge of PLGA is used to coat cations such as poly-L-lysine (Kim,
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Jeong et al. 2005), protamine (Martinez Gomez, Csaba et al. 2008), chitosan (Manca, 
Loy et al. 2008) or DEAE-dextran (Wischke, Zimmermann et al. 2009). The now 
positively charged particle can bind to anionic molecules such as proteins or nucleic 
acid (Kumar, Mohapatra et al. 2004). In some cases this may be beneficial when the 
cation has adjuvant properties e.g. chitosan (Sui, Chen et al. 2010). However, there are 
also potential disadvantages; strong cations may exhibit the ‘proton sponge’ effect in 
the endosome preventing acidification which would ultimately impact antigen 
processing (Akinc, Thomas et al. 2005) and cationic molecules are often toxic to cells, 
though it has been demonstrated that particles may dampen some of these effects 
(Fischer, Uetz-von Allmen et al. 2007). There was evidence for this in the current study, 
with DEAE-dextran coated particles rapidly reducing cell viability (data not shown), for 
these reasons alternatives were sought.
Carbodiimides are common cross-linkers in organic synthesis and have been 
used to link hydroxyl (N.N'-diisopropylcarbodiimide, DCC) and amine (1-ethyl-3-(3- 
dimethylaminopropyl) carbodiimide, EDC) containing molecules to a carboxyl capped 
PLGA backbone (Cheng, Teply et al. 2007; Ghotbi, Haddadi et al. 2011). This can be 
done prior to, or after nanoparticle formation (Wang, Li et al. 2003; Chen, Yang et al.
2009). In this study EDC conjugation was performed after particle synthesis since it 
enabled work in an aqueous environment. EDC was shown to conjugate OVA to the 
surface of the particles. More interestingly, we found that OVA became stably 
associated with the particle in the absence of EDC. This is independent of charge and 
is likely due to hydrophobic interactions as has been observed previously (Tsai, Mehta 
et al. 1996). These interactions have been found to be dependent on the pH of the 
medium as well as the salt concentration (Tsai, Mehta et al. 1996). This may explain 
the greater efficiency observed when EDC was used, because the provided conditions 
would favour carbodiimide bonding (i.e. low pH and no salt) as opposed to a neutral
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pH and high salt which would have favoured affinity interactions (Tsai, Mehta et al. 
1996).
Coating of particles with OVA increased their size by about 50 nm and that 
surface-bound protein could be detected using monoclonal antibodies and flow 
cytometry analysis. This method has been used before by other groups who assayed 
for antigen on the surface of polyester nanoparticles (Parlane, Wedlock et al. 2009). As 
had previously been shown in this study, proteins will bind to nanoparticles non- 
specifically and it was important to ensure antibody incubation periods were optimized 
and as brief as possible. Also, since EDC particles are reactive towards proteins it was 
important that reactive groups were neutralized. Before switching to TBS as the 
neutralization media, as described by (Brandhonneur, Chevanne et al. 2009), 
ethanolamine (Keegan and Saltzman 2006) was used and found to give inadequate 
neutralization and high back-ground staining (data not shown).
The coating of the particles, regardless of which method was used, was found 
to be stable for greater than one month under tissue culture conditions. This was found 
to be the case despite the presence of serum proteins which may compete with the 
OVA if binding is not stable. Other groups have performed similar experiments to this 
but have used BCA assay or UV absorbance to determine protein leeching (Corrigan 
and Li 2009). The application of flow cytometry analysis here allowed conditions 
containing serum since the coated protein could be distinguished from serum proteins 
on the basis of antibody staining.
In summary, this chapter describes the development and optimization of a novel 
nanoparticle synthesis procedure for use in subsequent vaccine formulation studies. To 
this extent, parameters deemed important in the production of nanoparticles including 
sonication and PVA concentration have been assessed and the characteristics of the 
emergent particles relevant to vaccine formulation, for instance size, charge and 
loading have been defined. Using both established methods, such as DLS, and more
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novel flow cytometric based methods, individual batches of particles have been 
standardized and quality controlled.
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Chapter 3
Interactions of Nanoparticles with Bovine 
Dendritic Cells and the Enhancement of 
Uptake through Targeting with Natural 
Ligands and Monoclonal Antibodies
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3.1 Abstract
Targeting of particles to specific cells or receptors is an appealing prospect in the 
production of novel particulate vaccines. To this end, this chapter describes the 
evaluation of the use of natural ligands and monoclonal antibodies as targeting motifs 
for bovine dendritic cells. Methods were established to associate targeting moieties 
with PLGA nanoparticles. To assess enhancement of uptake after the addition of 
natural ligands a monocyte derived dendritic cell (MoDC) based model was 
established. For the assessment of monoclonal antibody targeting the model was 
expanded to include afferent lymph dendritic cells (ALDCs). While the use of some 
natural ligands, in particular mannan, proved unsuccessful at enhancing uptake, others 
such as chitosan showed promising initial data. The use of monoclonal antibodies 
raised against the DEC205 receptor, present only on ALDCs, was shown in competitive 
uptake assays to improve the number of ALDC becoming associated with particles as 
well as the number of particles taken up by individual cells.
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3.2 Introduction
The interactions of nanoparticulate vaccine delivery systems with DCs have 
been described well in the literature. However, due to the range of methods used to 
synthesise particles, it is necessary to individually characterise the effect of particles on 
DCs in a specific setting. Indeed, many groups have reported differing observations 
such as particles inducing maturation of DC or not (Babensee 2008). It is likely that 
differences in size and charge play an important role in the complex interaction 
between the polymer and the cell. Also, most of the previous studies have worked on 
human or murine DCs which may not be representative of veterinary species.
It is generally acknowledged that DCs are capable of taking up particles with a 
varied range of physical properties. Several groups have shown in vitro enhanced DC 
uptake of particles and concluded that specific targeting has been achieved. This 
conclusion is seldom challenged and the uptake of particles by diverse cell types is 
often overlooked. Recent studies have demonstrated that liposomes are taken up 
mainly by CD11c+ DCs and macrophages in murine lymph nodes, with macrophages 
being more efficient (Moon, Suh et al. 2011). Using a similar model, it was shown that 
PLGA microparticles are highly efficiently taken up by B cells, while this is less 
apparent in macrophages and DC, which are approximately equal in their uptake ability 
(Jewell, Lopez et al. 2011). Since DCs rather than B cells and macrophages should be 
the primary target of most vaccine delivery systems, these data suggest that particulate 
systems may need to be tailored for optimal responses.
Targeting of vaccines to DCs via specific receptors, as reviewed in Chapter 1, 
can be facilitated with the use of natural receptor ligands or monoclonal antibodies 
(mAbs) specific for DC receptors. Targeting mannose receptors through mannosylation 
is by far the most common means of targeting DCs through natural ligands. Indeed, 
protein mannosylation has proved effective at both improving antigen uptake and 
adjuvanting immune responses. The fruit of this labour can be observed in results of a
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successful pilot phase III trial of mannosylated mucin peptide in cancer immunotherapy 
when compared to placebo (Apostolopoulos, Pietersz et al. 2006). Mannosylation of 
particles has been performed by several groups with differing success. Ghotbi et al. 
(2011) demonstrated that mannosylation of PLGA NPs increased murine MoDC uptake 
of particles by 2 fold. However, the same group later published papers suggesting 
minimal enhancement of uptake, approximately a 5% increase (Ghotbi, Haddadi et al. 
2011; Hamdy, Haddadi et al. 2011). The methods used in each paper differed as did 
their criteria for success; in the first case they directly assessed particle uptake by flow 
cytometry and in the second case they additionally monitored changes in cytokine 
release by DCs incubated with particles. The authors attributed this inconsistency to a 
slight difference in the particle charge caused by the use of different antigens. 
Wattendorf et al. (2008) performed a comprehensive assessment of mannan (Mn) 
coated microparticles and found neither an enhancement of uptake nor any maturation 
of DCs compared to control particles. This, they speculate, may be in part due the 
mannose receptor being a co-receptor for another unidentified receptor and unable to 
facilitate the phagocytosis of particles. Differences in these data may also be 
attributable to differing ratios of particles to APCs, since it has been shown with 
microparticles and mathematical models that in cases where there is a high particle to 
cell ratio non-specific uptake predominates (Brandhonneur, Chevanne et al. 2009). In 
contrast to Mn, macrophage uptake of PLGA particles conjugated to an intergrin 
binding RGD containing peptide or the lectin, wheat germ agglutinin, resulted in 
specific uptake at higher particle to cell ratios (Brandhonneur, Chevanne et al. 2009).
Targeting of particles to a cell type using specific antibody was first evaluated in 
the context of cancer drug delivery rather than for vaccines. It has been shown in vitro 
that particles coated with a tumour antigen specific mAb localise only with tumour cells 
within a mixed population (Kocbek, Obermajer et al. 2007). In this study, two cell lines 
were used with only one expressing the tumour antigen. This system may not be
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reflective of the in vivo micro-environment as there are likely to be additional 
penetrating phagocytes which may be superior at taking up particles. Indeed, it is 
possible to speculate that in order to gain the best efficiency from such a system a vast 
number of particles would be needed to overcome the losses during in vivo transit, 
which was not looked into. This, of course, is dependent on several factors such as the 
nature of the tumour and the injection site. Anti-CD3 mAb conjugation to particles has 
been shown to target particles to leukemic T cells, with a strong correlation between 
the levels of CD3 expression and the extent to which particles are taken up (Dinauer, 
Balthasar et al. 2005). A promising observation made in this study is that T cells, 
normally possessing minimal phagocytic ability, can take up targeted particles through 
receptor mediated endocytosis. In the late stages of leukaemia it is likely that the blood 
becomes saturated with cancerous cells and targeting may be redundant. Antibody 
conjugated particles may provide a means, if not to target specific transformed cells 
(the authors acknowledged that particles cannot discriminate between diseased and 
healthy T cells), but to target specific uptake pathways. Interestingly, it has been shown 
in vivo that the addition of a targeting mAb does not increase particle localisation to 
solid tumours but it does increase tumour uptake of particles by six fold (Kirpotin, 
Drummond et al. 2006).
While the same logic applied to targeting cancer cells can be applied to 
targeting vaccines to ARC, there are fundamental differences such as APCs natural 
ability to take up particulate material which must be considered. At the forefront of this 
research is the group of Dr. Carl Figdor, Institute for Bioengineering of Catalonia, 
Barcelona, Spain. This group has begun to characterise the desirable properties of 
particles for uptake by DCs. They have shown that it is only nanoparticles, as opposed 
to microparticles, which are capable of being endocytosed through mAb mediated 
targeting of DC-SIGN (Cruz, Tacken et al. 2010). Following targeting, antigen 
presentation can be induced using 10-100 fold less antigen (Cruz, Tacken et al. 2010).
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Whether this observation can be expanded to encompass all receptors that mediate 
endocytosis remains to be shown. They do however, highlight a case whereby 
targeting microparticles to DEC-205 results in a twofold enhancement of immune 
responses (Kwon, James et al. 2005). In contrast a further study looked at targeting 
nanoparticles using DEC-205 specific mAb and reported only a 15% increase in uptake 
over particles coated with an irrelevant isotype matched mAb when targeting immature 
DCs but a 70% increase when targeting mature cells (Badiee, Davies et al. 2007). This 
could be attributed to a negligible uptake of isotype control particles by mature cells 
rather than an improvement of uptake of targeted particles over immature cells. 
Combining the results of these studies it seems likely that targeted nanoparticles are 
superior to microparticles in terms of surface binding and receptor mediated 
endocytosis. This may be because smaller particles are superior at receptor mediated 
endocytosis or that smaller particles have a larger surface area to volume ratio.
More recent work has progressed into not only actively targeting specific cells 
but also reducing non-specific uptake. To do this the focus has been on developing 
‘stealth layers’ which, in effect, mask the particle from other cells of the immune system 
(Cavadas, Gonzalez-Fernandez et al. 2011). By using a PEG based homofunctional 
cross-linker, particles can be linked to antibody with a PEG spacer region between 
particle and mAb. These particles can then be delivered specifically to DCs and not to 
monocytes acting as a competing APC (Cruz, Tacken et al. 2011). Perversely however, 
it should be noted that in this study linking of an isotype control mAb to the particle’s 
surface increased uptake, albeit slightly, over unconjugated particles suggesting that 
the antibody may abrogate the stealth properties of the particle. Furthermore, 
monocytes may not be a good cell to use for comparative purposes as their endocytic 
capacity is likely to be more limited. Indeed it was shown that monocytes take up less 
of the unconjugated particles than DCs. If these differences were normalized the
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stealth effects would be less apparent. Nonetheless this study represents a significant 
step towards a rationally designed antigen delivery system.
Targeting should, however, not be considered in isolation. The effects of 
receptor activation must also be considered. As reviewed in Chapter 1, different 
receptors have differing biological roles. For instance anti-DEC-205 targeted particles, 
though in this study having little effect on uptake (at its peak a 13% enhancement), 
induced IL-10 release from DCs (Bandyopadhyay, Fine et al. 2011). This is consistent 
with the tolergenic nature ascribed to DEC-205. Interestingly, as more mAb was coated 
on the surface, IL-10 release increased correspondingly. Moreover, the DEC-205 mAb 
needed to be complexed in order to have this effect.
Targeting vaccine to specific cells is a difficult task nonetheless the advantages 
of doing such, as stressed in Chapter 1, are numerous. There have been a range of 
methods devised to target DCs, which can be subdivided into the use of natural ligands 
and mAbs. Each research group in this field has developed in vitro models to test the 
targeting capacity of vaccine preparations however there is great discrepancy within 
the published data. The work described in this chapter aimed to synthesise targeted 
particulate systems and to evaluate their uptake by bovine DC in vitro.
3.2.1 Hypothesis
This section aims to test the hypothesis that by coating particles with various ligands 
the corresponding receptor can be targeted. In particularly the use of mannan and 
monoclonal antibodies will be addressed.
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3.3. Materials & Methods
3.3.1. Isolation of bovine monocytes
All animal work was approved by the Animal Health and Veterinary Laboratories 
Agency (AHVLA) Ethics Committee and all procedures were conducted in accordance 
with the UK Animals (Scientific Procedures) Act 1986. Heparinised bovine blood was 
layered on Bicoll 1.077 separating solution (Autogen Bioclear, Caine, UK) and 
centrifuged for 30 min at 1500 g, room temperature, with the brake off. Peripheral blood 
mononuclear cells (PBMC) were harvested from the interface between the plasma and 
Bicoll and washed three times with 50ml cold DPBS without Mg2+ and Ca2+ (Invitrogen). 
Subsequently cells were pooled in DPBS without Mg2"1" and Ca2+ (Invitrogen) 
supplemented with 2% Foetal bovine serum (FBS) (Autogen Bioclear) (PBS/FBS). 
PBMCs were then counted using a volumetric flow cytometer (MACSQuant) and 
monocytes were separated by magnetic activated cell sorting (MACS). Firstly, cells 
were incubated for 20 min at room temperature with anti-human CD14-microbeads 
(Miltenyi Biotec) at a ratio of 10 pi of beads per 107 cells. Cells were washed twice in 
PBS/FBS, resuspended in 500 pi PBS/FBS supplemented with 5 mM EDTA (Sigma, 
Poole, UK) (MACS buffer). Cells were applied to a MACS LS column (Miltenyi Biotec) 
pre-wetted with 3 ml MACS buffer set up on a MidiMACS magnet (Miltenyi Biotec). 
Flow through was collected as the negative fraction, the column was washed twice with 
5 ml MACs buffer. The positive fraction was collected by removing the column from the 
magnetic and forcing through 7 ml of RPMI-1640 tissue culture medium supplemented 
with 10% FBS, 2 mM L-glutamine, 20 mM HEPES, 100 iU/ml penicillin, 100 pg/ml 
streptomycin, 50 mM 2-mercaptoethanol (all from Invitrogen, Paisley, UK) (cRPMI). 
Cells were counted as above and to test purity, an aliquot of cells was incubated (4°C, 
20 min) with rat anti-mouse polyvalent Ig-FITC diluted 1/200 in DPBS with 1% (v/v)
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FBS and 0.09% (w/v) sodium azide (Sigma) (flow cytometry buffer) and washed in 2 ml 
flow cytometry buffer. Cells were then analysed by flow cytometry using a MACSQuant 
flow cytometer (Miltenyi Biotec). Only cell purities of greater than 90% were the 
samples deemed acceptable.
3.3.2 Generation of monocyte derived dendritic cell (MoDC)
Monocytes were plated at 2-3x106 cells/well in 24 well ultra-low bind tissue culture 
plates (Costar Corning, Cambridge, USA) in 1ml of cRPMI supplemented with 
recombinant bovine GM-CSF and IL-4 according to manufacturer’s recommended 
concentration (AbD Serotec, Mordun research institute, UK). Cells were incubated for 
3-6 days at 37°C in a 5% C 02 humidified atmosphere. Post-incubation cells were 
harvested by repeat pipetting.
3.3.3. Bovine afferent lymph dendritic cells
Cells collected from afferent lymph following pseudo-afferent lymphatic cannulation 
(Hope, Howard et al. 2006), and cryopreserved in 10% (v/v) DMSO in FBS were a kind 
gift from Dr Brian Charleston (Institute of Animal Health, Compton, UK). Cells were 
thawed rapidly in a 37°C water bath and washed in cRPMI before use,
3.3.4. FACS phenotyping of cell populations
In brief, cells were harvested and approximately 5x104 cells were resuspended in 50 pi 
flow cytometry buffer and incubated (25 min, 4°C) with appropriate primary antibody at 
(suppliers recommended dilution) and Fixable live/dead viability dye (See Appendix 1 
for details). Cells were then washed twice with flow cytometry buffer and incubated as 
above with secondary antibody where required, then washed a further two times before 
being resuspended in 200 pi of flow cytometry buffer for flow cytometric analysis. Flow
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cytometry was undertaken using a MACSQuant flow cytometer with at least 10000 
events being acquired.
3.3.5. Annexin V apoptosis assay
An Annexin V apoptosis kit (BD Pharmingen, Oxford, UK) was used according to the 
manufacturer’s instructions. In brief, cells were harvested and resuspended in 100 pi 
binding buffer, to this 5 pi of Annexin V-FITC was added and incubated for 15 min room 
temperature. 5 pi propidium Iodide was added and incubated for a further 10 min room 
temperature. Cells were analysed using a MACSQuant flow cytometer.
3.3.6. Mixed leukocyte reaction
MoDCs from a donor cow were differentiated as described above and co-cultured with 
PBMCs from allogeneic cattle, at varying stimulator to responder cell ratios ranging 
between 1:10 to 1:80. The cells were incubated together for 72 hours after which they 
were pulsed with 1 pCi per well [3H]-thymidine (Amersham Life Sciences, Little 
Chalfont, UK) and incubated for a further 24 hours (37°C, 5% C 02). Finally the cells 
were harvested onto filter mats (Tomtec Harvester 96®, Tomtec Inc., Hamden, CT, 
USA) and [3H] thymidine incorporation measured by liquid scintillation counting (2450 
Microbeta2 Plate Counter, PerkinElmer, Seer Green, UK) and recorded as counts per 
minute (cpm).
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3.3.7. Adipic acid dihydrazide derivatization of mannan
Carbonyl groups were introduced into Mn as a result of oxidisation. In brief, Mn (Sigma) 
was resuspended in 0.1M phosphate buffer pH 6 at a concentration of 10 mg/ml. 
Sodium periodate (Sigma) was added to a final concentration of 100 pM and the 
reaction continued for 1 hr at room temperature in the dark. The reaction was stopped 
by addition of 10 pi ethylene glycol (Sigma) and incubation for a further 30 min. The Mn 
was purified using an Amicon Ultra 15 centrifugal filtration unit (15 kDa molecular 
weight cut-off; Millipore, Watford, UK) and the buffer was replaced with 0.1 M 
phosphate buffer pH 9. To this a molar excess of adipic acid dihydrazide (ADH; Sigma) 
was added and incubated overnight. Unreacted carbonyl functionalities were blocked 
with 0.1 M Tris buffer (Sigma) for 1 hr. The Mn was purified again by using an Amicon 
Ultra 15 centrifugal filtration unit
3.3.8. Mannosylation of nanoparticles
Mannosylation of PLGA nanoparticles was performed using carbodiimide chemistry as 
described for protein coating (2.3.6), except that in the place of protein an equivalent 
volume of Mn was used. The coating of particles was confirmed by staining with 
concanavalin A conjugated to FITC (ConA-FITC; Sigma). In brief, a 20 pi aliquot of 
particles was incubated with 2 pi ConA-FITC (5 mg/ml) for 20 min at room temperature. 
The particles were washed twice with DPBS by centrifugation at 10000 g for 2 min. 
Fluorescent staining of particles was assessed using a MACSQuant flow cytometer.
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3.3.9. Rescorcinol assay for mannose residues
This assay, which detects mannosyl and glucosyl residues, was performed as 
described by Monsigy et al. (1988). In brief, 20 pi resorcinol (6 mg/ml; Sigma), was 
added to 20 pi of mannose conjugation supernatant followed by 100 pi 75% (v/v)
H2SO4. The reaction was vortexed for 30 sec and heated to 100°C for 30 min. After 
incubation the optical density was read at 490 nm using a Victors multilabel plate 
reader (Perkin Elmer)
3.3.10. Fluorescamine assay for the detection of primary amine residues
This method was used as previously described (Stocks, Jones et al. 1986) and is a 
fluorescence based assay used for the detection of primary amine residues. Fifty pi of 
sample was mixed with 150 pi of fluorescamine (3 mg/ml in acetone; Sigma) and 
incubated for 7 min before fluorescence at 488 nm was read on a Victors multilabel 
plate reader (Perkin Elmer).
3.3.11. Uptake inhibition studies
Following 6 days in culture, MoDCs were harvested and plated in 96 well round 
bottomed plates (Corning). Cells were pre-treated with either; Mn (50 pg/ml), 5-(N,N- 
Dimethyl)amiloride hydrochloride (DMA; 50 mM), polyinosinic acid (poly I; 50 pg/ml) or 
amantidine (50 pg/ml) (all from Sigma) for 30 min at 37°C. PLGA nanoparticles loaded 
with fluorescent ovalbumin were then added to cells and plates incubated for 60 min at 
37°C or 4°C. After incubation, cells were washed 3 times with cold PBS to remove 
unbound particles. If cell surface marker expression was also being assessed, cells 
were stained as described above. Finally cells were analysed on a MACSQuant flow 
cytometer.
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3.3.12 Chitosan particles
Chitosan microparticles were synthesised using an ionic gelatination method (Lin, Liu 
et al. 2008). Medium molecular weight chitosan (Sigma) was dissolved in 1% acetic 
acid (Sigma) to a final concentration of 2 mg/ml. Under magnetic stirring, an aqueous 
solution of 2 mg/ml sodium tripolyphosphate (TPP; Sigma) was added at a rate of 1 
ml/min. The final volume ratio of TPP to chitosan was 2:5. Stirring continued for 30 min 
after which particles were collected by ultracentrifugation at 40,000g for 20 min. 
Batches of particles were coated with Mn by reacting the free amine groups of chitosan 
with the carbonyl groups introduced into Mn as a result of oxidisation as described 
above. Oxidised Mn was added to chitosan particles at a concentration of 5 mg/ml and 
incubated overnight. Excess Mn was removed from the particles by centrifugation at 
10,000 g for 3 min twice and the free carbonyl groups were blocked with 0.1 M Tris 
buffer (Sigma). Mn coating was verified by staining particles with ConA-FITC as 
described above.
3.3.13 Chitosan coated PL G A nanoparticles
PLGA nanoparticles were coated with chitosan by overnight incubation in a 1 mg/ml 
solution of chitosan salts or chitosan oligomers (both a kind gift from Dr Satyanaryana 
Somavarapu, London School of Pharmacy, London, UK). Unbound chitosan was 
removed by washing twice in DPBS after centrifugation at 10,000 g for 3 min. The 
chitosan molecules assessed included the salts; carboxy methyl chitosan and chitosan 
HCI. The oligomers included sizes ranging from; <1 KDa, 1-3 KDa, 3-5 KDa and >5 
KDa.
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3.3.14 Monoclonal antibody coated nanoparticles
To preserve conformation and function, monoclonal antibodies (mAb) were coated onto 
the surface of PLGA nanoparticles using an adherence based method. PLGA 
nanoparticles were synthesised as described, after which the batch was divided into 
equal aliquots. The particles were suspended in 1 ml 0.1 M 2-(N- 
morpholino)ethanesulfonic acid buffer (IVIES) pH 6.2 (Sigma), mAb added at a final 
concentration of 25 pg/ml and incubated overnight at room temperature. Excess 
antibody was washed from the particles with DPBS and centrifugation at 10,000 g for 3 
min twice.
3.3.15 Laser scanning con focal microscopy
MoDC uptake of nanoparticles were further characterised with the use of laser 
scanning confocal microscopy. 104 MoDC were cytospun onto a microscope slide and 
fixed using 4% (w/v) paraformaldehyde for 30 min at room temperature. Slides were 
washed twice by submerging them into PBS and cells permeablized with 0.1% v/v 
Triton X100 (Sigma) in PBS. The slides were then blocked with TBS supplemented 
with 1mM CaCI2 0.5 mM MgCI2, 10% (v/v) normal goat serum and 1% (w/v) gelatin (all 
from Sigma) for 30 min prior to incubation with primary antibody for 1 hour, following 
which, they were washed as above. Lysotracker® (Invitrogen) was added to slides 
according to supplied protocol to stain acidic compartments. To stain nuclei, 
Vectashield ® with DAP I (Vector Laboratories, Peterborough, UK) was spotted onto the 
cells before the cover slip was mounted and sealed with nail varnish. Slides were 
analysed using a Leica SP2 confocal microscope (Leica Microsystems, Wetzlar, 
Germany)
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3.3.16 Afferent lymph dendritic cell /MoDC competitive nanoparticle uptake assay.
MoDCs were resuspended in 1 ml PBS with 5% FBS and labelled with CFSE 
(Invitrogen) by addition of 1.1 pi CFSE (5 mM in DMSO). Cells were incubated for 5 
min at room temperature after which excess CSFE was removed by washing with PBS 
5% FBS and centrifugation at 1000 g for 5 min (Quah, Warren et al. 2007). Afferent 
lymph cells were analysed using a volumetric flow cytometer and the density of afferent 
lymph dendritic cells (ALDC), defined by high FSC/SSC profile, was determined. MoDC 
were mixed with afferent lymph cells at a ratio that ensured approximately equal 
numbers of both MoDC and ALDC in cRPMI. Fifty pi of cells were plated in wells of a 
96 well round bottom plate and pulsed with particles (25 pg per well) suspended in 100 
pi cRPMI for 60 min at 37°C. Cells were subsequently washed 3 times with cold PBS to 
remove unbound particles. DCs were then stained with pooled anti-bovine CD80 and 
CD86 mAbs (a kind gift from Dr Niall MacHugh, University of Edinburgh, Edinburgh, 
UK) conjugated to Alexa Fluor 405 using a Zenon Mouse lgG1 Labelling Kit as 
described by the manufacturer (Invitrogen). Cells were finally stained with Near-lnfra 
Red Fixable Live/Dead Cell stain (Invitrogen) to exclude dead cells. Analysis was 
undertaken on a MACSQuant flow cytometer.
3.3.17 Statistical analysis
All statistical analysis was performed using Graphpad prism 5.04. Two- 
way analysis of variance (ANOVA) followed by a Bonferroni’s post-test or unpaired 
student’s t-tests were used for the analysis where indicated.
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3.4. Results
3.4.1. Characterisation of APC Subsets
In order to confirm the MoDC model, monocytes cultured in the presence of GM-CSF 
and IL-4 (MoDC) were compared to their counterparts cultured in the absence of 
cytokine (cultured monocytes) and freshly isolated monocytes. Their ability to stimulate 
allogeneic T cells was assessed using a mixed leukocyte reaction (Figure 3.1). As 
shown, MoDCs statistically higher levels of allogeneic proliferation in all five calves 
compared to both cultured and fresh monocytes and this is apparent at a stimulator to 
responder ratio of 1:20. At a ratio of 1:10, the proliferation of allogeneic cells induced 
by MoDC is more than double that of cultured monocytes.
Flow cytometry was used to further describe the different APC populations used 
in this study. Figure 3.2 shows the analysis of surface expression of lineage, 
maturation and commonly described DC markers. ALDCs expressed high levels of co­
stimulatory molecules (CD80, CD86 , and CD40) compared to the MoDC population. 
Also they were the only cell type to express CD205. The MoDCs had a higher 
expression of CD14 compared to ALDC. The presence of the mannose receptor 
(CD206) has been well described on both MoDCs and ALDCs (Werling, Hope et al. 
1999; Gliddon, Hope et al. 2004)
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Figure 3.1 Comparison of the ability of MoDC and monocytes to stimulate 
allogeneic T cell proliferative responses.
Stimulation of allogeneic (Black) and autologous (Blue) PBMC (Responders) with 
varying number of stimulating cultured (•), fresh (■) monocytes or MoDC (A)  was 
assessed by 3H-thymidine incorporation. Allogeneic responses presented are the mean 
± SEM of five calves and statistical significance (**p<0.01, ***p<0.001) was determined 
by two-way AN OVA.
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3.4.2. Interactions o f PLGA nanoparticles with bovine MoDCs
Initial experiments were conducted in order to study potential detrimental effects 
of nanoparticles on MoDCs. Figure 3.3 shows the effect of adding an increasing 
concentration of PLGA nanoparticles on cell viability after 24h of culture. The particles 
appear to have little effect on viability until a concentration of 0.25 mg/ml is reached at 
which point viability decreases from c.75% to c.60%. This trend continues to 1 mg/ml at 
which point only 40% of the cells remain viable. From this result it was decided to use 
the particles at 0.25 mg/ml when conducting overnight co-culture experiments.
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Figure 3.3 The effect of PLGA nanoparticles on MoDC viability.
MoDCs cultured in the presence of PLGA nanoparticles at the concentration indicated 
for 24hr. After incubation cells were stained with Annexin V-FITC and 7-AAD and 
analysed by flow cytometry. The cells staining negatively for both Annexin V and 7- 
AAD were considered non-apoptotic viable cells. Error bars represent the SD, data 
representative of one of three experiments.
There has been an ongoing debate in the literature as to whether PLGA 
nanoparticles alone are capable of maturing DCs. The induction of DC maturation by 
particles may be a useful asset of PLGA was it to be used in a vaccine formulation. 
However, culture of bovine MoDC in the presence of a range of PLGA particle densities 
did not appear to induce maturation as assessed by up regulation of CD80 and CD40,
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both of which are co-stimulatory molecules which have, during the course of this study, 
given the clearest distinction between mature and immature cells, compared to more 
common markers such as MHC class II (Figure 3.4).
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Figure 3.4 The effect of PLGA nanoparticles on MoDC maturation.
MoDCs were incubated with PLGA nanoparticles at the concentration indicated for 
24hrs. After incubation, cells were stained with anti-bovine CD80 (A) or CD40 (B) 
mAbs. The mean fluorescent intensity (MFI) of staining was determined by flow 
cytometry, as the cells behaved as a single population all viable cells were gated on. 
Data representative of one of three experiments.
Active uptake of the particles by MoDC was confirmed using confocal laser 
scanning microscopy as shown in Figure 3.5A and B. Particles loaded with Alexa Fluor- 
488 conjugated OVA appeared to localise in the maturing endosome after 1 hr of co­
incubation as shown by the use of a lysotracker probe. This was not observed when 
MoDC were incubated with particles at 4°C, a temperature non-permissive to 
endocytosis. Flow cytometric analysis of MoDC pulsed with particles further confirmed 
that there was minimal uptake of particles at 4°C compared 37°C (Figure 3.5C). This 
demonstrates that particle uptake is an active process and particles are not simply 
becoming associated with the surface of the cell.
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Figure 3.5 Assessment of bovine MoDC uptake of fluorescent PLGA 
nanoparticles.
MoDCs were incubated with Alexa Fluor-488-OVA loaded PLGA nanoparticles (green) 
for 1 hr at either 4°C (A) or 37°C (B). After incubation, cells were fixed onto microscope 
slides, stained with Lysotracker (Red/Orange) to stain acidic compartments and DAPI 
to stain nucleic acid (Blue) and visualised by confocal microscopy. Cells were also 
analysed by flow cytometry and data presented as an overlaid histogram of cells 
incubated with particles at 4°C (Red) or 37°C (Blue) (C) Data representative of one of 
two experiments.
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3.4.3. Targeting man nose receptors on bovine DC through the mannosylation of 
nanoparticles.
Mn, as defined as the polymeric form of mannose, lacks any reactive functional 
groups. Thus in order to conjugate mannan to a nanoparticle it must be derivatized with 
a cross linker or spacer molecule. To this end we made use of adipic acid dihydrazide 
(ADH), a homo-functional cross-linker containing dual hydrazide functionalities. Figure 
3.6 shows the incorporation of amine groups into the Mn molecule as determined by 
fluorescamine assay. Here it can be seen that Mn itself exhibited some response to the 
fluorescamine molecule suggesting the presence of amine residues. When the amount 
on Mn was increased by a factor of five, however, the fluorescence only increased 
slightly suggesting this observation maybe artifactual. The Mn which had been 
subjected to the ADH derivitization displayed the highest number of amine residues 
almost three times as many as Mn without treatment.
3 4000
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Figure 3.6 The incorporation of amine groups into mannan.
The presence of amine groups on Mn or ADH derivatized Mn was detected using a 
fluorescamine assay and fluorescence read at an excitation of 488 nm n=1.
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Once amine groups had been established within the Mn molecule Mn could be 
conjugated to PLGA nanoparticles using EDO as has previously been described for 
protein. This is illustrated in Figure 3.7 which shows surface staining of particles using 
FITC labelled concanavalin A (ConA), a lectin specific for mannosyl and glucosyl 
residues. In this Figure it is apparent that the mannosylation has been successful with 
greater than 80% of the particles staining positively for mannose in the Mn-ADH EDO 
condition. Interestingly, OVA conjugated particles display some positive staining, 
18.66% of the particles being positive. This may reflect the glycosylation pattern of the 
OVA molecule being detected. There is minimal background staining observed in the 
untreated and EDO, only 2.61 and 3.63% respectively being positive in each case.
Taking these results into consideration the stability of mannosylation was 
looked into. Due to the hydrophilic nature of mannose it was expected that the bonding 
would be more liable to break down compared to protein. As Figure 3.8 shows, at day 0 
there was positive ConA staining of both Mn-ADH plus EDC as well as Mn plus EDC 
particles suggesting the ADH derivitization is perhaps unnecessary and adding 
verisimilitude to the fluorescamine data. There is also some surface staining in the Mn- 
ADH. After sixteen days of incubation at 37°C in cRPMI, the Mn could still be detected 
on the surface of Mn plus EDC particles whereas, in relative terms, there was less 
staining of the Mn-ADH plus EDC particles. The staining in the non EDC treated 
conditions does not surpass the negative controls after sixteen days suggesting loss of 
Mn from the surface of these particles.
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Figure 3.7 Assessment o f mannose residues on coated nanoparticles using 
ConA.
PLGA nanoparticles were either; left untreated (A), treated with EDC (B), treated with 
EDC and OVA (C) or treated with EDC and Mn-ADH (D). Particles were then stained 
with FITC labeled ConA and analysed by flow cytometry. Untreated particles were 
used to assign the gate for positive events. Data representative of one of three 
experiments.
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Figure 3.8 Persistence of mannan coating of nanoparticles in tissue culture 
conditions.
PLGA nanoparticles were coated with Mn under varying conditions. Mannose residues 
on the surface of particles were assessed by staining with FITC-conjugated ConA 
before (A) and after incubation in cRPMI for 16 days at 37°C (B). The mean 
fluorescence intensity (MFI) of ConA staining was assessed by flow cytometry. The 
mean of n=3 experiments is shown, statistical analysis was performed using a one way 
AN OVA ns -  non significant *** p<0.001, error bars correspond to the SEM.
With the data suggesting that derivitization of Mn was unnecessary and may be 
detrimental to the persistence of Mn on the particle surface, subsequent experiments 
were performed using native Mn. The ability of mannosylated PLGA nanoparticles to 
specifically target mannose receptors on bovine MoDC was analysed using Mn as a 
competitive inhibitor. Figure 3.9 shows the gating strategy used to analyse particle 
uptake with a representative plot showing typical, uninhibited, uptake (Figure 3.9F). 
Using these parameters Figure 3.10 shows the relative inhibition of uptake of particles 
when a panel of biochemical inhibitors were used to block specific uptake pathways.
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Interestingly, Mn had no inhibitory effect on uptake of mannosylated or OVA coated 
particles, but blocked nearly 70% of soluble OVA uptake. Amiloride, which inhibits 
pinocytosis, had a slightly greater impact on particle uptake, blocking between 20-40% 
of uptake in all conditions tested. Amantidine, an inhibitor of clathrin-mediated 
endocytosis, was by far the best inhibitor. It was able to block uptake equally as well as 
incubation of cells at 4°C, a temperature generally regarded to be non-conducive to 
active uptake and only allowing surface binding. Poly-inosine, a scavenger receptor 
inhibitor, had no discernible effect.
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Figure 3. 9 Gating strategy for particle uptake studies
Cells were first gated on their FSC/SSC profile (A) then singlets were discerned 
by SSC-H/SSC-A (B). To remove particle clumps and debris SSC-W was 
plotted against time (C). Finally viable cells were gated (D). The cells positive 
for particle uptake were selected by comparing unpulsed cells (E) with pulsed 
cells (F). Data representative of one of three experiments.
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Figure 3.10 Uptake inhibition of coated particles using a panel of inhibitors.
MoDCs were pre-incubated for 30 mins with a panel of inhibitors including; poly 
inosine (pi), mannan (Mn), amiloride (DMA), amantidine (Am) and cooling to 4°C. Cells 
were then exposed to fluorescent particles which were either uncoated (F), mannan 
coated (G) or OVA coated (H). Soluble OVA (I) was also used to control for the 
particulate nature of the particles. After 1 hr, uptake was visualised using flow 
cytometry Representative flow plots are shown for uninhibited (A), Am inhibited (B), 
Mn inhibited (C) pi inhibited (D) and 4°C (E). The percentage inhibition was calculated 
from the difference in mean fluorescence intensity (MFI) between the uninhibited and 
the inhibited conditions. Error bars correspond to the SEM, data representative of one 
of three experiments.
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The uptake of the coated particles never exceeded the uptake of the uncoated particles 
and coating with either Mn or OVA actually impeded uptake by 2-3% (Figure 3.11). An 
attempt to attribute this finding to a change in surface charge was made as shown in 
Figure 3.11. However, no correlation could be made as the OVA coated particle 
remained negatively charged whereas the Mn particle became neutrally charged yet 
both coatings were almost equally detrimental to uptake.
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Figure 3.11 Evaluation of the effect of coating PLGA nanoparticles on MoDC 
uptake and association with surface charge.
MoDC were pulsed with Mn or OVA coated or uncoated fluorescent particles and after 
1 hr, uptake was visualised using flow cytometry. The relative uptake of coated 
particles, as measured by mean fluorescence intensity (MFI), was calculated as a 
percentage of the MFI of cells pulsed by uncoated particles (A). Error bars correspond 
to the SEM. The effect of coating on surface charge was also assessed using dynamic 
light scattering as previously described, NT -  not treated (B). The mean of n=3 
experiments is shown, error bars correspond to SD.
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In an attempt to control for the properties inherent to PLGA, chitosan particles 
were used in place of PLGA. As Figure 3.12 shows the chitosan particles synthesised 
were much larger than PLGA and more disperse, they were also often associated with 
a larger plaque of chitosan. Nonetheless, they could incorporate OVA Alexa flour 488 
and were highly fluorescent (data not shown). The particles could be mannosylated by 
Schiff base formation between the amine group of the chitosan and the carbonyl group 
of oxidised Mn as was described for Mn-ADH. Figure 3.13 shows ConA-FITC staining 
of mannosylated chitosan particles in comparison with untreated particles, with 65.32% 
of the particles staining positive for Mn.
Figure 3.12 Scanning electron micrographs of chitosan particles.
Chitosan particles were synthesised based on an ionic gelatination method. After 
preparation, particles were sputter coated with gold and visualised by scanning 
electron microscopy. Particles often formed as pockets within a greater plaque of 
chitosan. The graticule reading is shown for size determination. Each micrograph 
represents an independent batch of chitosan particles.
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Figure 3.13 Flow cytometric evaluation of the mannosylation o f chitosan 
particles.
Chitosan particles were either left untreated (A) or incubated with oxidised Mn (B). 
Particles were then stained with FITC labeled ConA and analysed by flow cytometry, 
data representative of one of three experiments.
The chitosan coated and uncoated particles were then tested for their ability to 
be taken up by cells. Figure 3.14 displays the uptake of chitosan particles and the 
inhibition caused by co-incubation with Mn. It is apparent that the mannosylation 
enhanced uptake by greater than two-fold and that by co-incubating with Mn this effect 
can be abrogated. For the purpose of this study it is of interest that the uptake of the 
uncoated chitosan particles can be impeded by almost 50% by co-incubation with Mn 
suggesting chitosan alone may serve as a ligand for the mannose receptors.
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Figure 3.14 Assessment of the uptake of uncoated and mannan coated chitosan 
particles.
OVA-Alexa Fluor 488 loaded chitosan particles were left uncoated or incubated with 
oxidised Mn. MoDCs were either incubated with media (black bars) or with Mn (open 
bars) before addition of particles. After 1 hr incubation at 4 or 37°C, the fluorescence of 
cells was assessed by flow cytometry. Uptake of particles was calculated by 
subtraction of the mean fluorescence intensity (MFI) of cells incubated at 4°C from the 
values obtained at 37°C. Analysis was performed using a two way AN OVA *** 
p<0.001. Error bars represent SD, data representative of one of three experiments.
Having observed substantial inhibition of chitosan particle uptake when co­
incubated with Mn it was logical to combine the PLGA nanoparticles with chitosan. To 
this end, both chitosan salts and oligomers of chitosan were utilised, both of which 
were preferable over medium molecular weight chitosan as they are water soluble. 
Figure 3.15A shows the change in surface charge after coating. This was used as a 
means to confirm the process had been successful. The figure shows that non coated 
particles retain their negative charge whilst coating with positively charged oligomers 
reduces the negative charge and this correlates to the size of the molecule. The 
chitosan salts have converse effects, this is because the carboxy methyl chitosan has a
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slightly negative charge due to the carboxylic acid group, the chitosan HCI however, 
has a positive charge. How the chitosan coatings affected uptake of nanoparticles is 
shown in Figure 3.15B. Surprisingly, coating with chitosan was found to have a 
detrimental effect on particle uptake by MoDC and this was especially the case when 
the chitosan salts were used. The oligomer coated particles are taken up equally well 
regardless of molecular weight but this was still poorer than the uncoated particles. The 
co-incubation with Mn reduced uptake of the oligo chitosan coated particles by 
between 30-50% but had no effect on the uptake of chitosan salt coated particles. 
Though statistical significance could only be obtained with a single oligomer there are 
clear trends in each case and the inability to attain significance is likely to be due to 
batch variation.
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Figure 3.15 The uptake of chitosan coated or uncoated PLGA particles and its 
inhibition by co-incubation with mannan.
OVA-Alexa Fluor 488 loaded PLGA particles were either left uncoated or incubated 
with chitosan salts; carboxy methyl chitosan (mChitosan) or chitosan HCI (HCI). 
Alternatively oligomers of chitosan were used and are shown on the graph by their 
respective molecular weights. Coating was confirmed by assessing the change the 
surface charge by dynamic light scattering as described and error bars represent SD 
of 3 readings (A). To assess uptake MoDCs were either pre-incubated with media 
(filled bar) or with Mn (open bar) before addition of particles. After 1 hr incubation at 4 
or 37°C, the fluorescence of cells was assessed by flow cytometry. Uptake of particles 
was calculated by subtraction of the mean fluorescence intensity (MFI) of cells 
incubated at 4°C from the values obtained at 37°C. The mean of n=5 experiments is 
shown, error bars represent SEM and statistical analysis was performed by 2-way 
ANOVA *p<0.05 (B).
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3.4.4. Monoclonal antibody targeting of nanoparticles to DC receptor, CD205
A final set of experiments were conducted to assess whether conjugation of 
monoclonal antibody (mAbs) to the surface of nanoparticles could target specific 
receptors on bovine dendritic cell populations. Anti-bovine CD205 mAb was linked to 
the surface of PLGA nanoparticles, as described for protein. To comprehensively test 
the selective uptake of particles by a single subpopulation of DC, a novel uptake assay 
was established involving two populations of DCs (one pre-labelled with CFSE for 
discrimination) competing for particles with only one expressing the targeted lectin 
(ALDC, see Figure 3.2). Two DC populations were chosen in an attempt to represent 
the milieu of cells capable of endocytosing which are likely to be encountered by the 
nanoparticles in the body, and furthermore the ability of the targeting motif to skew the 
uptake to one such cell. The gating strategy used in the assessment of particle uptake 
in the competition assay is shown in Figure 3.16.
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Figure 3.16 Gating strategy for competitive uptake of mAb targeted nanoparticles 
between two DC populations.
A co-culture of CSFE labelled MoDCs and ALDC were incubated with OVA-Alexa Fluor 
647 loaded PLGA nanoparticles for 1 hr at 37°C. Cells were stained with live/dead stain 
(A, B) and doublets were excluded by plotting FSC-A against FSC-H (C). The total DC 
population was identified based on the expression of CD80/86 (D) and then MoDCs were 
separated from the ALDC based on their CSFE labeling and uptake of particles assessed 
(E).
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Figure 3.17 shows the relative enhancement of DC becoming associated with anti- 
CD205 mAb coated nanoparticles. Compared to ALDC there were far more MoDCs 
associated with particles regardless of their coating. Coating with the isotype control or 
CD205 mAbs increased the proportion of MoDC that had taken up particles by 10-25%. 
In the case of the ALDC, the percentage of cells that had taken up particles was 
significantly enhanced by the addition of anti-CD205 mAb (Figure 3.17A). When 
looking at uptake on a per cell basis both populations showed increased uptake over 
isotype when using anti-CD205 mAb coated particles. This effect was more apparent, 
as predicted, in ALDC (Figure 3.17B). Finally, the effect of coating with both chitosan 
and mAb was assessed in the competitive uptake assay. As previously observed, the 
addition of chitosan reduced overall uptake by almost five fold nonetheless the trend 
was conserved (Figure 5.17C).
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Figure 3.17 Assessment of the effect of anti-CD205 mAb coating of PLGA 
nanoparticles to target a specific DC population.
Co-cultures of ALDC and MoDC were pulsed with OVA-Alexa Fluor 647 loaded PLGA 
nanoparticles either uncoated (NT), or coated with an irrelevant isotype control mAb 
(isotype) or with anti-CD205 mAb (CD205). The proportion of each DC type that had taken 
up particles was assessed by flow cytometry (A). Error bars correspond to the standard 
deviation, statistical analysis was performed using a 2-way ANOVA ***p<0.001, *p<0.05 
ns -  not significant. The relative quantity of nanoparticles taken up by cells of each type 
was determined by the mean fluorescence intensity (MFI). To determine the effect of anti- 
CD205 mAb coating, the MFI of cells pulsed with anti CD205 mAb coated particles were 
expressed as a fold increase in uptake over those pulsed with isotype control mAb coated 
particles. Uptake was compared with PLGA particles coated with mAb alone (B) or coated 
with chitosan and mAb (C). The mean of n=3 experiments is shown, error bars correspond 
to the standard deviation, statistical analysis was performed using a t-test **p<0.05
***p<0.001.
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3.5. Discussion
This study began by demonstrating that PLGA had little impact on the 
maturation status of bovine MoDC. This is in contrast to earlier reports that showed that 
PLGA particles induced maturation in both murine BMDC and human MoDC (Yoshida 
and Babensee 2004; Yoshida, Mata et al. 2007). The reasons for this difference may 
be simply because of contamination in the other system which was absent in ours. The 
results reported here are supported by Wischke et al. (2009) who also observed no 
maturation of BMDC pulsed with empty PLGA nanoparticles.
Various methods have been devised to attach neutral sugars, such as Mn, to 
particles. Many involve attaching the sugar to a crosslinker which is often cationic, such 
as poly-L-lysine or chitosan. Furthermore, there is variation in the literature as to 
whether to choose a single mannose residue or to opt for the polymeric form, Mn, as 
described in this study (Brandhonneur, Chevanne et al. 2009; Ghotbi, Haddadi et al. 
2011). In the literature, both forms appear to have the desired effect. This may be 
because the mannose receptor only recognises terminal mannose residues, though a 
direct comparison has yet to be made and may make interesting future work.
A flow cytometric assay was established to assess mannosylation whereby 
ConA-FITC was used to stain mannose residues on the surface of the particles. ConA 
conjugates, including ConA-FITC, have been previously used to study the mannose 
composition of yeast cell walls (Tkacz, Cybulska et al. 1971; Horisberger and 
Vonlanthen 1977). This method is more sensitive than the assay based on the 
interactions of sugars with resorcinol sulphuric acid, which estimates mannosylation by 
assessing the quantity of unbound Mn (Ghotbi, Haddadi et al. 2011). Moreover, using 
the ConA FACS assay it was possible to show the number of particles to which the Mn 
is bound and this allowed a comparative assessment of mannosylation between
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batches/conditions. Furthermore, it also minimised the impact of Mn lost during the 
conjugation process due to, for instance, retention to surfaces.
Interesting results were obtained from evaluated particles, which were 
mannosylated under different conditions, in a time-course experiment. In particular, 
mannose residues were lost in the case of the derivatized Mn conjugated via EDC 
condition. This could be due to the hydrolysis of the unstable Schiff base in the 
derivatized Mn leading to loss of the mannose residues (Cordes and Jencks 1962). 
Native Mn linked by EDC was not lost suggesting a stable covalent bond had been 
formed between the particle and the polysaccharide. As to the location of the amine 
group or reactive group within the Mn molecule; it can only be speculated that 
impurities such as glucosamine and manno-proteins may have facilitated this. Analysis 
of the Mn in the fluorescamine assay supports this result since it suggested the 
presence of amine residues. Since this study, another group has used a similar method 
to conjugate Mn to particles with little explanation as to where the bonding on the Mn 
was occurring (Hamdy, Haddadi et al. 2011). There is data suggesting that either co- 
incubating or including Mn in the w2 phase can result in a Mn coated particle. However, 
this could not be repeated in this study (data not shown) (Ghotbi, Haddadi et al. 2011). 
There is considerable variation between groups in both the methods used to 
characterise uptake as well as the extent to which it is characterised. The 
enhancement of uptake itself is often used as a measurement of success in regards to 
uptake (Ghotbi, Haddadi et al. 2011). This alone, however, fails to take into account the 
relative efficiencies of different uptake methods furthermore it doesn’t control for other 
parameters, such as size and charge, which may be altered as a result of 
mannosylation.
In the present study, no enhancement of uptake using mannosylated particles 
was observed and uptake of these particles was not inhibited by addition of exogenous 
Mn as a competitive inhibitor. This could be due to the relatively neutral charge of the
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mannosylated particles since previous groups have found that mannosylation bestows 
a more negative charge attributed to phosphate groups being present in the sugar. 
Indeed, they found a strong correlation between the increasing negative charge of the 
particle and the enhancement of uptake (Ghotbi, Haddadi et al. 2011). Since it was 
noticed that soluble OVA uptake was strongly inhibited by Mn, particles were coated in 
OVA with the aim of replicating this effect. This could not be achieved, despite the 
particles retaining a negative charge, and the particle uptake resembled that of non­
coated particles. This led to the belief that perhaps the particulate nature and factors 
such as charge and size may play a more important role than the surface ligands. 
Uptake of all particles as well as soluble OVA was completely inhibited by amantidine, 
an inhibitor of clatherin mediated endocytosis (Perry, Daugherty et al. 1999). While 
there appears to be conflicting data as to whether mannosylation of particles enhances 
uptake, there are reports that mannosylation can have an adjuvant effect. Hamdy, 
Haddadi et al. (2011) reported little enhancement of uptake following mannosylation 
but did see an altered cytokine profile from DC after uptake of mannosylated particles. 
Indeed, the ability of Mn to mature and stimulate DCs via TLR4 has been described in 
the literature (Cheng, Pouniotis et al. 2006; Cheng, Kalkanidis et al. 2008). This may 
well be the case in our study, however, the onus was to assess targeting as opposed to 
any adjuvant effect but this must be considered as the next logical step. Others have 
used a ‘stealth’ layer such as polyethylene glycol when using mannosylated particles 
(Brandhonneur, Chevanne et al. 2009). This layer makes the particles more resistant to 
nonspecific uptake and thus the contrast between ligand targeted and untargeted 
particles is more apparent. It therefore could be speculated that though our particles 
can target mannose receptors this is masked by the sheer quantity of particles taken 
up non-specific mechanisms.
Chitosan particles were initially used as a control for the PLGA particles and 
surprisingly it was observed that chitosan particle uptake could be blocked by Mn
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suggesting it may be recognised by mannose receptors. Previously, this had been 
reported based on altered cytokine release profiles or the prevention of apoptosis 
induced by chitosan after blocking with Mn (Shibata, Metzger et al. 1997; Mori, 
Murakami et al. 2005). This, to the best of my knowledge, is the first suggestion of 
interaction between chitosan particles and the mannose receptor. There are, however, 
studies which have reported contrary findings (Hashimoto, Morimoto et al. 2006). 
There is some structural similarity between Mn and chitosan with both sharing a 
hexose ring. Recently, it was found that chitosan, like Mn, can stimulate through TLR4 
suggesting there may be some overlap with regards to receptor usage (Dang., Li. et al. 
2011). There are several studies that assessed mannosylation of chitosan with the aim 
of enhancing targeting to mannose receptors. For instance, it has been shown that 
immunisation with antigen loaded chitosan microparticles coated with monomeric 
mannose significantly enhanced antibody responses, though this did not improve the 
outcome to challenge infection or alter cytokine profiles (Jiang, Kang et al. 2008). 
Mannosylated chitosan particles have also been evaluated as DNA delivery vessels, 
the cationic nature of chitosan coupled with the targeting bestowed upon it by mannose 
has led to enhanced transfection efficiencies (Kim, Jin et al. 2006; Jiang, Kim et al.
2009). The present study suggests that mannosylation may be redundant in terms of 
targeting and that native chitosan will bind to mannose receptors. However, an 
enhancement of uptake using mannosylated chitosan was observed. In other studies 
this is used as a measure of targeting and thus would explain their rationale for 
mannosylation to target APCs (Kim, Nah et al. 2006).
When PLGA nanoparticles were coated with chitosan oligomers, the particles 
became larger, more disperse and less negatively charged, which is consistent with the 
literature (Guo and Gemeinhart 2008). The chitosan coated particles were taken up by 
the DCs to a lesser extent compared with non-coated particles. This effect may, in 
part, to be due to charge as oligomers showed a decreased negative charge. However,
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the two salts of chitosan were taken up with equal inefficiency even though their 
charges were the polar opposite. There are reports stating that chitosan coating 
enhances uptake. It should be noted that these particles were tested on tumour cell 
lines which may lack the necessary endocytic pathways to take up PLGA particles to 
the same extent. Moreover, chitosan is more adherent possibly co-localizing the 
particle to the cell surface prolonging the window of uptake (Yang, Shim et al. 2009). 
The fact that co-incubation with Mn inhibits uptake to some extent indicates that the 
chitosan coating may be conferring the ability to target the mannose receptors though it 
was difficult to demonstrate significance due to variability between batches. This effect 
has previously been described using non-particulate fluorophore labelled oligo chitosan 
with which it was demonstrated that it is the mannose receptor (CD206) which is 
specifically utilized (Feng, Zhao et al. 2004; Han, Zhao et al. 2005). As to why this is 
observed with chitosan, as opposed to Mn, may be due to stealth properties of chitosan 
preventing nonspecific uptake and restricting particles to receptor mediated 
endocytosis, although stealth like properties have also been attributed to Mn 
(Wattendorf, Coullerez et al. 2008). It could also be due to the number of ligands 
available, where Mn was dependent on the reaction between single residues on each 
of the particle’s polymers, chitosan could completely coat the surface due to 
electrostatic interactions. Chitosan has many appealing properties including its ability to 
improve muco-adhesion thus making chitosan particles or chitosan coated particles 
more applicable to mucosal administration routes (Takeuchi, Matsui et al. 2003). 
Chitosan has also been reported to have adjuvant effects (Stutter, Soema et al. 2010) 
but further study is needed to characterise these effects more fully.
The final component of this study sought to target particles via a receptor on a 
specific bovine DC population using mAb. This is a promising future direction for cell 
targeting, and has been used extensively in cancer cell targeting models. However, as 
mentioned previously, cancer cells differ from DCs in their endocytic capacity and are
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likely to be more selective in their uptake. Thus, in targeting specific DCs there is an 
additional hurdle in that the site of inoculation will contain multiple ARC types capable 
of taking up particles, to varying degrees. For instance, it has been shown that 
intraperitoneal inoculation of microparticles results in more macrophages taking up 
particles, while intradermal inoculation is favourable for DC uptake (Newman, 
Elamanchili et al. 2002). It has also been reported that subcutaneous administration 
results in a small population of DCs with enhanced uptake, though these results are 
poorly described (Lunsford, McKeever et al. 2000). Therefore, biasing uptake towards 
a selected ARC subset is a particular challenge. Previous in vitro models of uptake 
have used an isolated cell type, often the one targeted, and look for an enhancement of 
uptake; this is not representative of the in vivo milieu of cells. To this end, two DC 
populations, MoDCs and ALDC, were employed in a competitive uptake study. Only 
ALDCs express the C type lectin DEC-205 and this facilitated an evaluation of the 
ability of a mAb specific for this receptor to target particles to these cells. It was 
immediately obvious that MoDCs were far superior to ALDC at particle uptake; this may 
be because the ALDC migrating in afferent lymph represent a maturing population. 
Indeed, these cells express higher levels of the costimulatory molecules: CD80, CD86 
and CD40 in comparison to MoDC. Through mAb targeting, it was possible to 
specifically increase the number of ALDC taking up particles. Interestingly, coating with 
irrelevant istoype mAb significantly enhanced uptake of particles by MoDC. This could 
be due to a number of factors, for instance, binding of mAb coated particles to Fc 
receptors on the MoDC or a decrease in surface charge resulting in less electrostatic 
repulsion. The enhancement of uptake when particles are coated with Ab has 
previously been described using microparticles and this effect was not observed when 
coating with BSA (Thiele, Merkle et al. 2003). This suggests it is a property of 
immunoglobulin, not protein in general, which is responsible for improved uptake and is 
consistent with our finding that OVA coating did not augment uptake. When compared
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to MoDCs, the CD205 mAb coating increased the amount of particles taken up by 
ALDC on a per cell basis. This was only apparent when data was analysed using ‘fold 
increase in uptake over isotype’, and was not so clear from the raw data. When 
chitosan was added the uptake was reduced, however, specific uptake of CD205 mAb 
coated particles by ALDCs was still observed. This may be due to the chitosan 
restricting non-specific uptake as previously observed and thus limiting MoDC uptake. 
However, the use of chitosan in this role complicates the picture as the earlier 
experiments had suggested that it may interact with the mannose receptors on MoDC. 
Nevertheless, this is an interesting observation that warrants further study perhaps 
combining Fc and mannose receptor blocking to further dissect the mechanism.
In conclusion, this study presents a novel model to test DC targeted 
nanoparticulate formulations. This model should be built upon and the next stages 
involve assessment of DC cytokine release and stimulation of T cells using antigen 
recall assays. PLGA nanoparticles were efficiently taken up by bovine MoDC through a 
clathrin dependent process. Evaluation of modifications to enhance or tailor particle 
uptake generated mixed results which may reflect the propensity of particles to be 
taken up though certain mechanisms. Mannosylation of nanoparticles had no influence 
on particle uptake. Novel observations were made using chitosan and chitosan coated 
PLGA particles and both strategies should be considered when designing a particulate 
vaccine study. Indeed, there is potentially enough data to support a direct comparison 
between the three types of particles in vivo. However, this was beyond the scope of the 
current project, and an in vivo evaluation of a PLGA nanoparticulate formulation 
proceeded without the addition of DC targeting moieties.
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4.1 Abstract
As a final assessment of PLGA nanoparticles for use as a vaccine delivery system, an 
in vivo vaccination study was performed using a bovine viral diarrhoea virus challenge 
model. This study aimed to rationally formulate a nanoparticulate taking into account 
the localisation of the antigen in relation to the particle as well as the incorporation of 
the appropriate adjuvant. Using the technologies previously established, particles were 
formulated such that they spatially resembled the viral particle. To achieve this, the 
envelope protein was coated onto the surface whilst the non-structural protein and the 
adjuvant poly (l:C) were loaded. Particles were characterised using both DLS and flow 
cytometry. Animals were vaccinated in a prime/boost/challenge model. OVA containing 
particles and commercially available inactivated vaccine formed the negative and 
positive controls, respectively. As a result animals vaccinated with particles formulated 
with viral antigens showed reduced blood viral antigen and RNA compared to control 
animals, suggesting a degree of protection was afforded. The immune mechanisms 
underlying protection were monitored using a range of assays including specific 
antibody ELISA and interferon gamma ELISA. It was found that both a strong antibody 
and interferon gamma response were observed in the case of the vaccine particles, 
this was not present when particles contained model antigen OVA was used. This 
study, however, was unable to weigh the relative contribution of each arm of the 
immune system. Together these findings support the potential application of 
nanoparticulate vaccines for use in future veterinary vaccines.
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4.2 Introduction
This final experimental chapter sought to evaluate the ability of PLGA 
nanoparticles to deliver recombinant proteins and to induce protective antibody and T 
cell responses in vivo. This was assessed in cattle, a potential target species for such 
technology, using bovine viral diarrhoea virus (BVDV) as a natural viral model system.
4.2.1. Bovine viral diarrhoea virus
Bovine viral diarrhoea virus (BVDV) is an enveloped, positive sense single­
stranded RNA virus belonging to the pestivirus genera, of the order Flaviviridae. It is 
closely related to classical swine fever virus (CSFV) and border disease virus (BDV) 
which are important pathogens of pigs and sheep, respectively. Together the three 
viruses show marked genomic conservation. BVDV strains can be divided into two 
genotypes based on the sequence of the 5’ untranslated regions, BVDV1 and BVDV2, 
and both can be further divided into two biotypes, either cytopathic or noncytopathic 
(Goens 2002). The BVDV genome consists of a single open reading frame that 
encodes a single precursor polyprotein which must be cleaved into its constituent 
components (Collett, Anderson et al. 1988). It may be speculated that subunit vaccines 
are particularly suitable for the management of BVDV as the virus only codes eleven 
proteins so target antigens are limited (Goens 2002). However, as an RNA virus, BVDV 
is prone to mutation and recombination (Hamers, Dehan et al. 2001).
Clinically bovine viral diarrhoea (BVD) is usually a mild disease, 70-90% of 
infections being subclinical. Those cattle which do display clinical signs may develop 
diarrhoea, fever and anorexia (Liebler, Kusters et al. 1995; Hamers, Dehan et al. 
2001). BVDV infection also induced haematopathology with a transient leukopenia and 
thrombocytopenia, which is thought to play a role in the immunosuppression 
associated with BVD (Makoschey, Janssen et al. 2001). More seriously, the virus is 
capable of crossing the placenta of pregnant dams resulting in abortion. However,
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infection with non-cytopathic BVDV in the first trimester of pregnancy may induce 
tolerance in the neonate which leads to the birth of persistently infected (PI) calves 
capable of continually shedding virus. If these animals become super-infected with a 
cytopathic strain of BVDV then a fatal mucosal disease ensues (Bachofen, Braun et al.
2010). Approximately 60-85% of cattle in BVDV endemic regions are antibody positive 
while 0.5-2% are persistently infected (Houe 1999). Furthermore, it is estimated, on 
average, that the economic impact of the disease in the U.S is around $10-40 million 
per million calvings (Houe 2003).
There are two methods currently used to control BVDV infection; the first being 
elimination of PI animals, which has been successfully employed in Sweden leading to 
BVDV eradication (Greiser-Wilke, G rummer et al. 2003). As PI animals are the primary 
shedders of virus, early identification and culling of such animals will decrease the 
chances of outbreak. However, this is not always beneficial if herd immunity is not 
established, as the PI animal is likely to infect non-pregnant dams which may serve to 
immunise them against subsequent infection (Lindberg and Alenius 1999). The lack of 
sufficient herd immunity may be a reason why stamping out failed in Denmark (Bitsch, 
Hansen et al. 2000). The second approach is to combine systematic vaccination with 
eradication, and this approach has been used in Germany (Houe, Lindberg et al. 
2006). Both live attenuated and inactivated virus vaccines are currently licensed for use 
against BVDV (Lindberg, Brownlie et al. 2006; Ridpath, Dominowski et al. 2010). 
Though each has shown success under experimental and field conditions there are 
issues with each class of vaccine. Firstly, the live vaccines do not allow for DIVA and 
thus limits their suitability in eradication efforts utilising vaccination as a control tool, 
secondly, there are conflicting reports of whether live vaccines confer protection to the 
foetus (Brock and Chase 2000; Kovacs, Magyar et al. 2003; Meyer, Deplanche et al.
2011). Perhaps most importantly, there are safety concerns over live vaccines; since 
live virus has been isolated in the ovaries post-vaccination leading to speculation that
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vaccination may cause infertility (Grooms, Brock et al. 1998). Additionally, there is 
evidence to suggest that PI cattle vaccinated with an attenuated cytopathic virus 
vaccine may develop mucosal disease due to recombination between the two viruses 
(Becher, Orlich et al. 2001). Inactivated BVDV vaccines may allow for DIVA as, 
theoretically, the non-structural NS3 protein is absent in inactivated vaccine 
preparations meaning that antibodies to this protein do not develop in vaccinated 
animals but do so in the course of infection (Makoschey, Sonnemans et al. 2007). 
However, this has been recently contested, as it has been shown that many 
commercial inactivated vaccines do contain the NS3 protein and antibody responses 
are observed in vaccinated animals (Raue, Harmeyer et al. 2011). In addition, the 
immune responses provoked by inactivated vaccines are partial with CTLs failing to be 
stimulated (Platt, Coutu et al. 2008). This is unlike vaccination with live attenuated 
vaccines that have been shown to induce virus specific CTL responses (Beer, Wolf et 
al. 1997). This is particularly inopportune as there is evidence that CTL are activated 
during the course of natural infection and may play a role in the clearance of the virus 
(Beer, Wolf et al. 1997; Rhodes, Cocksedge et al. 1999). This is further supported by 
evidence that animals vaccinated with a live attenuated strain can be protected from 
BVDV challenge in the absence of antibody responses (Endsley, Roth et al. 2003). 
Inactivated vaccines also fail to prevent vertical transmission of the virus and 
vaccinated animals can still give birth to PI calves (Zimmer, Wentink et al. 2002)
Of the BVDV proteins, both E2 and NS3 have been identified as major BVDV antigens 
targeted by both antibody and T cell responses and their potential as subunit vaccine 
candidates has been evaluated in a variety of experimental settings.
4.2.3 BVDV E2
BVDV E2 is a 53kDa glycoprotein which is the major envelope protein of the 
virus (Pande, Carr et al. 2005). E2 is responsible for viral attachment to the
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complement regulatory protein CD46, the engagement of which facilitates virus entry in 
a clatherin dependent manner (Maurer, Krey et al. 2004; Lecot, Belouzard et al. 2005; 
Krey, Himmelreich et al. 2006). It is therefore this protein that dictates the host 
restriction of the virus.
E2 is the major antigen against which the primary humoral response is mounted 
(Paton, Lowings et al. 1992; Toth, Nettleton et al. 1999). Several neutralizing B cell 
epitopes have been mapped to the E2 protein (Deregt, Bolin et al. 1998; Deregt, van 
Rijn et al. 1998). However, it is thought that neutralizing antibodies are not enough to 
confer total protection and that a cell-mediated response is additionally required 
(Chimeno Zoth, Leunda et al. 2007). Indeed it has been shown that immunization with 
baculovirus expressed E2 protein induced neutralizing antibody titres but there was still 
a degree of systemic spread of infection upon challenge (Bolin and Ridpath 1996). 
Other reports have shown that immunization with recombinant E2 protein did not 
induce detectable antibody but responses were rapidly detected upon challenge and 
vaccinates showed a degree of protection (Chimeno Zoth, Leunda et al. 2007; Thomas, 
Young et al. 2009). Neither of these studies assessed T cell responses to 
vaccination/challenge although CD4 T cell epitopes have been identified on E2 
(Collen, Carr et al. 2002).
E2 has also been evaluated as a DNA vaccine and in such cases stimulation of 
both humoral and cellular responses occur in mice and cattle (Liang, van den Hurk et 
al. 2005). Two weeks post vaccination, a balanced lgG1/lgG2a antibody response was 
generated which coincided with the detection of antigen specific interferon-gamma 
(IFN-y) secreting cells (Liang, van den Hurk et al. 2005). In another study, an E2 DNA 
vaccine was either encapsulated in liposomes or left in soluble form. While the soluble 
form stimulated responses comparable to those already described and bestowed 
partial protection, the encapsulated DNA unexpectedly failed to stimulate immune 
responses and no protection was observed (Harpin, Hurley et al. 1999). The advantage
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of accompanying adjuvant alongside the plasmid DNA has been stressed by some 
groups, for instance co-administration of cytokine, such as IL-2, with vaccine has been 
previously trialled (Nobiron, Thompson et al. 2000; Nobiron, Thompson et al. 2001; 
Nobiron, Thompson et al. 2003). Elahi et al. (1999) showed that immunisation of mice 
with fowl pox virus or adenovirus vectors expressing E2 stimulated both arms of the 
adaptive immune system in mice (Elahi, Bergeron et al. 1999; Elahi, Shen et al. 1999; 
Elahi, Shen et al. 1999).
In CSFV models, vaccination with E2 protein protects pigs against the disease 
but cannot confer sterile immunity and fails to prevent horizontal or vertical 
transmission (Dewulf, Laevens et al. 2000; Dewulf, Laevens et al. 2001). Though when 
administered as a soluble protein high neutralizing antibody titres are observed (Lin, 
Liu et al. 2009), there are studies demonstrating that CSFV E2 expressed by a 
recombinant adenovirus virus vector can confer protection in the absence of 
neutralizing antibodies (Konig, Lengsfeld et al. 1995; Hammond, McCoy et al. 2000). 
This has led to speculation that cell mediated responses play a greater role than 
initially believed, with data to suggest that CDS epitopes are present on CSFV E2 
(Ceppi, de Bruin et al. 2005). Indeed it has been shown that IFN-y is a good correlate 
of protection afforded by a CSFV E2 DNA vaccination (Tarradas, Argilaguet et al.
2010). In this study it was also found that, like BVDV, antibody responses were only 
detected after challenge, at which point the vaccinees developed substantially higher 
titres than unvaccinated controls (Tarradas, Argilaguet et al. 2010).
4.2.4 BVDVNS3
The second BVDV antigen selected was the highly conserved SOkDa non- 
structural protein 3 (NS3). During the viral replicative cycle, NS3 acts as a serine 
protease with RNA helicase activity. Whilst the protease is responsible for degrading 
the viral polyprotein into its component parts, the helicase region has been shown to be 
essential for minus strand synthesis of the BVDV genome (Gu, Liu et al. 2000; Wen,
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Chen et al. 2007). In non-cytopathic BVDV, the NS3 protein remains bound to the 
NS2-NS3 precursor whereas the cytopathic biotype has an insertion or recombination 
event within the sequence allowing autocleavage of the protein into its two constituents 
(Vilcek, Greiser-Wilke et al. 2000). The cytopathic effect is possibly due to NS3’s ability 
to induce apoptosis through induction of caspase-8 and -9 (St-Louis, Massie et al. 
2005). NS3 is an attractive target for subunit vaccines as it is highly conserved, for 
instance between BVDV1 and BVDV2 there is 90% sequence homology (Deregt, 
Dubovi et al. 2005).
T cell epitopes are present on both BVDV and CSFV NS3 proteins, with several 
MHC class II epitopes having been identified (Armengol, Wiesmuller et al. 2002; 
Collen, Carr et al. 2002). In the case of CSFV, there is evidence to suggest that major 
CD8 epitopes are also present within the protein although similar data for BVDV are 
few (Ceppi, de Bruin et al. 2005; Rau, Revets et al. 2006). Non-neutralising antibodies 
are raised against NS3 during BVDV infection and their role in clearing infection is 
therefore debatable (Lecomte, Pin et al. 1990; Deregt, Dubovi et al. 2005). Only a few 
published studies have reported the evaluation of NS3 as a subunit vaccine candidate. 
Vaccination of calves with an NS3 DNA vaccine conferred a degree of protection 
against BVDV challenge (Young, Thomas et al. 2005). Since the antibody response 
induced by vaccination was non-neutralizing, the authors speculate that protection may 
have been provided by vaccine induced T cell responses (Young, Thomas et al. 2005). 
When administered as a recombinant adenovirus vaccine, NS3 was shown to induce 
both antibody and IFN-y responses in mice (Elahi, Shen et al. 1999). In the case of 
CSFV, immunization of pigs with recombinant NS3 protein failed to confer protection 
against challenge infection despite animals mounting antibody and IFN-y responses 
against the protein (Voigt, Wienhold et al. 2007).
One published study assessed the vaccine potential of combining CSFV E2 and 
NS3 proteins and compared this to E2 alone (Rau et al., 2006). While there was a
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trend towards enhanced antibody responses in the dual antigen immunized group, T 
cell IFN-y responses were weak or undetectable. The authors speculate that this was 
due to the antigen delivery system used being inappropriate for efficient T cell priming 
(Rau et al., 2006). In a second study E2 and NS3 were used together with a novel 
adjuvant Oprl. This formulation was inferior to the commercially available adjuvants in 
terms of overall protection despite improved T cell reactivity being observed (Rau, 
Revets et al. 2006). In 2010, a patent application was published that described that 
immunization of calves with a combination of BVDV E2 and NS3 provided protection, 
which was not afforded by either antigen alone (Brownlie, Collins et al. 2010).
4.2.5 Hypothesis
This Chapter describes the rational formulation of recombinant BVDV E2 and 
NS3 proteins together with the synthetic RAMP, poly(l:C), using the PLGA 
nanoparticulate system established through the course of this study. We aimed to 
utilize both the loading and coating techniques established to maximize the availability 
of antigen. Logically, E2 is more suited to being coated onto the surface, due to the fact 
that it is present on the surface of the virion and is the major target of the humoral 
response. NS3 was encapsulated so that nanoparticles delivered the protein to the 
cytosol of APC, mimicking the location of NS3 expression during virus infection (see 
figure 4.1) (Amigorena and Savina 2010). Thus, by assembling the particle in such a 
fashion it was this study’s hypothesis that induction of immune responses 
representative of those involved in the resolution of natural BVDV infection, should 
protect from viral challenge. To test this, the immunogenicity and efficacy of the subunit 
formulation was assessed against a licensed inactivated BVDV vaccine in calves.
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'Poly-(Lactic:Glycolic)Acid (PLGA)
BVDV E2 coated onto the surface
Ilia
pipe
BVDV NS3 encapsulated
Molecular adjuvant Poly(l:C) 
double stranded RNA analogue
200nm-500nm
Figure 4 .1  Schematic representation of the nanoparticulate vaccine formulation 
evaluated in vivo.
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4.3 Materials & Methods
4.3.1 Animals
18 Holstein-Friesian bull calves aged 4-6 months were locally sourced and confirmed 
to be BVDV seronegative using a commercially available BVDV antibody ELISA 
(IDEXX Laboratories Ltd, Whetherby, UK). Animals were randomly assigned into one 
of three groups (n=6), one receiving vaccine particles, another receiving control 
particles and a final group receiving a commercially available inactivated BVDV 
vaccine, Bovidec® (Novartis, Frimley, UK). All work was performed under a Home 
Office Project Licence (PPL70/6836) in accordance with the UK Animals (Scientific 
Procedures) Act 1986.
4.3.2 PLGA nanoparticle synthesis
PLGA nanoparticles were synthesised as described in Chapter 2.3. A batch production 
system was set up whereby a single batch constituted sufficient particles for a single 
dose. Each batch consisted of 800 pg of E. coli expressed BVDV NCP7 NS3 helicase 
domain (a kind gift from Prof. Till Rümenapf, Institute of Virology, Giessen, Germany) 
and 500 pg poly (l:C) which were incorporated into the w-i phase to formulate the 
vaccine particle. Equivalent quantities of ovalbumin and poly (l:C) were loaded into 
control particles. The o phase consisted of 50 mg of PLGA dissolved in ethyl acetate as 
described. Vaccine particles were further coated with 200 pg baculovirus expressed 
BVDV NCP7 E2 protein and 80 pg BVDV NADL E2 protein (a kind gift from Dr. 
Thomas Krey, Pasteur Institute, Paris, France) using carbodiimide as previously 
described (2.3.6). All of the batches were pooled together and divided into doses to 
ensure each animal received equivalent quantities of protein. Characterisation of 
vaccine and control nanoparticles was performed by DLS and flow cytometry staining 
as outlined in 2.3.4. The amount of poly (l:C) loaded was determined through analysis
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of the particle supernatant using UV absorbance at 260 nm on a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA.
4.3.3 In vitro stimulation of T cells
CD4 and CDS T cells were purified from the peripheral blood of BVDV naïve and 
immune cattle. Cells were isolated using a MACS sorting method essentially as 
described in Section 3.3.1, except that an indirect staining method was used. PBMC 
were first stained with anti-bovine CD4 or CDS mAbs (both AbD Serotec), followed by 
staining with anti-mouse IgG microbeads (Miltenyi Biotec). Autologous MoDCs were 
generated as described (3.3.2) and served as APCs. Enriched CD4 or CDS T cells 
resuspended in cRPMI, were plated (105 per well) in a 96 well round bottomed plate 
(Costar) together with MoDCs (104 per well). To this, particles were added at a 
concentration of 0.25 mg/ml bringing the total volume per well to 200 pi. Cells were 
cultured for 72 hr at 37°C and 5% C02 after which the supernatants were collected and 
IFN-y content measured by ELISA (see 4.3.4).
4.3.4. lnterferon-y enzyme linked immunsorbent assay (ELISA)
Luminunc ® white ELISA plates (Nunc, Fisher Scientific) were coated with 100 pI/well 
anti-bovine IFN-y mAb (AbD Serotec) diluted 1/400 in carbonate/bicarbonate buffer 
0.05M pH 9.6 and incubated overnight at room temperature. Plates were washed twice 
with PBS supplemented with 0.05% Tween 20 (wash buffer), blocked by the addition of 
300 pl/well wash buffer supplemented with 1% BSA and incubated for 1 hr at room 
temperature. Blocking buffer was removed and replaced with 100 pi of cell culture 
supernatants diluted 1:2 in PBS supplemented with 1% BSA (reagent buffer) or 
recombinant bovine IFN-y (AbD Serotec) serially diluted in reagent buffer and 
incubated for 1 hr at room temperature before being washed five times with wash 
buffer. Biotinylated anti-bovine IFN-y mAb (AbD Serotec) diluted 1/200 in reagent
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buffer was added 100 pl/well and plates incubated for 1 hr before being washed 5 
times. Streptavidin linked HRP (GE Healthcare) diluted 1/1000 in reagent buffer was 
added 100 pl/well, plates incubated for 45 min at room temperature and washed as 
before. Femto super signal ELISA substrate (Thermo Scientific) was used according to 
the provided instructions. In brief, equal quantities of lumniol/enhancer and peroxide 
buffer were mixed immediately before use. To each well 100 pi of the solution was 
added, the plates were shaken for 2 min and luminescence was read on a Victors plate 
reader (Perkin Elmer)
4.3.5 Vaccination and challenge of cattle
Six calves were immunized subcutaneously (s.c.) on day 0 with 2 ml of vaccine 
nanoparticle emulsions in PBS. This equated to 50 mg PLGA and 163 pg NS3, 50 pg 
E2 and 17 pg per dose. Six control animals received control particles containing 
equivalent amounts of OVA protein and poly (l:C) administered in an identical fashion. 
A further six animals received 4 ml of a commercial inactivated BVDV vaccine 
(Bovidec®, Novartis) injected s.c. into the neck, according to manufacturer’s 
instructions. All animals received an identical booster inoculation on day 21 post 
vaccination. On day 42 post vaccination, all animals were challenged by intranasal 
inoculation of 10678 TCID5o of a genotype 1 BVDV UK isolate, Horton-916 (Hibberd, 
Turkington et al. 1993). Over the course of vaccination and challenge, venous blood 
was collected into heparin, EDTA and SST vacutainer tubes (BD, Oxford, UK) for 
analyses of T cell responses, assessment of viral load by quantitative RT-PCR and 
antibody responses, respectively.
4.3.6 Assessment of antigen specific T cell IFN-y responses.
Thirty millilitres of heparinised blood was layered onto 20 ml Bicoll 1.077 separating 
solution (Autogen Bioclear, Caine, UK) and centrifuged for 30 mins at 1500 g, room
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temperature, with the brake-off in a rotating bucket centrifuge (Beckman Coulter, High 
Wycombe, UK). PBMC were harvested from the plasma/Bicoll interface and washed 
three times with 50ml cold DPBS without Mg2+ and Ca2+ (Invitrogen). Subsequently 
cells were resuspended in cRPMI, counted using a MACSQuant flow cytometer 
(Miltenyi Biotec) and density adjusted to 5x106/ml. 100 pi of cell suspension was added 
to wells of a round bottom 96 well plate (Corning) and duplicate wells stimulated by 
addition of, BVDV NS3 helicase, E2 and OVA proteins. Media (cRPMI) and pokeweed 
mitogen served as a negative and positive control respectively. Proteins and mitogen 
was used at 5 pg/ml final concentration in 200 pi total volume per well. Cells were 
cultured for 48 hr at 37°C, 5% C 02 after which the cell-free supernatants were collected 
and IFN-y content measured by ELISA.
4.3.7 Measurement of relative OVA antibody levels
MaxiSorb ELISA plates (Nunc) were coated 100 pl/well OVA diluted 25pg/ml in 
carbonate/bicarbonate buffer 0.05M pH 9.6 and incubated overnight at room 
temperature. Plates were washed twice with PBS supplemented with 0.05% Tween 20 
(wash buffer) and blocked with 300 pl/well wash buffer supplemented with 1 % BSA. 
After being incubated for 1 hr at room temperature, blocking buffer was removed and 
replaced with 100 pi of test serum which was serially diluted from 1:2 in PBS 
supplemented with 1% BSA (reagent buffer). Plates were washed five times as 
described above and 100 pi rabbit anti-bovine Ig-HRP (Dako), diluted 1:5000 in reagent 
buffer, was added. Plates were incubated for a further hour after which they were 
washed as above and 100 pi of TMB substrate was added. The reaction was stopped 
after 15 mins with the addition of 100 pl/well 1.8N sulphuric acid. Absorbance was read 
at 450nm on a Victors plate reader (Perkin Elmer)
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4.3.8. NS3 and E2 specific antibody competitive ELISAs
E2 and NS3 competitive antibody ELISAs were purchased from Jeno Biotec Inc 
(Korea) and Insititut Pourquier (France), respectively and performed according to the 
manufacturers’ instructions. In brief, 50 pi test serum was added to 50 pi of dilution 
buffer in antigen coated plates. Plates were incubated for one hour followed by 
washing three times with wash buffer provided. 100 pi of anti-BVDV E2 or NS3 IgG 
conjugated HRP was added and incubated for 30 mins. Plates were washed again 
three times before 100 pi of TMB substrate was added for 15 mins. The reaction was 
stopped by addition of sulphuric acid and absorbance was read at 450nm on Victors 
plate reader (Perkin Elmer). Relative antibody titre values were extrapolated from both 
positive and negative controls included in the kits.
4.3.9 Detection of BVDV RNA by quantitative RT-PCR
RNA was extracted from whole EDTA blood using the QIAamp Viral RNA mini kit 
(Qiagen, Crawley, UK) according to the supplied protocol. BVDV RNA was then 
detected using a nested qPCR as described (McGoldrick, Bensaude et al. 1999). This 
is a complex nested PCR in which both the reverse transcription and the amplification 
are carried out in the same tube with the primers for the second round of amplification 
being dried in the lid of the reaction tube until required. Lids were prepared by the 
addition of a master mix containing; 5 pi 22% (w/v) trehalose, 1 pi 10 mM deoxy 
nucleotides (Promega), 1 pi of each of the two inner primers (20 pM) and 0.25 pi Taq 
polymerase (5 U/pl; Promega), per reaction. These reagents were allowed to dry on the 
lid overnight. The reagents for the reverse transcription and the primary amplification 
were assembled in the tube itself and consisted of: 5 pi of 10x Taq polymerase buffer 
(Promega), 12 pi MgCI2 (25 mM; Promega), 2 pi deoxy nucleotides (10 mM; Promega), 
0.25 pi of each of the outer primers (20 pM), 1 pi Triton X100 (10% v/v), 0.75 pi ROX 
reference dye (2 pM) (Stratagene, Stockport, UK), 1 pi pan-pesti FAM conjugated
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probe (5 pM), 0.25 pi RNAsin (40 U/pl; Promega), 0.5 pi RT MMLV enzyme (200 U/pl; 
Promega) and 0.5 pi Taq Polymerase (5 U/pl; Promega) per tube. The tubes were 
then made up to a volume of 47 pi with the addition of 23.5 pi per well of nuclease free 
water. Extracted RNA (3 pi) was then added and the tubes were then capped with the 
lids containing the dried second round reagents. The reaction was carried out using an 
MxSOOO qPCR machine (Stratagene) with the following cycling conditions for the first 
step; 42°C, 30 mins; 95°C 3 mins, (RT step) followed by 10 cycles of 94°C, 1min, 60°C, 
1 min and 72°C, 1 min (Primary amplification). After this, the tubes were removed and 
inverted 4-5 times, tubes were then centrifuged briefly to collect the reagents at the 
bottom of the tube. The second round was then performed with the following cycling 
conditions; 40 cycles of 94°C, 1 min, 60 °C, 1 min and 72 °C, 1 min. A final extension 
step of 72 °C, 10 min was included as the final stage. The samples were quantified 
against a tenfold dilution series of RNA extracted from a BVDV stock of known TCID5o 
(La Rocca and Sandvik 2009).
4.3.10 Serum neutralization test
Bovine turbinate cells (BT) were grown in DMEM supplimented with 10% FBS and 1% 
sodium pyruvate (Invitrogen, Paisley, UK) until confluent. Serum to be tested was first 
heat inactivated at 56°C for 30 min. Twenty pi of test serum was added to 80 pi of 
media and titrated using a twofold serial dilution. 100 TCID5o of BVDV C24V (50 pi)
was added to each of the test wells and incubated at 37°C and 5% C 02 for 1 hr. To
each well, 1.5x104 BT cells (50 pi) were added and the plate was incubated in a
humidified incubator at 37°C and 5% C 02 for 5 days. Following this, an
immunoperoxidase test was performed to detect BVDV infection. In brief, the plates 
were fixed with 20% (v/v) acetone for 5 min. The plates were then drained, dried under 
a lamp and frozen at -20°C. When ready, the cells were rehydrated with PBS and 
excess buffer removed. A pan-pesti mAb cocktail (Mammalian Virus Investigation Unit,
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AHVLA, Addlestone, UK) diluted to a predetermined optimal concentration in 0.01 M 
PBS, 1% (v/v) Tween 80, 2% (w/v) NaCI (conjugate buffer) was added to each well (50 
pl/well) and incubated for 15 min at 37°C. Plates were washed three times with 200 pi 
per well of 0.1 M PBS, 0.5% (v/v) Tween 80 (wash buffer). After this 50 pi of rabbit anti­
mouse IgG-HRP conjugate (Dako) diluted 1:1000 in conjugate buffer was added to 
each well and incubated as above, followed by washing as described. Plates were then 
washed with 200 pi of water and blotted dry and 50 pi of carbazole substrate (5 ml 
0.5M acetic buffer pH5 and 3% (v/v) hydrogen peroxide supplemented with 0.3 ml of a 
stock solution of 0.5% (v/v) 3-amino-9-ethyl carbazole in n,n-dimethyl-formamide) was 
added to each well and incubated as previously described. Once 15 min had elapsed, 
the substrate was removed and replaced with 100 pi wash solution. Characteristic 
red/brown staining was assessed using light microscopy at 400x magnification.
4.3.11 Detection of BVDV antigen by ELISA
The presence of BVDV Erns antigen in the blood was detected using Herdchek BVDV 
Ag/Serum plus ELISA (IDEXX, Hoofddorf, Holland). In brief, 50 pi test, positive or 
negative serum was added to an anti-Erns coated ELISA plate along with 50 pi 
detection antibody and incubated for 2 hr at 37°C. The plates were washed with 300 pi 
of wash buffer three times. HRP-conjugated secondary antibody (100 pi) was added to 
each well and incubated for 30 mins followed by washing as described above. 
Substrate was then added, incubated for 10 mins and the plates read at 450 nm.
4.3.12 Statistical Analysis
All statistical analysis was performed using GraphPad Prism 5.04 (GraphPad Software 
Inc). Two-way analysis of variance (ANOVA) followed by a Bonferroni's post-test 
was used for the analysis of given effects on different traits. The unpaired Student’s t- 
test was also used where indicated.
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4.4 Results
4.4.1 PLGA nanoparticle characterisation
Both the BVDV antigen loaded particles (vaccine NR) and OVA loaded particles 
(control NR) used in this study were characterised using the methods previously 
described. As illustrated by Figure 4.2, the vaccine particles were 200 nm larger than 
the control particles; the particles being sized at 500 nm and 300 nm respectively. The 
vaccine particles also exhibited a higher polydispersity index value of 0.318 compared 
to the control particles which were slightly more uniform having a polydispersity of 0.22. 
With regards to surface charge, after coating, the vaccine particles increased their 
charge becoming effectively neutrally charged whereas the control particles remained 
negatively charged. This is consistent with visual observations that the vaccine 
particles were more prone to clump formation. The surface E2 coating was also 
confirmed using flow cytometry, as shown in Figure 4.2. After being stained with an 
anti-E2 mAb, the MFI of the vaccine particles far exceeded that of the control particles 
with nearly 90% of the particles staining positive for E2. Table 4.1 shows the estimated 
loading and coating of the vaccine particles, with an NS3 loading efficiency of 20% and 
an E2 coating efficiency of 16%. This translated to 163 pg NS3, 50 pg E2 and 17 pg 
poly (l:C) per dose.
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Figure 4.2 Characterisation of nanoparticles used for the inoculation in vaccine 
trial.
PLGA particles were synthesised as described with either BVDV antigens (Vaccine) or 
OVA (Control). Particles were then analysed with dynamic light scattering to assess 
size (A) and charge (B). Size bars are annotated with PDI values and error bars 
represent the SD. Surface coating of nanoparticles with BVDV E2 was determined by 
flow cytometry following staining control particle (red) and vaccine (blue) particles with 
a BVDV E2 specific mAb followed by anti-mouse IgG 1-APC (C).Data represents the 
pooled particles used in this study read in triplicate runs.
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Calculation of particle content (per dose)
Component Starting quantity (pg) Quantity loaded (pg) Efficiency (%)
PLGA 50,000 50,000 na
Protein Loaded 800 163.7 ±23 2O.5±2.5
Protein Coated 280 45.3±5 16.2+1.8
Poly (l:C) Loaded 500 88.6±48 17.7±9.5
Table 4.1 Estimation of vaccine particle loading and coating.
The synthesised particles were assessed in vitro for their ability to stimulate the 
production of IFN-y from antigen-specific T cells in a recall assay. As Figure 4.3 shows, 
significantly greater antigen-specific IFN-y responses could be detected from CD4 T 
cells from BVDV immune animals compared to naïve animals. While the release of 
IFN-y from CDS T cells was higher from immune animals, statistical significance could 
not be obtained as there was considerable variation between animals.
?
Responder T cells
Figure 4.3 In vitro stimulation of naïve and primed T cell IFN-y responses by vaccine 
nanoparticles.
MoDCs were mixed with autologous CDS or CD4 T cells from either naïve or BVDV- 
immune (primed) calves at a ratio of 1:10. An equal number of either control or vaccine 
nanoparticles were added. After 72 hr culture supernatants were assessed for IFN-y by 
ELISA. Antigen specific IFN-y production was determined by subtracting the values 
obtained for the control particles from the vaccine particles. Error bars represent SËM and 
statistical analysis was performed by Student’s t-test ** p<0.01, ns -  not significant, n=6.
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4.4.2 Antigen specific antibody responses
The development of antibody responses post-vaccination and challenge was 
monitored using ELISAs specific for E2 and NS3. As shown in Figure 4.4A both the 
inactivated vaccine and the vaccine NR group developed antibodies to the E2 protein 7 
days after the booster immunization and these levels were sustained until challenge. It 
should be noted that in the case of the inactivated vaccine group the test was saturated 
from day 28 onwards. After challenge, the control group also became positive for anti- 
E2 antibodies. At day 58, the assay was saturated however by serially diluting the 
serum to a dilution of 1/256 (Figure 4.4B) significant differences between the groups 
were observed with the inactivated vaccine group showing higher E2 specific antibody 
compared to the Vaccine NR group. The titrations also revealed that the vaccinated 
groups had significantly greater E2 antibody levels compared to the unvaccinated 
controls.
The development of NS3 specific antibodies differed slightly (Figure 4.4C). 
Post-boost, the inactivated vaccine group showed substantial levels of anti-NS3 
antibodies, whilst the antigen NP group did not develop antibody levels significantly 
different from the controls until day 35 and these levels were nearly 4 fold less than the 
inactivated vaccine group. Once again, by day 58 post vaccination, the read out for the 
inactivated vaccine group and the vaccine NP group were saturated. However, on 
titration significant differences between the two groups could be detected at a dilution 
of 1/128 (Figure 4.4D).
The antibodies raised were then assessed for their ability to neutralize BVDV 
infection in vitro using a serum neutralization test. As Figure 4.5 shows, neutralizing 
antibody responses could be detected in the case of both the vaccine nanoparticle and 
the inactivated vaccine group post-boost and these responses could not be detected in 
the control group. However, the vaccine nanoparticle group had lower titres than the 
inactivated vaccine group at all time points prior to challenge. Following challenge, all
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groups became positive for neutralizing antibodies. Antibody responses could also be 
detected to OVA in the control group post vaccination as shown in Figure 4.6. 
However, the magnitude of this response relative to BVDV antigen specific antibody 
could not be determined due to the nature of the test.
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Figure 4.4 Detection of E2 and NS3 specific antibodies following vaccination and 
challenge.
Sera from animals receiving either inactivated vaccine (blue), Vaccine NP (red) or control 
NP (orange) were collected longitudinally over the course of vaccination and challenge and 
assessed for the presence of antibodies against E2 (A) and NS3 (C) by competitive ELISA. 
Serum samples from Day 58, at which time the signals in the ELISAs were saturated, were 
serially diluted and assayed again on the E2 (B) and NS3 (D) ELISAs. Error bars represent 
SD and statistical analysis was performed using a 2-way AN OVA, * p<0.05 *** p<0.001 n=6 
animals.
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Figure 4.5 BVDV neutralizing antibody responses following vaccination and 
challenge.
Serum from animals receiving either inactivated vaccine (blue), antigen loaded NP (red) 
or control NP (orange) were assessed for the presence of antibodies capable of 
neutralizing BVDV infection in vitro. The mean and SD of each group are presented n=6 
animals. Data collected in part through collaboration with V. Riitho.
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Figure 4.6 OVA specific antibody responses of animals immunized with control 
particles.
Sera from animals immunized with OVA encapsulated control particles, were collected 
at the designated time points and OVA specific antibodies detected using an indirect 
ELISA. A pool of serum taken from the inactivated vaccine and vaccine particle groups 
on Day 65 (irrelevant serum) served as an additional negative control. Error bars 
represent SD and statistical analysis was performed using a 2-way AN OVA, ** p<0.01 
*** p<0.001 n=6 animals.
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4.4.3. Antigen-specific IFN-y responses following vaccination and challenge.
The ability of the vaccine formulation to evoke a cell mediated response was 
addressed using ex vivo stimulation of PBMC with recombinant antigen and IFN-y 
release as a read-out (Figure 4.7). Both the vaccine particle and inactivated vaccine 
groups mounted an IFN-y response against both the E2 and NS3 antigens used in this 
study, which were statistically different from the control particle group. In the case of 
NS3 responses, the inactivated group was significantly different from day 28 onwards 
where the vaccine particle group was different from day 51 onwards. E2 responses 
differed slightly; both the inactivated and vaccine particle groups became significantly 
different from the controls at day 51. These differences were maintained until day 54. 
At day 61, they once again became comparable to the control group. At only one time 
point (day 44, NS3 only) was the IFN-y released by the inactivated vaccine group 
statistically greater than that of the vaccine particle group. By the time of challenge 
almost all the animals of both the inactivated vaccine and vaccine particle groups had 
become positive for IFN-y release. The reactivity against NS3 in both the vaccine 
particle and inactivated vaccine groups was detectable at all time points post­
challenge. The control group, even after challenge, did not mount a significant IFN-y 
response against the viral proteins (Figure 4.7 A, B). Interestingly, the re-stimulation of 
cells obtained from the control group with OVA yielded no increase in IFN-y secretion 
at any time point (data not shown).
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Figure 4.7 Ex vivo antigen-specific IFN-y responses following vaccination and challenge.
PBMCs from animals receiving either inactivated vaccine (blue), antigen loaded (red) or 
control NP (orange), were stimulated with BVDV E2 (A) or NS3 helicase (B) proteins for 48 
hr. After which supernatants were assayed for IFN-y using ELISA. The mean of each group 
was plotted after being corrected for background using the media only condition. Statistical 
analysis was performed using a 2 way AN OVA *p<0.05 **p<0.01 ***p<0.001 ns -  non 
significant. Statistical differences between control group and the other groups are shown 
n=6 animals. Data collected in part through collaboration with V. Riitho.
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4.4.4 Outcome to BVDV Challenge Infection
Protection against BVDV challenge infection was assessed by measurement of 
viral antigen and RNA in peripheral blood. As shown in Figure 4.8, blood antigen levels 
became detectable at day 6 post-challenge and reached their peak at day 9 after which 
they began to decline. This trend was consistent between all three groups, however, 
there were significant differences between each group; the group receiving the 
inactivated vaccine had the least blood antigen, the vaccine particle group had an 
intermediate level whilst the control particle group had the highest. There were 
significant differences between the control and vaccine particle groups at both day 6 
and day 9 post challenge. These differences were also present between the vaccine 
particle and inactivated vaccine groups.
The levels of BVDV RNA in blood followed a similar trend to that observed for 
viral antigen. They peaked at day 9 post challenge in the case of the vaccine and 
control particle groups; however, there were significantly higher levels of BVDV RNA in 
the control group. The inactivated vaccine group showed a peak in viral RNA on day 6 
post challenge. Interestingly, all groups showed a second peak in viral RNA, which was 
particularly apparent in the vaccine particle and the inactivated vaccine group, where 
the two groups show the same trend albeit offset. Viral RNA was cleared from the 
blood of the vaccine particle and inactivated vaccine group on day 21 and 18 
respectively, whereas, viral RNA was still detectable in the blood of control animals at 
the termination of the experiment (day 24 post-challenge).
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Figure 4.8 Detection of BVDV in the blood of vaccinated animals following 
challenge infection.
Animals receiving either inactivated vaccine (blue), antigen loaded (red) or control NP 
(orange) were assessed for their ability to control viraemia following challenge infection 
with BVDV. BVDV Erns antigen was detected by ELISA (A) and RNA detected by 
quantitative RT-PCR (B). Error bars represent SEM, statistical analysis was performed 
using a 2 way AN OVA * p<0.05 ** p<0.01. Statistical differences between control group 
and the other groups are shown n=6 animals.
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4.5 Discussion
This study aimed to evaluate the potential a nanoparticulate system for the 
delivery of vaccine candidate antigens to cattle. A rational approach was taken to the 
design of the vaccine particles incorporating multiple antigens. BVDV proteins E2 and 
NS3 were selected based on their reported vaccine potential as well as unpublished 
observations made within our laboratory (Collen, Carr et al. 2002; Thomas, Young et 
al. 2009). RIGA NPs were chosen as the delivery vehicle due to a large body of 
literature supporting their adjuvant properties as well as their relative safety (see 
Chapter 2.2 for a detailed review). Poly (l:C) was selected as the molecular adjuvant 
because of its ability to mimic viral infection and thus trigger an appropriate immune 
response (Wong, Saravolac et al. 1995; Trumpfheller, Caskey et al. 2008). The size 
range of the particles was selected to enable endocytosis as opposed to phagocytosis 
(Rejman, Oberle et al. 2004). With regards to the arrangement of these components; it 
was decided to have them arranged so as to closely resemble a viral particle i.e 
external surface antigen, E2, internal nucleic acid, poly (l:C), and non-structural protein, 
NS3. It should be noted NS3 does not form part of the BVDV virion. It is however, 
found within the infected cell. In the case of NP, the protein would not be released until 
the polymer shell is broken down within the cell.
BVDV E2 protein was coated onto the surface of the PLGA NP using the 
method developed during this study (Chapter 2.3.6). Using this method, we were able 
to attain a large number of coated particles. Furthermore the protein could still be 
detected by a panel of neutralizing antibodies suggesting antigenic conformity was 
unaffected by the coating process. A loading efficiency of only 20% was achieved in 
the vaccine preparations. This is slightly less than the 25-30% attained when optimising 
the procedure with the model antigen OVA. This is probably due to the presence of the 
poly (l:C) altering the osmotic stresses in the forming particle. Likewise, we were able 
to coat only 16% of the starting protein onto the surface of the particle compared to the
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30% previously observed. This is perhaps due to the sensitivity of the test used to 
measure binding: when optimizing the method UV absorbance was used, whereas for 
the vaccine preparation the BCA assay was used. The method was altered in the 
vaccine preparation contained both loaded protein and coated protein both needed to 
be calculated alongside each other in a single assay. Nonetheless, the vast majority of 
particles were coated with protein. There were considerable physical differences 
between the control and vaccine particles, many of which were unavoidable. For 
instance, the vaccine NP was some 200 nm larger than the control NP. This is due 
primarily to the coating with E2 but the fact that NS3 helicase is approximately 10 kDa 
larger than OVA may also have contributed to this. The negation of charge from the 
surface of the vaccine NP is also due to the coating with E2, this result is consistent 
with the visual observation that the vaccine NP emulsion was unstable (Data not 
shown). This outcome was difficult to predict prior to particle synthesis and conjugation. 
To control for this, an innocuous protein of similar charge and size would need to be 
coated on the surface. Coating with OVA in place of a matched protein would not 
suffice as it was previously shown particles coated with OVA retain a negative charge. 
In vitro we were able to show that the vaccine particles could stimulate specific recall 
responses from primed CD4 T cells. However, the responses from CDS T cells were 
not so clear. This is probably an issue regarding non-specific release of IFN-y by CDS 
T cells which was variable between animals and assays. The fact that when isolating 
CDS T cells it is necessary to remove the CD4+ T regulatory cells which have 
contributed to the more ‘unrestricted’ cytokine release.
We decided to coat the major neutralising antigen onto the surface of the 
particle as opposed to co-encapsulation with the rationale that it would provide direct 
access for B cell recognition. There have been studies looking into the advantages of 
coating over loading in terms of antibody production. For instance in a liposomal model 
it was shown that it is only by using coated antigen that antibody production is
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observed, which the authors likewise attribute to the accessibility of the antigen to B 
cells (Guan, Budzynski et al. 1998). There are several other studies using liposomes 
reporting similar findings (Latif and Bachhawat 1987; Vannier and Snyder 1988). 
However, comparative studies of coating versus loading, as of present knowledge, 
have never been repeated in a PLGA based system which would make interesting 
future work. However, it has been shown that a robust humoral response can be 
achieved by antigen loaded PLGA particles, a response superior to incomplete 
Freund’s adjuvant and alum, and comparable to complete Freund’s adjuvant (Gutierro, 
Hernandez et al. 2002a; Rosas, Pedraz et al. 2002). There is also recent evidence that 
the stimulation of multiple TLRs is important in the induction of an antibody response, 
and that this is enhanced if the TLR ligands are encapsulated in separate particles 
(Kasturi, Skountzou et al. 2011). TLR engagement on the B cell is becoming more 
recognised as an important factor in stimulating a strong humoral response 
(Lanzavecchia and Sallusto 2007). In this case the choice of poly(l:C) as the adjuvant 
may be improved upon as it is unsure at present whether bovine B cells express TLR3 
(Werling, Piercy et al. 2006). In future studies the combination of loaded/coated 
antigen, the type of adjuvant and co-encapsulation of antigen/adjuvant must be 
considered to make a more comprehensive study. Recently, it has been shown that 
multiple adjuvants are far superior at stimulating both humoral and cellular responses 
and that MPLA and natural killer cell activating a-galactosylceramide are the best 
combination for a type 1 response (Salvador, Igartua et al. 2012)
In the present study, good antibody titers were observed following immunization 
with the inactivated vaccine and the vaccine NP. In the case of the vaccine NP this 
response was almost entirely directed against the E2 protein. The antibody responses 
induced by the vaccine particle were not as strong as those observed to the inactivated 
vaccine. As predicted, the anti-E2 responses correlated well with the serum 
neutralization titers. There were major differences between the results obtained for
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NS3 antibody titers. Though there were statistically different results observed between 
the vaccine and the control NP groups, these differences were slight when compared 
to the inactivated vaccine. It was speculated that the detection antibodies used in the 
blocking ELISA were raised against NS3 protease domain, since we only used the 
helicase domain in the vaccine NP no antibodies against the protease domain would 
be raised, thus there would be no competition. However, this was ruled out as both 
antibodies used in the test ELISA recognised epitopes within the helicase domain (data 
not shown). The lack of antibody responses was also not due to an inherent property of 
the protein since antibodies against NS3 developed in the inactivated vaccine group. 
Indeed B cell epitopes have been described on NS3 (Deregt, Dubovi et al. 2005). This 
leaves two solutions to this paradox; firstly, the NS3 being inside the particle resulted in 
an impaired antibody response. This solution is plausible. Given that some antibody 
reactivity was observed, it maybe that it is only relative to the inactivated vaccine that 
the NS3 responses were impaired. This hypothesis also calls into question the adjuvant 
used in the inactivated vaccine, QuilA, which has been shown to be a good stimulator 
of antibody production (Shu, Bir et al. 2001). The second possibility is that the NS3 
protein lost conformation/integrity either during particle preparation or as a result of 
being inside a particle. This may be due to protein interactions with the polymer itself, 
such as hydrophobic interactions or acidification of the internal environment, or protein 
degradation as a result of the process parameters for instance dénaturation due to 
interactions with the solvent or intensive sonication (van de Weert, Hennink et al. 
2000). However, antibodies to OVA protein, which was also encapsulated, did develop 
in the control group as has been previously described, though the exact titres could not 
be calculated and may be comparable to those for NS3 (Lefevre, Carr et al. 2009; 
Nonnecke, Waters et al. 2012). It is possible to speculate that B cell epitopes on NS3 
helicase are highly dependent on conformity, more so than OVA, which were lost 
during formulation. Indeed, there are groups demonstrating the necessity of conformity
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in the helicase domain. They also highlight the fact that conformational epitopes are 
also found in the helicase domain of hepatitis C virus, another member of the 
Flaviviridae (Brown, Papa et al. 2002).
Though we observed antibodies against NS3 following immunization with the 
Bovidec vaccine this is not always the case. For instance, using an alternative 
inactivated vaccine in one study NS3 antibodies developed and in another they did not 
(Raue, Harmeyer et al. 2011; Alvarez, Donate et al. 2012). Since antibody responses 
against NS3 are non-neutralising they are unlikely to play a significant role in the 
resolution of BVDV infection. We cannot be sure as to whether the vaccine particles 
could potentially be used as a DIVA vaccine. While a weak anti-NS3 antibody response 
was observed this was below the diagnostic cut-off of the ELISA assay. Thus in a 
diagnostic setting the antibody responses detected would have registered as being 
negative. To validate the vaccine’s DIVA potential it would need to be tested over a 
longer time period, in the absence of challenge, to ensure anti-NS3 antibody responses 
are not delayed.
Ex vivo stimulation of PBMC with antigen followed by IFN-y ELISA analysis of 
supernatants was used as the readout of cellular responses. The use of IFN-y as a 
measurement of cellular responses is justified as the mounting of an IFN-y response 
correlates well with protection from pestivirus infection (Tarradas, Argilaguet et al. 
2010; Graham, Everett et al. 2012; Graham, Haines et al. 2012). IFN-y responses to 
viral antigens were observed in both the inactivated vaccine and vaccine particle 
groups. These responses were significantly different from the control group but not 
significantly different from each other, with the exception of a single time point. This 
suggests the particulate vaccine was at least comparable to the commercially available 
product. Even at the final time point, the control group had not begun to mount an IFN- 
y response that was statistically different from pre-challenge levels. Interestingly, the 
level of IFN-y produced in response to stimulation with E2 in the inactivated vaccine
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and vaccine particle groups was lower at the final time point when compared to the 
subsequent one, and was no longer statistically different from the control. In contrast, 
the responses to NS3 at the final time point remained on par with the previous time 
point. What this indicates we can only speculate; it could suggest that the vaccination 
regimes were more efficient at stimulating the formation of memory T cells specific for 
NS3 compared to E2. This could be tested by looking into the phenotype of the 
cytokine secretion profile of the antigen-specific T cells as has recently been described 
for bovine tuberculosis (Whelan, Villarreal-Ramos et al. 2011). It would make 
interesting further work to extend the timescale of this study and monitor for the 
presence of specific memory T cell formation. The control group did not mount an IFN- 
Y  response against viral antigen even after challenge despite mounting an antibody 
response.
In this study, no IFN-y production was observed in the control group when re- 
stimulated with OVA (data not shown). A bovine IFN-y response to OVA has, however, 
been observed in previous studies (Foote, Nonnecke et al. 2007; Nonnecke, Waters et 
al. 2012). The difference in observations is likely to be due to the quantity of protein 
used or the adjuvant, in these previous studies 4 mg of protein in incomplete Freund’s 
adjuvant was used, which is approximately 20 times the amount used in this study 
(Foote, Nonnecke et al. 2007; Nonnecke, Waters et al. 2012). It has also been shown 
that the bovine response to OVA is complex. For instance there is substantial variation 
in responses depending on the MHC class II haplotype of the animal (Glass, Oliver et 
al. 1990). Some have further speculated that there is a fine balancing act between 
humoral responses and cellular responses, and have shown that animals with a 
stronger antibody response seem to be impaired in their cellular response to OVA 
(Burton, Mallard et al. 1993). This was not explored further in this study.
The vaccine particle group showed reduced blood viral antigen and RNA levels 
compared to the control group. However, these levels were higher than those observed
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in the inactivated vaccine group. This suggests a degree of protection afforded by the 
NP formulation of BVDV antigens. There was a significant difference between the 
vaccine and control particle groups, as detected by PCR and ELISA, at day 49, the 
peak of viremia. BVDV RNA could still be detected in the blood of the control group up 
to and including day 24 post challenge whereas BVDV antigen could not. It is a 
common assumption that this is due to the qRT-PCR being a more sensitive assay 
compared to the antigen ELISA. However, it may be due to the fact that the ELISA 
detects the Erns protein in serum. This protein is secreted by infected cells, where it 
serves to suppress the antiviral type I IFN response (Iqbal, Poole et al. 2004), and 
active replication required to continue secretion of protein which would be continually 
‘mopped up’ by the immune system (Magkouras, Matzener et al. 2008). The BVDV 
qPCR however, only detects RNA and doesn’t discriminate between cell associated, 
free, and virion bound nucleic acid. It might be of interest in a future study to look at 
virus isolation to assess whether the vaccine reduces the peak and duration of 
infectious virus in circulation.
This study attempted to test a rationally designed subunit vaccine in an in vivo 
challenge model. Whilst it is encouraging that both T cell and antibody responses were 
induced against both antigens, which translated into a degree of protection, the 
immunogenicity and efficacy was inferior to the commercial QuilA adjuvanted 
inactivated virus. Upon reflection, the study could have been improved with the 
inclusion of a group immunised with antigens in soluble form, to directly determine the 
effect of the nanoparticulate formulation. Future work should be focussed on testing 
individual combinations of antigen, adjuvant, delivery vessel and the spatiotemporal 
relationship between them. For instance, coating the one antigen and loading the other 
then alternating the configuration, or testing multiple combinations of TLR ligands in a 
matrix panel. Though measurement of viraemia (antigen/RNA) provided a quantitative 
assessment of immunological protection, there were few other parameters that could
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be additionally assessed. Despite a high dose of challenge virus, the infection was 
mild, with only two control animals displaying measurable clinical signs. To improve 
upon the BVDV model, a foetal protection study could be utilized. (Brock and Chase 
2000) Furthermore CSFV, a close relative of BVDV, which readily induces clinical 
disease under experimental settings, could be a more suitable model to evaluate 
modifications of the vaccine formulation as protection and against clinical disease could 
readily be used as a measure of protection.
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Vaccination with antigenically defined protein subunits offers many advantages 
over more traditional strategies such as being safer and allowing for DIVA. However, 
subunits seldom stimulate the same quality of response as provided by live attenuated 
vaccines. Adjuvants are normally required to evoke the required immune responses 
and as such they are the key to the development of the next generation of vaccines. By 
carefully selecting the appropriate adjuvant, responses can be tailored to meet 
immunological requirements for combating a particular pathogen (Lima, dos Santos et 
al. 2004). According to the classical paradigm, as outlined by Schijns (2003), adjuvants 
work in two ways; firstly by prolonging the release of antigen (signal one) and secondly 
by causing ARC maturation (signal zero) and delivery of co-stimulation (signal two) 
(Schijns 2003). The perfect adjuvant system should aim to fulfil both of these criteria, 
whilst also being biodegradable, cheap and safe (Aguilar and Rodriguez 2007). Indeed 
the desired characteristics of third generation adjuvants (the first two being emulsions 
and emulsions containing immunostimulatory molecules) as outlined by O’Hagan and 
DeGregorio (2009), should consist of local delivery of antigen and immunopotentiator. 
To this end they advocate the use of particulate systems. The licensing of MPLA for 
use in human vaccines has highlighted the potential of TLR ligands for use as 
immunopotentiators in rationally formulated subunit vaccines (Mbow, De Gregorio et al.
2010) and this is likely to represent the future trajectory of molecular adjuvant research 
(Hedayat, Netea et al. 2011). Previous generations of adjuvants licensed for human 
vaccines are based on aluminium salts and while these may be effective they stimulate 
mainly a Th2 mediated antibody response through a mechanism that is poorly 
understood (Tritto, Mosca et al. 2009). It is believed to include the induction of the 
innate inflammatory response through triggering of multiple NOD-like receptors by 
damage associated molecular patterns such as uric acid (Kool, Fierens et al. 2011). 
The role of the depot effect of alum, originally believed to play a part in the adjuvant 
effect, has now been contested (Hutchison, Benson et al. 2011). However, it is likely
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that the antigen forms a particulate system with alum, which may be responsible for 
some of its potentiating effects (de Veer, Kemp et al. 2010)
A core objective of this study was to optimize a system to synthesise and 
characterise PLGA nanoparticles. PLGA is a popular choice for the synthesis of 
polymeric nanoparticles for a number of reasons (see Chapter 2). There exists, 
however, a number of means of producing and characterising PLGA nanoparticles, 
each with merits. Based on its representation in the literature, this study not only aimed 
to develop a w/o/w double emulsion method but also to characterise the particles using 
the facilities available. This should be seen as the ground work and the basis for future 
experimentation. These aims were achieved, however, the work highlighted a few 
areas which may become a concern if production using this method was scaled up to 
meet commercial needs. These include the relatively high polydispersity of the particle 
batches and the fairly low loading efficiency. PLGA microparticles are currently used in 
the delivery of drugs for cancer treatment, thus good manufacturing practice developed 
in one field may be transferable to another (Klose, Siepmann et al. 2008). However, 
even with these current methods there are serious concerns, which include poor 
characterisation and cost (Jiang, Gupta et al. 2005). Jiang et al. (2005) highlight the 
specific case of Nutropin Depot® which was removed from the market due to it not 
being commercially viable. Though it has been suggested this was due to problems 
inherent to the drug rather than the means of delivery (Bossart 2005). If these issues 
could be overcome, it is conceivable that, given the right disease, PLGA nanoparticles 
will become a commercial prospect in the future (Johansen, Men et al. 2000). With the 
use of protein loaded particles there are additional concerns such as the maintenance 
of antigenic conformity during processing (potentially due to the effect of solvents and 
high energy émulsification procedures) and within the particle (van de Weert, Hennink 
et al. 2000). During the course of this study however, we have shown that both 
encapsulated and conjugated antigen could be recognised by the cells of the immune
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system. However, to date there have been no clinical trials of PLGA nanoparticles in a 
vaccine setting, whereas there have been several using liposomes for diseases such 
as influenza, cancer and malaria (Powers 1997; Agnandji, Asante et al. 2010; Butts, 
Maksymiuk et al. 2011). This could be because lipososomes have been subject to 
study for a longer duration or perhaps because greater loading efficiencies can be 
achieved.
The success of any subunit vaccine is dependent on both the antigenicity of the 
protein and the stimulatory properties of the adjuvant; the two cannot be divorced from 
each other or considered in isolation. It is the opinion of this study that nanoparticles 
offer a potentially viable adjuvant when coupled with the correct antigen and 
immunostimulant. Indeed the potential of nanoparticulate systems to deliver antigens 
and stimulate good immune responses has been previously observed using various in 
vitro and mouse models (Elamanchili, Diwan et al. 2004; Chong, Cao et al. 2005). 
From an immunological perspective, the use of particulate systems in the correct model 
may yield great insight into the fundamental mechanisms of the immune response for 
example cross-presentation (Schliehe, Redaelli et al. 2011). From the point of view of 
the vaccinologist, particulates provide the opportunity to rationally design and formulate 
protein subunits into usable vaccines and this was the overarching aim of this study. 
Though the exact mechanisms by which particles adjuvant vaccines is unsure, it is 
believed to be a combination of factors such as sustained release and delivery of 
antigen to the appropriate cell or cellular compartment (Singh and O'Hagan 2003). 
Depending on their physical parameters, PLGA particles are known to prolong the 
release of antigen over a period of time far greater than that of alum or mineral oil 
based adjuvants (Sivakumar, Safhi et al. 2011). Due to this fact, a single dose may be 
sufficient to establish strong immune response and the persistence of antigen may act 
as both the prime and boost (Johansen, Estevez et al. 2000). Interestingly, this work 
and others have shown that in vitro PLGA particles do not stimulate APCs to mature
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and thus cannot provide the signal zero required to initiate an immune response 
despite antigen presentation being increased (Sun, Pollock et al. 2003). While this 
may, to some, be seen as a disadvantage possibly leading to tolerance, to others this 
offers an immunological ‘blank slate' with the opportunity to combine particles with 
other defined adjuvants thus truly tailoring the immune response (Perrie, Mohammed et 
al. 2008). However, whether this is a realistic picture in vivo is debatable. For instance, 
it has also been shown that without further stimulation, PLGA particles, in some 
models, stimulate antibody production better than complete Freund’s adjuvant 
(O'Hagan, Rahman et al. 1991; Igartua, Hernandez et al. 1998). Whether this is due to 
the depot effect and the persistence of antigen is unclear at present. The interactions of 
particles with B cells are particularly interesting as shown by this study and others 
(Kasturi, Skountzou et al. 2011). Though not the main focus of this study it has 
identified several areas of future research such as looking into coating versus loading 
of antigen, co-delivery of relevant adjuvants and uptake of particles by B cells. The 
specific uptake of surface coated compared to non-coated particles by the B cell 
receptor could be tested. The potency of the formulation with the addition of specific 
ligands for TLRs known to be endosomally bound (such as TLR 9/7) and required for 
good B cell responses could also be tested (Lanzavecchia and Sallusto 2007). 
Furthermore, the effect on APC in vivo is likely to differ from in vitro and it may be 
speculated that particles, at significant concentrations and after a significant amount of 
time, within cells are detrimental to viability. This hypothesis would be in keeping with 
the findings of this study. Cells bearing particles or antigens may die within the 
microenvironment and release inflammatory mediators which may serve to propagate 
an immune response. Thus modelling particulate systems in vitro is difficult. Many 
groups understandably use recall responses as a measurement of the immune 
response, however, though co-stimulation does play a role in the memory response
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(stimulating IL-2 release) it is overlooked in many common read-out assays, such as 
IFN-y production (Ndejembi, Teijaro et al. 2006).
As previously stated, the appropriate adjuvant must efficiently stimulate the 
cells necessary to potentiate the immune response. In some cases, such as with 
Freund’s complete adjuvant, stimulation results in localized inflammation and the 
adjuvant is poorly tolerated (Billiau and Matthys 2001). These contraindications may be 
bypassed if the vaccine is targeted. It is clear that particulate systems undergo complex 
interactions with the APC and therein lies some of their adjuvant properties. Substantial 
innovation in this area is found in the targeting of particles to specific cells within the 
body. This field has been spurred on by the positive results observed in cancer 
immunotherapy and has led some to speculate that this is possibly the future of 
nanoparticulate vaccines (Lu, Wang et al. 2009). Targeting particles however is a 
particularly difficult task and this was reflected in this work (Chapter 3) and in published 
reports. As an example, a group has reported that the addition of an endoplasmic 
reticulum targeting peptide actually, for an unexplained reason, targets particles away 
from the ER compared to control peptide (Sneh-Edri, Likhtenshtein et al. 2011). 
Targeting motifs may work in some models but not in others. For instance, the same 
group has reported that mAb targeting of protein to DEC-205 may or may not enhance 
immune responses depending on the antigen (Bonifaz, Bonnyay et al. 2004; Tewari, 
Flynn et al. 2010). The data generated by this study supports the further investigation 
of mAbs to target particles to specific cells but as a standalone dataset it was not 
strong enough to advocate its use in vivo. Indeed some have cast doubt over whether 
the use of antibody targeting is a realistically feasible option as a long term solution 
(McCullough and Summerfield 2009). Likewise with Mn targeting, there are groups 
publishing both positive and negative data with regards to enhanced uptake 
(Wattendorf, Coullerez et al. 2008; Ghotbi, Haddadi et al. 2011; Hamdy, Haddadi et al.
2011). The data gathered by this study supports the argument that targeting with Mn
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using particles of this nature does not lead to an improved uptake by bovine MoDC. 
This is not to say there is no interaction with the mannose receptor; the readouts used 
could not detect this, only this interaction did not lead to endocytosis above that 
observed with uncoated particles and uptake could not be blocked with exogenous Mn. 
Although not well studied, there is likely to be an inherent bias of particles towards a 
certain cell or a certain uptake pathway which may overcome the pressure selected by 
the addition of a targeting motif. Another consideration is how the addition of targeting 
molecules affects the physical parameters of the particle, some of which were 
assessed in this study, since this in itself may lead to ambiguity in the results. Future 
work should involve a systematic study of how changing single parameters affects the 
uptake route of particles in both in vitro and in vivo models. It may be argued that, 
tailoring the physical parameters, as opposed to the addition of targeting moieties, may 
lead to enhancement of specific cell uptake. Localisation of particles within the in vivo 
environment may also help delivery to the desired cell, for instance by using particles of 
20 nm with a PEG coat, particles could be delivered to lymphatic DCs (Reddy, Rehor et 
al. 2006). Another line of future inquiry could be the use of acid sensitive polymers 
which will degrade after a given time in acidic compartments e.g. maturing endosomes 
allowing for bespoke release of antigen (Kwon, Standley et al. 2005). Building on this, 
particles may be held in the endosome until the APC has reached the lymph node 
where particles degrade allowing antigen release and subsequent 
processing/presentation (De Temmerman, Rejman et al. 2011). This goal could also be 
achieved through the use of multilamellar vesicles which are only broken down in the 
presence of cellular lipases and have displayed a remarkable ability to stimulate 
memory responses (Moon, Suh et al. 2011). By modifying particles to be of the correct 
physical parameters to reach the lymph node it has been speculated that a targeting 
motif is unnecessary (Reddy, Swartz et al. 2006). Selecting the appropriate route of 
immunization may result in the particles reaching the desired cell more efficiently. It has
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been demonstrated that intravenous immunization with particles leads to greater APC 
uptake as they can easily reach the spleen resident populations (Lunsford, McKeever 
et al. 2000). This has to be considered in the context of particle size as it has been 
shown that different sized particles, at least in terms of total antibody titres, fare better 
when administered by certain routes (Gutierro, Hernandez et al. 2002b). For example, 
500 nm nanoparticles were better than 200 nm particles only when administered 
intranasally (Gutierro, Hernandez et al. 2002b). There is also data to suggest that an 
intralymphatic route seems to give the best IFN-y response (Mohanan, Slutter et al. 
2010). These differences, it could be speculated, are perhaps due to the differential 
uptake of particles by APC. Future work could consist of a more comprehensive study 
of the ultimate fate of these particles in terms of the types of APC taking up the 
particles after administration through various routes.
Together these data perhaps call into question the accuracy of any in vitro 
model, and this is a current dilemma in the development of novel adjuvants (Coffman, 
Sher et al. 2010). Often there are numerous cell types geographically defined 
interacting with adjuvants which in turn will have a direct effect on the immune 
response. These interactions cannot be encompassed within a single model. At best a 
measure of simple parameters such as protein release from particles and particle 
uptake may be obtained using these models, but the extrapolation of these results to in 
vivo large animal systems should not be made lightly (Shi, Caulfield et al. 2002; 
Panyam, Dali et al. 2003).
The potential of chitosan was touched upon in this study and these findings 
could easily be expanded. There is a growing body of evidence suggesting cationic 
particles improve immune responses through endosomal escape and enhanced cross­
presentation of antigens (Han, Zhu et al. 2011; Vue, Wei et al. 2011).The nature of the 
stimulation delivered by chitosan could also be looked into in more detail, for instance, 
it could be directly compared to LPS and MPLA. There is some data to suggest there
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are differences; for example by incubating macrophages with chitosan, the 
inflammatory response triggered by LPS can be removed suggesting blocking (Yoon, 
Moon et al. 2007). While other studies have shown chitosan promotes the release of 
IL-1 and TNF-a from macrophages (Feng, Zhao et al. 2004). Due to its cationic nature, 
chitosan could be partnered with multiple negatively charged nucleic acid based TLR 
ligands, such as CpG oligodeoxynucleotides and poly (l:C), while also stimulating 
through TLR4 itself (Dang., Li. et al. 2011). It has been shown that TLR3, 4 and 8 can 
act in synergy to elicit stronger immune responses. Such a combination of TLR 
agonists has been shown to stimulate improved immune responses including cytotoxic 
T cell responses (Warger, Osterloh et al. 2006) Furthermore, the timing of delivery is 
important, as demonstrated by a study in which delivery of the TLR8 agonist, R848, 
subsequent to poly (l:C) increase IL-12 production from DC in vitro (Napolitani, Rinaldi 
et al. 2005). A particle could encapsulate R848 and, through a chitosan intermediate, 
have poly (l:C) coated on the outside to meet the temporal requirements for optimal 
delivery. Such a particle would represent a logical consequence of both this study (the 
use of PLGA to encapsulate, chitosan to target and poly (l:C) to stimulate) and reports 
in the literature (the use of multiple TLR ligands, chitosan’s stimulatory properties and 
cationic particles) (Dang., Li. et al. 2011; Han, Zhu et al. 2011; Salvador, Igartua et al. 
2012).
The BVDV vaccination/challenge calf model marked the climax of this study; it 
produced interesting data which can be carried forwards and built upon in future work. 
The most notable result was that the particulate formulation afforded a significant 
degree of protection against the challenge infection. Particulate systems, other than 
PLGA, have been trialled in various veterinary models reviewed in (Scheerlinck and 
Greenwood 2006). Some have used small animals to model PLGA particulate 
vaccination using bovine pathogen antigens, though few of these have progressed into 
cattle trials (Sales-Junior, Guzman et al. 2005; Brandhonneur, Loizel et al. 2009).
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PLGA particles have been used previously to vaccinate and protect from foot and 
mouth disease and Fasciolosis. The present study contributes with this previous work 
to suggest that PLGA is suitable for use in the manufacture of cattle vaccines 
(Estunningsih, Smooker et al. 1997; Wang, Pan et al. 2011). While the outcomes of this 
study were positive, the appropriateness of the BVDV challenge model could be called 
into question as we observed only a few, slight clinical manifestations and only in a 
proportion of the un vaccinated animals. It was only through analysis of viral loads that 
differences between groups could be discerned. A follow-up experiment should directly 
assess the effect of the particle delivery system by comparing immunisation with 
soluble proteins. Alternatively, several different batches of particles varied in their 
protein coating/loading, types of adjuvant and perhaps chitosan coated could be used. 
However, such an experiment in cattle is likely to run at considerable expense.
In conclusion, this study has succeeded in its objectives to develop and 
optimize a PLGA nanoparticle based system for use in the formulation of novel 
vaccines. This should be seen as the foundation for future research and not an end in 
itself. What is more, this study has looked into the application of these new techniques 
in targeting DC specific receptors. This is an up and coming field of research which is 
likely to gain prominence in the scientific literature in the near future. Though this study 
obtained mixed results with regards to targeting, these reflect the status of the currently 
published literature. The final in vivo experiment provided promising evidence to 
suggest suitability of PLGA for use in large animal vaccination.
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Appendix: Staining Reagents
Specificity Labelling Isotype Supplier
Primary Antibodies
Bovine CD 14 FITC Mouse lgG1 Serotec
Bovine CD80 Mouse lgG1 A kind gift from Dr Niall 
MacHugh, (University of 
Edinburgh, Edinburgh, 
UK)
Bovine CD86 Mouse lgG1
Bovine CD40 Mouse lgG1
Bovine MHC class II Mouse lgG2
BVDV E2 Mouse lgG1
Mammalian Virology 
Investigation Unit, AHVLA
Bovine CD205 Mouse lgG2a Serotec
Human CD206 PE Mouse lgG2b BD Biosciences
Bovine CD 172a Mouse lgG2 Serotec
Bovine CD11c Mouse IgM VMRD
Bovine IFN y Biotin Mouse lgG1 Serotec
Bovine IFN y Mouse lgG1 Serotec
Bovine CD4 Mouse lgG2a Serotec
Bovine CD8 Mouse lgG2a Serotec
Ovalbumin Mouse lgG1 Sigma
Pan pesti mAb pool Mouse IgG
Mammalian Virology 
Investigation Unit, AHVLA
Secondary Antibodies
Anti Bovine Ig HRP Rabbit Dako
Anti Mouse IgG FITC Goat Sigma
Anti Mouse Ig HRP Rabbit Dako
Anti Mouse lgG1 APC Rat lgG1 BD Biosciences
Anti Mouse lgG2 PE Rat lgG1 BD Biosciences
Anti Mouse IgM FITC Rat lgG2 BD Biosciences
Others
Streptavidin HRP HRP BD Biosciences
Con-A FITC Sigma
Fixable Live/Dead AF 405 Invitrogen
Mouse IgG Microbead
Paramagnetic
Bead Goat Fabs Miltenyi Biotec
Human CD14 
Microbead |
Paramagnetic
Bead Mouse lgG2a Miltenyi Biotec
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